

# ***Evidence Synthesis***

---

## **Number 216**

### **Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: An Evidence Review for the U.S. Preventive Services Task Force**

**Prepared for:**

Agency for Healthcare Research and Quality  
U.S. Department of Health and Human Services  
5600 Fishers Lane  
Rockville, MD 20857  
[www.ahrq.gov](http://www.ahrq.gov)

**Contract No. HHS-290-2015-00007-I, Task Order No. 9**

**Prepared by:**

RTI International–University of North Carolina at Chapel Hill Evidence-based Practice Center  
Research Triangle Park, NC 27709

**Investigators:**

Daniel E. Jonas, MD, MPH  
Emily Vander Schaff, MD, MPH  
Sean Riley, MA, MSc  
Bianca Allison, MD, MPH  
Jennifer Cook Middleton, PhD  
Claire Baker  
Rania Ali, MPH  
Christiane E. Voisin, MSLS  
Erin LeBlanc, MD, MPH

**AHRQ Publication No. 21-05288-EF-1  
December 2021**

This report is based on research conducted by the RTI International–University of North Carolina Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (HHSA-290-2015-00007-I, Task Order No. 9). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help healthcare decision makers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of healthcare services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information (i.e., in the context of available resources and circumstances presented by individual patients).

The final report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.

## **Acknowledgments**

The authors gratefully acknowledge the following individuals for their contributions to this project: Justin Mills, MD, MPH, AHRQ Medical Officer; Tracy Wolff, MD, MPH, Scientific Director, USPSTF Division, AHRQ; current and former members of the U.S. Preventive Services Task Force; Sharon Barrell, MA, editor; Loraine Monroe, publications specialist; and Carol Woodell, BSPH, EPC Program Manager.

## Structured Abstract

**Purpose:** To review the evidence on benefits and harms of (1) screening children and adolescents for prediabetes and type 2 diabetes and (2) interventions for prediabetes or type 2 diabetes that was screen detected or recently diagnosed for populations and settings relevant to primary care in the United States.

**Data Sources:** PubMed/MEDLINE, the Cochrane Library, and trial registries through May 3, 2021; reference lists of retrieved articles; outside experts; and reviewers, with surveillance of the literature through October 31, 2021.

**Study Selection:** English-language controlled studies evaluating screening for prediabetes or type 2 diabetes or evaluating interventions for prediabetes or type 2 diabetes that was screen detected or recently diagnosed.

**Data Extraction:** One investigator extracted data and a second checked accuracy. Two reviewers independently rated quality for all included studies using predefined criteria.

**Data Synthesis:** This review included eight publications (856 participants). Of those, six were from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study. No eligible studies directly evaluated the benefits or harms of screening. One included randomized, controlled trial (RCT) (TODAY, n=699 adolescents who were obese) reported that two youths with recently diagnosed type 2 diabetes developed renal impairment (0 vs. 1 vs. 1, p=1.00) and 11 developed diabetic ketoacidosis (5 vs. 3 vs. 3, p=0.70), finding no significant difference between metformin, metformin plus rosiglitazone, and metformin plus lifestyle, respectively. One trial of 75 adolescents who were obese with prediabetes compared an intensive lifestyle intervention versus standard care and reported that no participants in either group developed diabetes, although followup was only 6 months. Regarding harms of interventions, two RCTs assessing different comparisons enrolled youths with recently diagnosed diabetes. Major hypoglycemic events were reported by less than 1 percent of participants. Minor hypoglycemic events were more common among youths treated with metformin plus rosiglitazone than among those treated with metformin or metformin plus lifestyle. In one study, gastrointestinal adverse events were more commonly reported by those taking metformin than by those taking placebo.

**Limitations:** The included trials generally focused on intermediate outcomes rather than health outcomes of interest. Duration of followup was too short to assess health outcomes in most studies. Evidence was limited by imprecision, unknown consistency (single study for most key questions), and risk of bias (with a single good-quality study).

**Conclusions:** No eligible studies directly evaluated the benefits or harms of screening for prediabetes and type 2 diabetes in children and adolescents. For youths with prediabetes or recently diagnosed (not screen-detected) diabetes, the only eligible trials reported few health outcomes and found no difference between groups, although evidence was limited by substantial imprecision and a duration of followup likely insufficient to assess health outcomes. Limited data showed that the combination of rosiglitazone plus metformin was associated with hypoglycemic events (compared with metformin alone or metformin plus lifestyle) and that

metformin was associated with gastrointestinal adverse events, consistent with studies conducted in adults.

# Table of Contents

<b>Chapter 1. Introduction.....</b>	<b>1</b>
Scope and Purpose .....	1
Condition Definition .....	1
Etiology and Natural History .....	1
Risk Factors .....	2
Prevalence and Burden .....	3
Rationale for Screening and Screening Strategies .....	4
Treatment Approaches .....	5
Clinical Practice in the United States and Recommendations of Other Organizations .....	6
<b>Chapter 2. Methods .....</b>	<b>7</b>
Key Questions and Analytic Framework .....	7
Data Sources and Searches .....	7
Study Selection .....	8
Quality Assessment and Data Abstraction.....	8
Data Synthesis and Analysis.....	8
Expert Review and Public Comment.....	9
USPSTF Involvement .....	9
<b>Chapter 3. Results.....</b>	<b>10</b>
Literature Search.....	10
Results by Key Question.....	10
KQ 1. Is There Direct Evidence That Screening for Type 2 Diabetes and Prediabetes in Asymptomatic Children and Adolescents Improves Health Outcomes? .....	10
KQ 2. What Are the Harms of Screening for Type 2 Diabetes and Prediabetes in Asymptomatic Children and Adolescents?.....	10
KQ 3a. Do Interventions for Screen-Detected Type 2 Diabetes and Prediabetes Provide an Incremental Benefit in Health Outcomes When Delivered at the Time of Detection Compared With Initiating Interventions Later, After Clinical Diagnosis?.....	10
KQ 3b. Do Interventions for Screen-Detected Type 2 Diabetes and Prediabetes Improve Health Outcomes Compared With No Intervention, Usual Care, or Interventions With Different Treatment Targets?.....	10
KQ 3c. Do Interventions for Recently Diagnosed Type 2 Diabetes Improve Health Outcomes Compared With No Intervention, Usual Care, or Interventions With Different Treatment Targets? .....	10
KQ 4. What Are the Harms of Interventions for Prediabetes, Screen-Detected Type 2 Diabetes, or Recently Diagnosed Type 2 Diabetes?.....	12
KQ 5. Do Interventions for Prediabetes Delay or Prevent Progression to Type 2 Diabetes?.....	13
KQ 6. After Interventions for Prediabetes Are Provided, What Is the Magnitude of Change in Health Outcomes That Results From the Reduction in Type 2 Diabetes Incidence?.....	14
<b>Chapter 4. Discussion .....</b>	<b>15</b>
Summary of Evidence.....	15
Evidence for Benefit and Harms of Screening .....	15
Benefits of Interventions for Screen-Detected or Recently Diagnosed Diabetes .....	15
Benefits of Interventions for Prediabetes.....	15
Harms of Interventions for Prediabetes or Type 2 Diabetes.....	16

Limitations .....	16
Future Research Needs .....	16
Conclusion .....	17
<b>References.....</b>	<b>18</b>

## **Figures**

Figure 1. Analytic Framework

Figure 2. Summary of Evidence Search and Selection

## **Tables**

Table 1. Classification of Diabetes (Adapted From ADA Guidelines)

Table 2. Criteria for the Diagnosis of Type 2 Diabetes and Prediabetes (Adapted From ADA Guidelines)

Table 3. Characteristics of Included Randomized Trials of Children and Adolescents With Prediabetes or Type 2 Diabetes (KQs 3, 4, and 5)

Table 4. Results of Trials of Children and Adolescents With Prediabetes or Type 2 Diabetes Reporting Health Outcomes (KQ 3) or Progression From Prediabetes to Type 2 Diabetes (KQ 5)

Table 5. Results of Included Trials of Children and Adolescents With Type 2 Diabetes Reporting Harms/Adverse Events Due to Treatment (KQ 4)

Table 6. Summary of Evidence on Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents

## **List of Appendixes**

Appendix A. Additional Background and Contextual Questions

Appendix B. Additional Methods Information

Appendix C. Excluded Articles

Appendix D. Quality Assessments

# Chapter 1. Introduction

## Scope and Purpose

This evidence review will be used by the United States Preventive Services Task Force (USPSTF) to make a recommendation on screening asymptomatic children and adolescents for prediabetes and type 2 diabetes. The USPSTF does not have a previous recommendation on this topic for children and adolescents. The USPSTF recommends screening for prediabetes and type 2 diabetes in adults ages 35 to 70 years who are overweight or who have obesity (B recommendation). The USPSTF states that clinicians should offer or refer patients with prediabetes to effective preventive interventions. The USPSTF has I statements for screening for high blood pressure in children and adolescents and for screening for lipid disorders in children and adolescents. The USPSTF recommends that clinicians screen for obesity in children and adolescents age 6 years or older and offer or refer them to comprehensive, intensive behavioral interventions to promote improvements in weight status (B recommendation).

## Condition Definition

Diabetes mellitus (DM) refers to a range of metabolic disorders characterized by hyperglycemia. **Table 1** shows general categories and definitions of DM used by the American Diabetes Association (ADA).<sup>1</sup> The ADA guidelines emphasize that type 1 and type 2 diabetes are heterogeneous diseases in which clinical presentation and disease progression may vary considerably. Both type 1 and type 2 diabetes may present in children or adults.<sup>1</sup> The focus of this review is on screening for asymptomatic type 2 diabetes, which is characterized by insulin resistance and relative insulin deficiency.

Definitions of prediabetes and diabetes in children and adolescents are the same as in adults. Three tests can be used to identify prediabetes and type 2 diabetes: hemoglobin A1c, fasting plasma glucose, or an oral glucose tolerance test (OGTT) (**Table 2**). Prediabetes is the term used for individuals whose blood glucose levels are considered higher than normal but do not meet criteria for diabetes. Individuals diagnosed with prediabetes include those who meet criteria for impaired fasting glucose (IFG), meet criteria for impaired glucose tolerance (IGT), and have a glycated hemoglobin (A1c) from 5.7 to 6.4 percent.

## Etiology and Natural History

Type 2 diabetes in youth is characterized by insulin resistance combined with relative insulin deficiency.<sup>2,3</sup> At diagnosis or in the following years, some youth have lost approximately 80 percent of their pancreatic beta cell function, resulting in an inability to compensate for increased insulin resistance.<sup>3-5</sup> This pancreatic dysfunction does not appear to be mediated by antibodies against the pancreatic islet cells (as occurs in type 1 diabetes).<sup>6</sup> Although the progression through obesity, insulin resistance, glucose intolerance, and type 2 diabetes is not fully understood in youth, the timing of this progression appears to be shorter and less predictable compared with adults.<sup>6,7</sup>

The major acute complications of type 2 diabetes in youth are diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS), which can both result in death if left untreated.<sup>8</sup> Rates of DKA have been decreasing over time with the most recent estimates from 2008 to 2014 indicating that 6 percent to 11 percent of youths with type 2 diabetes had DKA at presentation.<sup>6, 9-11</sup> Higher prevalence of DKA has been associated with younger age at diagnosis, minority race/ethnicity, male gender, and lower family income and parental education.<sup>6, 10</sup> Although less frequent than DKA, the incidence of HHS in youth is increasing.<sup>12, 13</sup> A 2016 study found HHS in 2 percent of youth at diagnosis of diabetes.<sup>9</sup> HHS also appears to be more frequent in non-Hispanic black youths and Hispanic youths than in non-Hispanic white youths.<sup>6</sup>

Youth with type 2 diabetes have an increased prevalence of associated chronic comorbidities, including hypertension, dyslipidemia, and nonalcoholic fatty liver disease. Development of type 2 diabetes during childhood or adolescence results in a longer duration of exposure to a dysfunctional metabolic milieu over the lifetime. This may result in an increased risk of chronic microvascular complications including retinopathy, nephropathy, and neuropathy compared with those who develop type 2 diabetes in adulthood. The impacts on macrovascular complications such as cardiovascular and renal disease and long-term mortality have not been well studied in youth. However, in a study of Pima Indian youth, those with onset of type 2 diabetes before 20 years of age had mortality rates at aged 20 to 54 years that were 2.1 times higher than among persons with diabetes onset at or after age 20 years and 3.1 times higher than nondiabetic persons.<sup>14</sup>

Relatively few data are available to ascertain the natural history of prediabetes in youth. Placebo arms of randomized, controlled trials (RCTs) have found that anywhere from 22 percent to 52 percent of children and adolescents with prediabetes returned to normal glycemia or normal glucose tolerance without intervention over 6 months to 2 years (Contextual Question [CQ] 1 in **Appendix A**).

## Risk Factors

Obesity and excess adipose tissue (especially when centrally distributed) are the most important risk factors for type 2 diabetes in youth.<sup>15-17</sup> The SEARCH for Diabetes in Youth study (SEARCH) reported that between 2001 and 2004 nearly 80 percent of youth with type 2 diabetes were obese and that an additional 10 percent were overweight.<sup>16</sup> Family history is a strong risk factor, with estimates that 50 to 75 percent of youth with type 2 diabetes have at least one parent with type 2 diabetes and nearly 90 percent may have a positive family history if grandparents are also included.<sup>18-21</sup>

The vast majority of pediatric cases occur after age 10, with the peak age for presentation occurring at mid-puberty (approximately age 14 years).<sup>22, 23</sup> This timing is likely related to the physiologic, but transient, pubertal insulin resistance that can aggravate the preexisting metabolic challenges of obesity.<sup>17, 24, 25</sup> Some studies indicate that adolescent girls are 1.3 to 1.7 times more likely than boys to be diagnosed with type 2 diabetes, although the reasons are not well understood.<sup>15, 19, 26, 27</sup> Research suggests that maternal obesity and gestational diabetes contribute to obesity and type 2 diabetes in youth.<sup>6, 17</sup> For example, in the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) cohort, one third of youth with type 2 diabetes had



been born after a pregnancy complicated by preexisting diabetes or gestational diabetes mellitus.<sup>17</sup>

A review summarizing differences in the frequencies of type 2 diabetes by race, ethnicity, socioeconomic position, area of residence, and environmental toxins noted that the causes of differences (e.g., between different racial and ethnic groups) are not well understood.<sup>28</sup> Compared with the type 2 diabetes rate in non-Hispanic white youth, the rate in Native American, African American, and Hispanic youth has been shown to be 8, 5, and 4 times higher, respectively.<sup>26</sup> The relative contributions of various factors to racial/ethnic differences are largely unknown.<sup>28</sup> As with many other health disparities,<sup>29-31</sup> structural factors that disproportionately affect nonwhite populations (e.g., toxic stress, structural and interpersonal racism, economic inequities) may contribute significantly to differences by race/ethnicity. Other potential contributing factors include metabolic characteristics, cultural/environmental influences, and quality of and access to healthcare.<sup>17</sup>

CQ 5 (**Appendix A**) summarizes risk assessment tools that are feasible for use in primary care settings, accurately predict the risk of prediabetes or type 2 diabetes for children and adolescents, and have been externally validated in U.S. populations. Briefly, two such tools were identified: one using an automated computer system based on ADA guidelines and one that adapted the Tool for Assessing Glucose Impairment (TAG-IT) adult risk assessment tool for pediatrics.

## Prevalence and Burden

The 2017–2018 National Health Interview Survey from the Centers for Disease Control and Prevention (CDC) estimated that 210,000 children and adolescents younger than age 20 years (or 2.5 per 1,000 U.S. youths) had been diagnosed with diabetes, of which approximately 23,000 had type 2 diabetes.<sup>32</sup>

Most prevalence and incidence data on type 2 diabetes in children come from a limited number of subjects from the SEARCH for Diabetes in Youth Study, a population-based study of children under age 20 years in several geographic regions (county-based from 4 states, insurance-based from 1 state, and from select Native American reservations from 2 additional states) that the CDC and National Institutes of Health have funded since 2000. It found that of 3.5 million children under age 20 years in 2009, 837 (or 0.24 per 1,000) had type 2 diabetes. Based on these data, an estimated 20,262 youth under age 20 years had type 2 diabetes in the United States at that time.<sup>33</sup> This same dataset found that the prevalence of type 2 diabetes was highest in American Indian/American Native (0.63/1,000), black (0.56/1,000), and Hispanic (0.40/1,000) youth and lowest in Asian/Pacific Islander (0.19/1,000) and non-Hispanic white (0.09/1,000) youth.<sup>33</sup> The generalizability of this demographics data is uncertain. It is limited by its small sample size (fewer than 900 people contributing to the data) and selection from particular geographic regions, insurance coverage, and/or specific reservations with low numbers in each.

Data indicate that the prevalence and incidence of type 2 diabetes are rising; in 2001, the overall prevalence of type 2 diabetes in children ages 10 to 19 years was 0.34 per 1,000 and in 2009 was 0.46 per 1,000.<sup>26</sup> SEARCH found that 5,758 children and adolescents ages 10 to 19 years were diagnosed with type 2 diabetes from 2014 to 2015, and the overall incidence of type 2 diabetes in

10- to 19-year-olds has increased significantly from an incidence rate of 0.09 per 1,000 in 2002 to 2003 to 0.14 per 1,000 in 2014 to 2015.<sup>34</sup>

Most of that increase in the incidence rate is in nonwhite and non-Asian children and adolescents. The incidence rate in non-Hispanic white children remained stable between 0.04 and 0.05 children per 1,000 between 2002 and 2015 and for Asian/Pacific Islander children between 0.11 and 0.12 per 1,000 between 2002 and 2015. During the same time period, the incidence rate in non-Hispanic black children increased from 0.20 to 0.38 per 1,000, in Hispanic children the rate increased from 0.13 to 0.21 per 1,000, and in American Indian children (from primarily one southwestern tribe) the rate increased from 0.23 to 0.33 per 1,000.<sup>34</sup>

Children who are obese and overweight are more likely to develop type 2 diabetes than peers who are underweight or who are at a healthy weight. This association between weight and diabetes is stronger in children than in adults.<sup>15</sup> SEARCH data from 2001 to 2004 showed that about 80 percent of 400 children with type 2 diabetes were obese and 10 percent were overweight (compared with 17% of children without diabetes being obese).<sup>16</sup>

Type 2 diabetes is more common in older than younger children, often presenting at the onset of puberty.<sup>27</sup> It is estimated that, based on 2009 SEARCH data, 74 percent of pediatric type 2 diabetes cases are in youths ages 15 to 19 years, 23 percent are in those ages 10 to 14 years, and only 2 percent are in those ages 5 to 9 years.<sup>33</sup>

In terms of burden of disease, diabetes (both type 1 and type 2) is the third most common chronic disease in childhood.<sup>35</sup> In all age groups (not limited to children and adolescents), diabetes was estimated to be the seventh leading cause of overall death in the United States in 2015 based on the Underlying Cause of Death database.<sup>36</sup> Approximately 3 percent of deaths (79,535 of 2,712,630 total deaths) were attributed to diabetes based on death certifications for U.S. residents. Cause of death was based on International Classification of Diseases, Tenth Revision codes, and estimates do not differentiate between type of diabetes. Morbidity from type 2 diabetes is due to both macrovascular disease (atherosclerosis) and microvascular disease (retinopathy, nephropathy, and neuropathy). Complications may begin in childhood or later in adulthood. Among those with type 2 diabetes diagnosed during childhood and adolescence, an estimated 19.9 percent, 9.1 percent, and 17.7 percent had complications of kidney disease, retinopathy, and peripheral neuropathy, respectively, during teenage years and young adulthood.<sup>37</sup> Diabetes is the leading cause of kidney failure, lower-limb amputations other than those caused by injury, and new cases of blindness among adults of all age groups in the United States.<sup>38</sup> Estimates based on results of the Global Burden of Disease Study indicate that diabetes was the third leading cause of years lived with disability in 2016, which is an approximate 30 percent increase from 1990 (when it ranked eighth).<sup>39</sup> In terms of causes of disability-adjusted life-years in the United States, diabetes ranked fourth in 2016, an increase from the sixth leading cause in 1990 (an approximate 11% change).<sup>39</sup>

## **Rationale for Screening and Screening Strategies**

Screening asymptomatic at-risk children and adolescents for prediabetes and type 2 diabetes may allow earlier detection, diagnosis, and interventions for both conditions, with the goal of improving health outcomes by preventing serious complications from type 2 diabetes. In children

and adolescents, earlier detection of prediabetes may lead to interventions to prevent or delay progression to type 2 diabetes.<sup>40</sup> Early diagnosis of type 2 diabetes could potentially lead to earlier treatment to prevent diabetic complications.<sup>41-44</sup> Early diagnosis also may enable clinicians to treat patients with diabetes more effectively without requiring insulin. Strategies for screening for prediabetes and type 2 diabetes generally involve targeted screening of children who are overweight or obese for the presence of one or more risk factors (e.g., type 2 diabetes in a first- or second-degree relative, member of a high-risk racial/ethnic group, maternal history of diabetes or gestational diabetes) followed by fasting glucose, hemoglobin A1c, or OGTT.<sup>1, 45, 46</sup>

## Treatment Approaches

### For Reducing Progression From Prediabetes to Diabetes

Lifestyle interventions to achieve weight loss and increase physical activity are the first-line therapies for preventing progression of prediabetes to diabetes. ADA guidance underlines the value healthy nutrition plays in preventing diabetes, with particular emphasis on the avoidance of sugar-sweetened beverages and sugary snacks.<sup>47</sup> The U.S. Food and Drug Administration (FDA) has not approved any medications to prevent progression of prediabetes to diabetes for any age group, nor has the Canadian Medicare System.<sup>48, 49</sup> Some studies in children and adolescents have shown that metformin can improve metabolic parameters such as body mass index (BMI), fasting glucose, and insulin resistance index.<sup>50</sup>

### Management of Diabetes in Children

Goals for HbA1c and fasting glucose levels are the same for children as for adults.<sup>47</sup> Lifestyle interventions are included in first-line therapies for children and adolescents diagnosed with diabetes. Modifications to lifestyle choices, such as increased exercise and improved nutrition, are recommended by the ADA, CDC, and National Institute for Health and Care Excellence.<sup>51, 52</sup> It is recommended that these programs be accompanied by extensive education campaigns on promoting awareness and self-management skills, including establishing individualized regimes for self-monitoring of glycemic targets. Formal programs to improve diet and increase exercise are often paired with pharmacotherapy as first-line therapy.<sup>47, 53</sup>

The FDA has approved three drugs for treatment of type 2 diabetes in children: metformin, insulin, and liraglutide. Metformin is the initial preferred pharmacological treatment for mild to moderate hyperglycemia (HbA1c<8.5%) without metabolic complications. The ADA recommends starting with both basal insulin and metformin if there is marked hyperglycemia (but no ketosis) and insulin alone for those with ketosis. Insulin can be tapered and metformin used as a single therapy if glycemic targets are met.<sup>54</sup> The ADA recommends considering liraglutide therapy if glycemic targets are no longer met with metformin (with or without basal insulin) for children age 10 years or older if they have no past medical history or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.<sup>47</sup> It also notes that the use of medications not approved by the FDA for youth with type 2 diabetes is not recommended outside of research trials.<sup>47</sup> These non-FDA-approved medications include thiazolidinediones (rosiglitazone, pioglitazone), sulfonylureas (glyburide, glimepiride), dipeptidyl peptidase 4 inhibitors (saxagliptin, alogliptin, linagliptin), alpha glucosidase inhibitors (acarbose, miglitol), sodium-glucose cotransporter-2 (SGLT2) inhibitors (canagliflozin, dapagliflozin, empagliflozin),

glucagon-like peptide-1 (GLP1) receptor agonists other than liraglutide (exenatide, dulaglutide, semaglutide, lixisenatide), and meglitinides and have been assessed for type 2 diabetes treatment in children in a number of small pilot studies and case reports. Some professionals recommend anti-obesity drugs (orlistat) and bariatric surgery to treat some children and adolescents who are obese who also have diabetes.<sup>52, 55</sup>

## **Other Treatments to Reduce Cardiovascular Disease Risk and Complications**

Complications of diabetes include nephropathy, neuropathy, retinopathy, and cardiovascular disease. To detect the presence of comorbidities, the ADA recommends blood pressure measurement, a fasting lipid panel, assessment of random urine albumin-to-creatinine ratio, and a dilated eye examination at the time of the diabetes diagnosis.<sup>54</sup> Treatments to decrease cardiovascular risk can include antihypertensive medications. Management to decrease microvascular complications includes routine eye exams for retinopathy, urinary albumin excretion for nephropathy, and foot exams for neuropathy. The ADA encourages the cessation or abstinence of smoking and substance use in children and young adults with type 2 diabetes because it may increase their risk of cardiovascular and blood glucose control problems.

## **Clinical Practice in the United States and Recommendations of Other Organizations**

In recent years, several U.S. and international professional organizations have issued recommendations for screening asymptomatic at-risk children and adolescents for prediabetes and type 2 diabetes (**Appendix A Table 1**). In 2020, the ADA published a position statement on managing youth-onset type 2 diabetes.<sup>47</sup> The ADA recommends risk-based screening for type 2 diabetes in children after onset of puberty or age 10 years who are overweight (BMI  $\geq 85^{\text{th}}$  percentile) or obese (BMI  $\geq 95^{\text{th}}$  percentile) and have one or more additional risk factors for diabetes. Such additional risk factors include maternal history of diabetes or gestational diabetes mellitus during the child's gestation; family history of type 2 diabetes in first- or second-degree relative; being a member of a high-risk racial/ethnic group, including Native American, African American, Latino, Asian American, and Pacific Islander; or signs of insulin resistance or conditions associated with insulin resistance, including acanthosis nigricans, hypertension, dyslipidemia, polycystic ovary syndrome, or small-for-gestational-age birth weight.<sup>17</sup> In terms of screening frequency, the ADA recommends screening to be repeated every 3 years if tests are normal or more frequently if BMI increases.<sup>47</sup> The ADA recommends testing with fasting plasma glucose, 2-h plasma glucose (PG) after 75-g OGTT, or an A1c. Further, the ADA recommends that children and adolescents who are overweight or obese for whom the diagnosis of type 2 diabetes is being considered have a panel of pancreatic autoantibodies tested to exclude the possibility of autoimmune type 1 diabetes.

## Chapter 2. Methods

### Key Questions and Analytic Framework

The scope and key questions (KQs) were developed by the Evidence-based Practice Center (EPC) investigators, USPSTF members, and Agency for Healthcare Research and Quality (AHRQ) Medical Officers. The analytic framework and KQs that guided the review are shown in **Figure 1**. Six KQs were developed for this review:

1. Is there direct evidence that screening for type 2 diabetes and prediabetes in asymptomatic children and adolescents improves health outcomes?
2. What are the harms of screening for type 2 diabetes and prediabetes in asymptomatic children and adolescents?
3.
  - a. Do interventions for screen-detected type 2 diabetes and prediabetes provide an incremental benefit in health outcomes when delivered at the time of detection compared with initiating interventions later, after clinical diagnosis?
  - b. Do interventions for screen-detected type 2 diabetes and prediabetes improve health outcomes compared with no intervention, usual care, or interventions with different treatment targets?
  - c. Do interventions for recently diagnosed type 2 diabetes improve health outcomes compared with no intervention, usual care, or interventions with different treatment targets?
4. What are the harms of interventions for prediabetes, screen-detected type 2 diabetes, or recently diagnosed type 2 diabetes?
5. Do interventions for prediabetes delay or prevent progression to type 2 diabetes?
6. After interventions for prediabetes are provided, what is the magnitude of change in health outcomes that results from the reduction in type 2 diabetes incidence?

In addition to addressing the KQs, this review also looked for evidence related to five CQs that focused on progression from prediabetes to diabetes, whether screening or interventions change intermediate outcomes, agreement among screening tests, and risk assessment tools. These CQs were not a part of this systematic review. They are intended to provide additional background information. Literature addressing the CQs is summarized in **Appendix A**.

### Data Sources and Searches

PubMed/MEDLINE and the Cochrane Library were searched for English-language articles published through May 3, 2021. Medical Subject Headings were used as search terms when available and keywords when appropriate, focusing on terms to describe relevant populations, tests, interventions, outcomes, and study designs. Complete search terms and limits are listed in **Appendix B**. Targeted searches for unpublished literature were conducted by searching ClinicalTrials.gov. To supplement electronic searches, the reference lists of pertinent review articles and studies that met the inclusion criteria were reviewed. Studies suggested by peer reviewers or public comment respondents will also be reviewed and, if appropriate, will be incorporated into the final review. The same inclusion and exclusion criteria will be used to determine if the new citations should be incorporated into the review. Since May 3, 2021,

ongoing surveillance will be conducted through article alerts and targeted searches of journals to identify major studies published in the interim that may affect the conclusions or understanding of the evidence and the related USPSTF recommendation. The last surveillance was conducted on October 31, 2021 and no additional studies meeting eligibility criteria were identified. All literature search results were managed using EndNote™ version 9.2 (Thomson Reuters, New York, NY).

## Study Selection

Inclusion and exclusion criteria for populations, interventions, comparators, outcomes, timing, settings, and study designs were developed with input from the USPSTF (**Appendix B**). English-language studies of asymptomatic, nonpregnant people younger than age 18 conducted in countries categorized as very high on the 2019 Human Development Index were included. For all KQs, controlled clinical trials were eligible. Controlled prospective cohort studies were also eligible for KQs on harms (KQs 2 and 4) and the change in health outcomes after reduction in type 2 diabetes incidence (KQ 6); case-control studies were eligible for KQs on harms (KQs 2 and 4). For KQs 1 and 2 (direct evidence of benefits and harms of screening), studies that compared screening with A1c, fasting glucose, or OGTT with no screening or alternative screening strategies were eligible. For KQs 3 through 6 (benefits and harms of interventions), studies were eligible that evaluated primary care–relevant behavioral counseling interventions or pharmacologic interventions for glycemic control for prediabetes or type 2 diabetes.

Titles and abstracts were independently reviewed by two investigators; those marked for potential inclusion by either reviewer were retrieved for evaluation of the full text. The full texts were then independently reviewed by two investigators to determine final inclusion or exclusion. Disagreements were resolved by discussion and consensus.

## Quality Assessment and Data Abstraction

We assessed the quality of studies as good, fair, or poor, using predefined criteria developed by the USPSTF and adapted for this topic (**Appendix B**). Two independent investigators assigned quality ratings for each study. Disagreements were resolved by discussion. Only studies rated as having good or fair quality were included.

For each included study, one investigator extracted pertinent information about the methods, populations, interventions, comparators, outcomes, timing, settings, and study designs. All data extractions were checked by a second investigator for completeness and accuracy.

## Data Synthesis and Analysis

Findings for each KQ were summarized in tabular and narrative format. The overall strength of the evidence for each KQ was assessed as high, moderate, low, or insufficient based on the overall quality of the studies, consistency of results between studies, precision of findings, risk of reporting bias, and limitations of the body of evidence, using methods developed for the USPSTF (and the EPC program).<sup>56</sup> Additionally, the applicability of the findings to U.S. primary care populations and settings was assessed. Discrepancies were resolved through consensus discussion.

To determine whether meta-analyses were appropriate, the clinical and methodological heterogeneity of the studies was assessed according to established guidance.<sup>57</sup> The populations, tests, treatments, comparators, outcomes, and study designs were assessed qualitatively, looking for similarities and differences. Because of the limited number of similar studies for each KQ, meta-analyses were not conducted.

## **Expert Review and Public Comment**

A draft research plan for this topic was posted on the USPSTF website for public comment from July 30, 2020 to August 26, 2020. In response to comments, the USPSTF changed the title to include prediabetes, added socioeconomic status to the list of prespecified specific populations, clarified the eligibility of school-based health centers and community settings, and added more intermediate outcomes to the CQs. The final version of the research plan was posted on the USPSTF website on November 12, 2020. The draft evidence review will be reviewed by content experts, representatives of Federal partners, USPSTF members, and AHRQ Medical Officers and will be revised based on comments received, as appropriate. The draft evidence review will also be posted for public comment. Revisions will be made based on comments received, and any references suggested by expert or public reviewers will be evaluated for inclusion/exclusion.

## **USPSTF Involvement**

This review was funded by AHRQ. AHRQ staff and members of the USPSTF participated in developing the scope of work and reviewed draft reports, but the authors are solely responsible for the content.

# Chapter 3. Results

## Literature Search

We identified 4,334 unique records and assessed 523 full-text articles for eligibility (**Figure 2**). We excluded 515 articles for various reasons, detailed in **Appendix C**, and included eight articles representing three studies. Details of quality assessments of included studies are in **Appendix D Tables 1 and 2**.

## Results by Key Question

### **KQ 1. Is There Direct Evidence That Screening for Type 2 Diabetes and Prediabetes in Asymptomatic Children and Adolescents Improves Health Outcomes?**

We found no eligible studies that addressed this question.

### **KQ 2. What Are the Harms of Screening for Type 2 Diabetes and Prediabetes in Asymptomatic Children and Adolescents?**

We found no eligible studies that addressed this question.

### **KQ 3a. Do Interventions for Screen-Detected Type 2 Diabetes and Prediabetes Provide an Incremental Benefit in Health Outcomes When Delivered at the Time of Detection Compared With Initiating Interventions Later, After Clinical Diagnosis?**

We found no eligible studies that addressed this question.

### **KQ 3b. Do Interventions for Screen-Detected Type 2 Diabetes and Prediabetes Improve Health Outcomes Compared With No Intervention, Usual Care, or Interventions With Different Treatment Targets?**

We found no eligible studies that addressed this question.

### **KQ 3c. Do Interventions for Recently Diagnosed Type 2 Diabetes Improve Health Outcomes Compared With No Intervention, Usual Care, or Interventions With Different Treatment Targets?**

In summary, one included RCT (699 participants) that focused on intermediate outcomes reported that two youths with type 2 diabetes developed renal impairment and 11 developed DKA, finding no significant difference between treatments (metformin, metformin rosiglitazone,



and metformin plus a lifestyle intervention). One smaller trial reported that one person in the placebo control group developed DKA. No eligible studies reported on other health outcomes.

### **Characteristics of Included Studies**

We included two RCTs (described in 7 articles) (**Table 3**).<sup>53, 58-63</sup> One was rated as good quality and one was rated as fair quality. The one good-quality RCT (described in 6 articles) enrolled 699 participants and evaluated interventions for recently diagnosed type 2 diabetes.<sup>53, 58-62</sup> The Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study was a 15-site multicenter trial conducted in the United States. The trial randomized adolescents who were obese (BMI  $\geq$ 85th percentile for age and sex) with recently diagnosed type 2 diabetes to metformin monotherapy, metformin plus rosiglitazone, or metformin plus a lifestyle intervention. Prior to randomization, all participants completed a run-in of 2 to 6 months that involved weaning from nonstudy diabetes medications, initiating metformin at a dose of up to 1,000 mg twice daily, attaining glycemic control with metformin alone (A1c $<$ 8.0%), providing standard diabetes education and ensuring the participants' mastery of the material, and confirming adherence. The mean age of participants was 14; mean BMI was 35 kg/m<sup>2</sup>; mean baseline A1c values were 7.0 to 7.3 percent across the three study groups; 65 percent were female; 79 percent were nonwhite, 32.5 percent were non-Hispanic black, 39.7 percent were Hispanic, and 20.3 percent were non-Hispanic white. The duration of followup ranged from 2 to 6.5 years (mean 3.8 years). The lifestyle intervention focused on diet/nutrition, physical activity, and family support. The program included three phases of in-person contacts: once weekly for the first 6 to 8 months, twice-weekly for months 6 to 8 through months 12 to 16, and then once-monthly until the end of the study. The primary outcome of the trial was loss of glycemic control, defined as HbA1c level of at least 8 percent for 6 months or sustained metabolic decompensation requiring insulin (described in CQ 2), and the study focused largely on intermediate outcomes (e.g., glycemic control, BMI) rather than on health outcomes.

The second trial<sup>63</sup> compared metformin and placebo in 82 treatment-naïve adolescents ages 10 to 16 years with previous or newly diagnosed type 2 diabetes.<sup>63</sup> It was a 16-week double-blind placebo-controlled trial of 82 adolescents recruited from 44 sites in multiple countries, including the United States, Russia, Belarus, Ukraine, and Poland. Most participants were from the U.S. sites. The intervention group received up to 2,000 mg daily of metformin for 16 weeks. The mean age of participants was 13; mean BMI was 34 kg/m<sup>2</sup>; mean baseline A1c values were 8.3 to 9.0 percent across the study groups; 69 percent were female; and 63 percent were nonwhite. The primary outcome was change in fasting PG from baseline (described in CQ 2).

### **Renal Impairment**

The TODAY study reported two cases of renal impairment (**Table 4**). One case was in the metformin plus rosiglitazone group, and one was in the metformin plus lifestyle intervention group (p=1.00). Renal impairment was defined as an estimated creatinine clearance of less than 70 ml per minute or a serum creatinine of more than 1.5 mg/dl.

### **Diabetic Ketoacidosis**

The TODAY study reported that 11 participants developed DKA. There was no statistically

significant difference across treatment groups (5 [2.1%] vs. 3 [1.3%] vs. 3 [1.3%],  $p=0.70$ , for metformin monotherapy vs. metformin plus rosiglitazone vs. metformin plus lifestyle, respectively). The smaller trial reported that zero participants in the metformin group developed DKA and that one person in the control group developed DKA.

### **Other Health Outcomes**

No eligible studies reported other health outcomes, including mortality, cardiovascular morbidity (including myocardial infarction, stroke, congestive heart failure), amputation, skin ulcers, visual impairment (including blindness), neuropathy, and quality of life.

## **KQ 4. What Are the Harms of Interventions for Prediabetes, Screen-Detected Type 2 Diabetes, or Recently Diagnosed Type 2 Diabetes?**

Overall, two RCTs that enrolled youths with recently diagnosed type 2 diabetes were eligible. The two trials assessed different comparisons. Major hypoglycemic events were reported by less than 1 percent of participants. Minor hypoglycemic events were more common among youths treated with metformin plus rosiglitazone than among those treated with metformin or metformin plus lifestyle. In one study, gastrointestinal (GI) adverse events were more commonly reported by those taking metformin than by those taking placebo. GI adverse events, infections, and muscle aches and pains were less common among youths treated with metformin plus rosiglitazone than with metformin alone or metformin plus a lifestyle intervention. No eligible studies assessed harms for youths with screen-detected diabetes or prediabetes, and no eligible studies reported on harms of lifestyle interventions provided without pharmacotherapy.

### **Harms of Interventions for Recently Diagnosed Type 2 Diabetes**

Two RCTs (described in 7 articles) reported on harms of interventions for recently diagnosed type 2 diabetes (**Table 3**).<sup>53, 58-63</sup> The TODAY trial is described above in KQ 3; it compared metformin monotherapy, metformin plus rosiglitazone, or metformin plus a lifestyle intervention. The second trial<sup>63</sup> was also described in KQ 3; it reported on harms related to metformin (up to 2,000 mg daily) compared with placebo in treatment-naïve adolescents ages 10 to 16 years with previous or newly diagnosed type 2 diabetes.<sup>63</sup> The duration of followup ranged from 16 weeks<sup>63</sup> to a mean of 3.8 years (TODAY). Both studies reported on withdrawals, hypoglycemic events requiring medical attention, gastrointestinal adverse events, and lactic acidosis (**Table 5**). The TODAY study reported on other adverse events, including rash, infection, sprain or fracture, muscle ache or pain, anemia, and edema. The TODAY study reported zero deaths during the trial.

### **Hypoglycemic Events**

Serious hypoglycemic events requiring medical attention were reported in both trials and were rare (**Table 5**). The TODAY study reported that four youths had severe hypoglycemia (1 [0.4%] vs. 1 [0.4%] vs. 2 [0.8%] for metformin monotherapy vs. metformin plus rosiglitazone vs. metformin plus lifestyle, respectively,  $p=1.00$ ). It also reported that more youths had repeated mild hypoglycemia in the group that received metformin plus rosiglitazone (10 [4.3%] vs. 19 [8.2%] vs. 8 [3.4%] for metformin monotherapy vs. metformin plus rosiglitazone vs. metformin

plus lifestyle, respectively,  $p=0.05$ ). The 16-week trial<sup>63</sup> comparing metformin monotherapy with placebo reported zero hypoglycemic events requiring medical attention in either study group.

### **Gastrointestinal Adverse Events**

GI adverse events were common in both studies. The TODAY study reported lower rates of GI symptoms in the metformin plus rosiglitazone group than in the metformin monotherapy or metformin plus lifestyle intervention groups (129 [55.6%] vs. 100 [42.9%] vs. 136 [58.1%], for metformin monotherapy vs. metformin plus rosiglitazone vs. metformin plus lifestyle, respectively,  $p=0.002$ ). The 16-week trial<sup>63</sup> reported that more youths treated with metformin than with placebo had abdominal pain (25% vs. 12%,  $p$  not reported) and nausea or vomiting (17% vs. 10%,  $p$  not reported).

### **Other Adverse Events**

Both studies reported other adverse events; types of events reported (and definitions) varied and most found no difference between groups or reported that no adverse events were attributed to study interventions (**Table 5**). The TODAY study found higher rates of infection ( $p=0.005$ ) and muscle ache or pain ( $p=0.05$ ) in the metformin monotherapy and metformin plus lifestyle intervention groups than in the metformin plus rosiglitazone group. The TODAY study reported on rash, sprain or fracture, anemia, and edema, but found no statistically significant difference between groups. The TODAY study reported that one participant in the metformin plus rosiglitazone group developed heart failure and one participant in the metformin monotherapy group developed lactic acidosis. The 16-week trial<sup>63</sup> reported that few participants had serious adverse events, all deemed unrelated to the study drug.

## **KQ 5. Do Interventions for Prediabetes Delay or Prevent Progression to Type 2 Diabetes?**

In summary, the one included study reported no evidence that lifestyle interventions were associated with a reduction in the incidence of diabetes, although followup was only 6 months and the study had zero participants progress to type 2 diabetes in either group. No eligible studies that evaluated pharmacologic interventions were identified.

### **Study Characteristics**

We included one fair-quality RCT (75 participants) that compared the Bright Bodies Healthy Lifestyle Program with standard care for adolescents who were obese ( $BMI > 95^{\text{th}}$  percentile) ages 10 to 16 years with prediabetes (**Table 3**).<sup>64</sup> The trial was conducted in the United States in a pediatric obesity clinic starting in September 2009. Regarding prediabetes ascertainment, the trial focused on IGT for participant eligibility, defined as an elevated 2-h OGTT (after a glucose load of 1.75 g/kg, maximum 75 g) result between 130 and 199 mg/dL (using a range that was slightly wider than the current prediabetes criteria of 140 to 199 mg/dL). The mean age of participants was 12, mean BMI was 33 kg/m<sup>2</sup>, mean baseline A1c was 5.6 to 5.7 across the groups, 64 percent were female, and 31 percent were nonwhite. The duration of followup was 6 months. The lifestyle program focused on both diet/nutrition and physical activity. The high-contact program included twice-weekly 50-minute exercise classes, a once-weekly weigh-in, and

a one-time 40-minute nutrition/behavior modification class (all administered in group settings). Participants were encouraged to exercise 3 additional days per week and record the duration and type of exercise. The study used raffle tickets for gift cards to motivate participants; tickets could be earned if weight stayed the same or decreased and, in some cases, for returning their weekly exercise log. The trial was rated as fair quality mainly because of the overall attrition (of 23%) and having some participants withdrawn because of starting metformin (**Appendix D**).

The primary outcome of the trial was the 6-month change in PG 2 hours after OGTT (intermediate outcomes are described in CQs 2 and 3). The trial reported that zero participants developed diabetes during the trial (**Table 4**).

### **KQ 6. After Interventions for Prediabetes Are Provided, What Is the Magnitude of Change in Health Outcomes That Results From the Reduction in Type 2 Diabetes Incidence?**

We found no eligible studies that addressed this question.

# Chapter 4. Discussion

## Summary of Evidence

**Table 6** provides a summary of the main findings in this evidence review organized by KQ along with a description of consistency, precision, quality, limitations, strength of evidence, and applicability. Overall, limited data were eligible for this review, and the strength of evidence was graded as insufficient or low for all KQs.

### Evidence for Benefit and Harms of Screening

This review found no eligible studies that directly addressed the overarching question (i.e., no studies evaluated screening for prediabetes or type 2 diabetes among asymptomatic youths compared with no screening or alternative screening strategies). Therefore, the strength of evidence was graded as insufficient for KQs 1 and 2.

### Benefits of Interventions for Screen-Detected or Recently Diagnosed Diabetes

For screen-detected diabetes, this review found no eligible studies. For recently diagnosed diabetes, two eligible trials were identified. Evidence from one RCT (TODAY) designed to evaluate intermediate outcomes reported very few health outcomes, finding no difference between groups for renal impairment in adolescents who were obese treated with metformin only versus metformin plus rosiglitazone versus metformin plus a lifestyle intervention, and finding no difference for DKA. The other trial reported that 1 adolescent with diabetes in the placebo group developed DKA compared with zero in the metformin group. The strength of evidence was graded as insufficient because of unknown consistency, substantial imprecision, and a duration of followup likely insufficient to assess health outcomes.

CQs 2 and 3 (**Appendix A**) address whether interventions for children and adolescents with screen-detected or recently diagnosed type 2 diabetes or prediabetes change intermediate outcomes. In summary, CQ 2 found that, among those recently diagnosed with type 2 diabetes, lifestyle and pharmacological interventions (metformin, rosiglitazone, liraglutide) improved glycemia, but data were limited or lacking about the impact of pharmacological interventions on other intermediate outcomes (microalbuminuria, subclinical retinopathy, subclinical neuropathy). CQ 3 found that, for those with diabetes, metformin alone and metformin plus a lifestyle intervention were associated with decreases in BMI and weight when compared with metformin plus rosiglitazone in TODAY,<sup>18, 53, 65, 66</sup> but another study reported that metformin was not associated with significant changes when compared with control.<sup>63</sup>

### Benefits of Interventions for Prediabetes

This review found one eligible trial that assessed whether lifestyle interventions for prediabetes can help prevent progression to type 2 diabetes. However, the strength of evidence was graded as insufficient because followup was only 6 months, results were imprecise (with zero events in either group), consistency is unknown (single study), and the study had high attrition. Among

adults who were obese and overweight, recent meta-analyses for the USPSTF found high strength of evidence that lifestyle interventions were associated with reduction in the incidence of diabetes in trials with followup ranging from less than 1 year to 30 years (pooled relative risk, 0.78 [95% confidence interval {CI}, 0.69 to 0.88], 23 trials, 12,915 participants).<sup>67</sup>

CQs 2 and 3 (**Appendix A**) address whether interventions for children and adolescents with screen-detected or recently diagnosed type 2 diabetes or prediabetes change intermediate outcomes. In summary, CQ 2 found that, among those with prediabetes, lifestyle interventions improved 2-h glucose (after OGTT), but not fasting glucose or A1c in one trial, and data on rosiglitazone were inconclusive because of early trial discontinuation. CQ 3 found that lifestyle interventions for children and adolescents with prediabetes improved weight and BMI compared with controls in one study<sup>64</sup> and that prediabetes identification was associated with decreases in BMI in adolescents who were obese and overweight.<sup>68</sup>

## **Harms of Interventions for Prediabetes or Type 2 Diabetes**

Low strength of evidence from the two included trials indicates that minor hypoglycemic events were more common among youths treated with metformin plus rosiglitazone than among those treated with metformin or metformin plus lifestyle; GI adverse effects were commonly associated with metformin; and GI adverse events, infections, and muscle aches and pains were more common among youths treated with metformin and metformin plus a lifestyle intervention than with metformin plus rosiglitazone. The strength of evidence was downgraded to low because of imprecision, unknown consistency (studies assessed different comparisons), and one study was rated as medium risk of bias.

## **Limitations**

This review has limitations. The limitations of the included studies are discussed above in Results and Discussion. Here we focus on limitations of this review. We excluded non-English-language articles. This review was limited to asymptomatic children and focused on the overarching question of screening for prediabetes or type 2 diabetes. This review did not evaluate diagnostic testing of symptomatic children or those with signs of insulin resistance, diagnostic testing of children with conditions associated with insulin resistance, or screening for type 1 diabetes. This review excluded studies limited to or predominately comprising adults or pregnant women and children and adolescents with symptomatic diabetes (e.g., weight loss, polyuria, blurred vision, headache). For studies of recently diagnosed diabetes, this review excluded studies of children and adolescents who had diabetes for more than 1 year or with more advanced diabetes, aiming to identify the studies with good applicability to a screen-detected population.

## **Future Research Needs**

Screening trials of sufficient duration and sample size that focus on health outcomes are needed, as are eligible studies evaluating interventions for prediabetes and screen-detected type 2 diabetes among children and adolescents.

## Conclusion

No eligible studies directly evaluated the benefits or harms of screening for prediabetes and type 2 diabetes in children and adolescents. For youths with prediabetes or recently diagnosed (not screen-detected) diabetes, the only eligible trials reported few health outcomes and found no difference between groups, although evidence was limited by substantial imprecision and a duration of followup likely insufficient to assess health outcomes. Limited data showed that the combination of rosiglitazone plus metformin was associated with hypoglycemic events (compared with metformin alone or metformin plus lifestyle) and that metformin was associated with gastrointestinal adverse events, consistent with studies conducted in adults.

## References

1. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. *Diabetes Care*. 2020 Jan;43(Suppl 1):S14-S31. doi: 10.2337/dc20-S002. PMID: 31862745.
2. American Diabetes A. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2013 Jan;36 Suppl 1:S67-74. doi: 10.2337/dc13-S067. PMID: 23264425.
3. Elder DA, Hornung LN, Khoury JC, et al. Beta-cell function over time in adolescents with new type 2 diabetes and obese adolescents without diabetes. *J Adolesc Health*. 2017 Dec;61(6):703-8. doi: 10.1016/j.jadohealth.2017.06.007. PMID: 28935388.
4. Weiss R, Caprio S, Trombetta M, et al. Beta-cell function across the spectrum of glucose tolerance in obese youth. *Diabetes*. 2005 Jun;54(6):1735-43. doi: 10.2337/diabetes.54.6.1735. PMID: 15919795.
5. Elder DA, Hornung LN, Herbers PM, et al. Rapid deterioration of insulin secretion in obese adolescents preceding the onset of type 2 diabetes. *J Pediatr*. 2015 Mar;166(3):672-8. doi: 10.1016/j.jpeds.2014.11.029. PMID: 25557969.
6. Dabelea D, Hamman RF, Knowler WC. Chapter 15. Diabetes in youth. In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, et al., eds. *Diabetes in America*. 3rd ed. Bethesda, MD: National Institutes of Health; 2018.
7. Weiss R, Taksali SE, Tamborlane WV, et al. Predictors of changes in glucose tolerance status in obese youth. *Diabetes Care*. 2005 Apr;28(4):902-9. doi: 10.2337/diacare.28.4.902. PMID: 15793193.
8. Wolfsdorf JI, Glaser N, Agus M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: diabetic ketoacidosis and the hyperglycemic hyperosmolar state. *Pediatr Diabetes*. 2018 Oct;19 Suppl 27:155-77. doi: 10.1111/pedi.12701. PMID: 29900641.
9. Klingensmith GJ, Connor CG, Ruedy KJ, et al. Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium. *Pediatr Diabetes*. 2016 Jun;17(4):266-73. doi: 10.1111/pedi.12281. PMID: 25951940.
10. Dabelea D, Rewers A, Stafford JM, et al. Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study. *Pediatrics*. 2014 Apr;133(4):e938-45. doi: 10.1542/peds.2013-2795. PMID: 24685959.
11. Rewers A, Klingensmith G, Davis C, et al. Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: the Search for Diabetes in Youth Study. *Pediatrics*. 2008 May;121(5):e1258-66. doi: 10.1542/peds.2007-1105. PMID: 18450868.
12. Canarie MF, Bogue CW, Banasiak KJ, et al. Decompensated hyperglycemic hyperosmolarity without significant ketoacidosis in the adolescent and young adult population. *J Pediatr Endocrinol Metab*. 2007 Oct;20(10):1115-24. doi: 10.1515/jpem.2007.20.10.1115. PMID: 18051930.
13. Rosenbloom AL. Hyperglycemic hyperosmolar state: an emerging pediatric problem. *J Pediatr*. 2010 Feb;156(2):180-4. doi: 10.1016/j.jpeds.2009.11.057. PMID: 20105637.
14. Pavkov ME, Bennett PH, Knowler WC, et al. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. *JAMA*. 2006 Jul 26;296(4):421-6. doi: 10.1001/jama.296.4.421. PMID: 16868300.
15. Awa WL, Fach E, Krakow D, et al. Type 2 diabetes from pediatric to geriatric age: analysis of gender and obesity among 120,183 patients from the German/Austrian DPV



- database. *Eur J Endocrinol*. 2012 Aug;167(2):245-54. doi: 10.1530/EJE-12-0143. PMID: 22645200.
16. Liu LL, Lawrence JM, Davis C, et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. *Pediatr Diabetes*. 2010 Feb;11(1):4-11. doi: 10.1111/j.1399-5448.2009.00519.x. PMID: 19473302.
  17. Arslanian S, Bacha F, Grey M, et al. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association. *Diabetes Care*. 2018 Dec;41(12):2648-68. doi: 10.2337/dci18-0052. PMID: 30425094.
  18. Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. *J Clin Endocrinol Metab*. 2011 Jan;96(1):159-67. doi: 10.1210/jc.2010-1642. PMID: 20962021.
  19. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. *J Pediatr*. 2000 May;136(5):664-72. doi: 10.1067/mpd.2000.105141. PMID: 10802501.
  20. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. *J Pediatr*. 2005 May;146(5):693-700. doi: 10.1016/j.jpeds.2004.12.042. PMID: 15870677.
  21. Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham Offspring Study. *Diabetes*. 2000 Dec;49(12):2201-7. doi: 10.2337/diabetes.49.12.2201. PMID: 11118026.
  22. American Diabetes Association. Type 2 diabetes in children and adolescents. *Diabetes Care*. 2000 Mar;23(3):381-9. doi: 10.2337/diacare.23.3.381. PMID: 10868870.
  23. Writing Group for the Search for Diabetes in Youth Study Group, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States. *JAMA*. 2007 Jun 27;297(24):2716-24. doi: 10.1001/jama.297.24.2716. PMID: 17595272.
  24. Ball GD, Huang TT, Gower BA, et al. Longitudinal changes in insulin sensitivity, insulin secretion, and beta-cell function during puberty. *J Pediatr*. 2006 Jan;148(1):16-22. doi: 10.1016/j.jpeds.2005.08.059. PMID: 16423592.
  25. Amiel SA, Sherwin RS, Simonson DC, et al. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. *N Engl J Med*. 1986 Jul 24;315(4):215-9. doi: 10.1056/NEJM198607243150402. PMID: 3523245.
  26. Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. *JAMA*. 2014 May 7;311(17):1778-86. doi: 10.1001/jama.2014.3201. PMID: 24794371.
  27. Pinhas-Hamiel O, Dolan LM, Daniels SR, et al. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. *J Pediatr*. 1996 May;128(5 Pt 1):608-15. doi: 10.1016/s0022-3476(96)80124-7. PMID: 8627431.
  28. Golden SH, Yajnik C, Phatak S, et al. Racial/ethnic differences in the burden of type 2 diabetes over the life course: a focus on the USA and India. *Diabetologia*. 2019 Oct;62(10):1751-60. doi: 10.1007/s00125-019-4968-0. PMID: 31451876.
  29. Bailey ZD, Krieger N, Agenor M, et al. Structural racism and health inequities in the USA: evidence and interventions. *Lancet*. 2017 Apr 8;389(10077):1453-63. doi: 10.1016/S0140-6736(17)30569-X. PMID: 28402827.
  30. Trent M, Dooley DG, Douge J, et al. The impact of racism on child and adolescent health. *Pediatrics*. 2019 Aug;144(2)doi: 10.1542/peds.2019-1765. PMID: 31358665.

31. Odoms-Young A, Bruce MA. Examining the impact of structural racism on food insecurity: implications for addressing racial/ethnic disparities. *Fam Community Health*. 2018 Apr/Jun;41 (Suppl 2 Suppl, Food Insecurity and Obesity):S3-S6. doi: 10.1097/FCH.000000000000183. PMID: 29461310.
32. Centers for Disease Control and Prevention. National diabetes statistics report, 2020. Centers for Disease Control and Prevention. Atlanta, GA: US Department of Health and Human Services; 2020. [https://www.cdc.gov/diabetes/data/statistics/statistics-report.html?CDC\\_AA\\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fdiabetes%2Fdata%2Fstatistics-report%2Fdiagnosed.html](https://www.cdc.gov/diabetes/data/statistics/statistics-report.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fdiabetes%2Fdata%2Fstatistics-report%2Fdiagnosed.html)
33. Pettitt DJ, Talton J, Dabelea D, et al. Prevalence of diabetes in U.S. youth in 2009: the SEARCH for diabetes in youth study. *Diabetes Care*. 2014 Feb;37(2):402-8. doi: 10.2337/dc13-1838. PMID: 24041677.
34. Divers J, Mayer-Davis EJ, Lawrence JM, et al. Trends in incidence of type 1 and type 2 diabetes among youths - selected counties and Indian reservations, United States, 2002-2015. *MMWR Morb Mortal Wkly Rep*. 2020 Feb 14;69(6):161-5. doi: 10.15585/mmwr.mm6906a3. PMID: 32053581.
35. Allen PJ, Vessey JA. Primary care of the child with a chronic condition. 4th ed. St. Louis: Mosby-Yearbook; 2004.
36. Heron M. Deaths: leading causes for 2015. *Natl Vital Stat Rep*. 2017 Nov;66(5):1-76. PMID: 29235984.
37. Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. *JAMA*. 2017 Feb 28;317(8):825-35. doi: 10.1001/jama.2017.0686. PMID: 28245334.
38. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
39. U. S. Burden of Disease Collaborators, Mokdad AH, Ballestros K, et al. The state of US health, 1990-2016: burden of diseases, injuries, and risk factors among US states. *JAMA*. 2018 Apr 10;319(14):1444-72. doi: 10.1001/jama.2018.0158. PMID: 29634829.
40. American Diabetes Association. 3. Prevention or delay of type 2 diabetes: standards of medical care in diabetes-2020. *Diabetes Care*. 2020 Jan;43(Suppl 1):S32-S6. doi: 10.2337/dc20-S003. PMID: 31862746.
41. American Diabetes Association. 8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2020. *Diabetes Care*. 2020 Jan;43(Suppl 1):S89-S97. doi: 10.2337/dc20-S008. PMID: 31862751.
42. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. *Diabetes Care*. 2020 Jan;43(Suppl 1):S98-S110. doi: 10.2337/dc20-S009. PMID: 31862752.
43. Copeland KC, Silverstein J, Moore KR, et al. Management of newly diagnosed type 2 Diabetes Mellitus (T2DM) in children and adolescents. *Pediatrics*. 2013 Feb;131(2):364-82. doi: 10.1542/peds.2012-3494. PMID: 23359574.
44. Springer SC, Silverstein J, Copeland K, et al. Management of type 2 diabetes mellitus in children and adolescents. *Pediatrics*. 2013 Feb;131(2):e648-64. doi: 10.1542/peds.2012-3496. PMID: 23359584.


45. Lee JM, Gebremariam A, Wu EL, et al. Evaluation of nonfasting tests to screen for childhood and adolescent dysglycemia. *Diabetes Care*. 2011 Dec;34(12):2597-602. doi: 10.2337/dc11-0827. PMID: 21953800.
46. Eehalt S, Wiegand S, Korner A, et al. Diabetes screening in overweight and obese children and adolescents: choosing the right test. *Eur J Pediatr*. 2017 Jan;176(1):89-97. doi: 10.1007/s00431-016-2807-6. PMID: 27888412.
47. American Diabetes Association. 13. Children and adolescents: standards of medical care in diabetes-2020. *Diabetes Care*. 2020 Jan;43(Suppl 1):S163-S82. doi: 10.2337/dc20-S013. PMID: 31862756.
48. Diabetes Canada Clinical Practice Guidelines Expert Committee, Prebtani APH, Bajaj HS, et al. Reducing the risk of developing diabetes. *Can J Diabetes*. 2018 Apr;42 Suppl 1:S20-S6. doi: 10.1016/j.jcjd.2017.10.033. PMID: 29650097.
49. American Diabetes Association. 5. Prevention or delay of type 2 diabetes: standards of medical care in diabetes-2018. *Diabetes Care*. 2018 Jan;41(Suppl 1):S51-S4. doi: 10.2337/dc18-S005. PMID: 29222376.
50. Khokhar A, Umpaichitra V, Chin VL, et al. Metformin use in children and adolescents with prediabetes. *Pediatr Clin North Am*. 2017 Dec;64(6):1341-53. doi: 10.1016/j.pcl.2017.08.010. PMID: 29173789.
51. Centers for Disease Control and Prevention. Prevent type 2 diabetes in kids. 2017. <https://www.cdc.gov/diabetes/prevent-type-2/type-2-kids.html>.
52. National Collaborating Centre for Women's and Children's Health (UK). Diabetes (type 1 and type 2) in children and young people: diagnosis and management. National Institute for Health and Care Excellence (UK). London: 2015. <https://www.ncbi.nlm.nih.gov/books/NBK315806/>
53. Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. *N Engl J Med*. 2012 Jun 14;366(24):2247-56. doi: 10.1056/NEJMoa1109333. PMID: 22540912.
54. American Diabetes Association. 13. Children and adolescents: standards of medical care in diabetes-2019. *Diabetes Care*. 2019 Jan;42(Suppl 1):S148-S64. doi: 10.2337/dc19-S013. PMID: 30559239.
55. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. *Diabetes Care*. 2002 Jul;25(7):1123-8. doi: 10.2337/diacare.25.7.1123. PMID: 12087008.
56. U.S. Preventive Services Task Force. Procedure manual. Rockville, MD: U.S. Preventive Services Task Force,; 2015. <https://www.uspreventiveservicestaskforce.org/Page/Name/procedure-manual>.
57. West SL, Gartlehner G, Mansfield AJ, et al. Comparative effectiveness review methods: clinical heterogeneity. Rockville, MD; 2010.
58. Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience. *Diabetes Care*. 2013 Jun;36(6):1765-71. doi: 10.2337/dc12-2390. PMID: 23704676.
59. Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study. *Int J Obes (Lond)*. 2010 Feb;34(2):217-26. doi: 10.1038/ijo.2009.195. PMID: 19823189.
60. Levitt Katz L, Gidding SS, Bacha F, et al. Alterations in left ventricular, left atrial, and right ventricular structure and function to cardiovascular risk factors in adolescents with

- type 2 diabetes participating in the TODAY clinical trial. *Pediatr Diabetes*. 2015 Feb;16(1):39-47. doi: 10.1111/pedi.12119. PMID: 24450390.
61. Zeitler P, Epstein L, Grey M, et al. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. *Pediatr Diabetes*. 2007 Apr;8(2):74-87. doi: 10.1111/j.1399-5448.2007.00237.x. PMID: 17448130.
  62. Kelsey MM, Geffner ME, Guandalini C, et al. Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY study. *Pediatr Diabetes*. 2016 May;17(3):212-21. doi: 10.1111/pedi.12264. PMID: 25690268.
  63. Jones KL, Arslanian S, Peterokova VA, et al. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. *Diabetes Care*. 2002 Jan;25(1):89-94. doi: 10.2337/diacare.25.1.89. PMID: 11772907.
  64. Savoye M, Caprio S, Dziura J, et al. Reversal of early abnormalities in glucose metabolism in obese youth: results of an intensive lifestyle randomized controlled trial. *Diabetes Care*. 2014 Feb;37(2):317-24. doi: 10.2337/dc13-1571. PMID: 24062325.
  65. Treatment effects on measures of body composition in the TODAY clinical trial. *Diabetes Care*. 2013 Jun;36(6):1742-8. doi: 10.2337/dc12-2534. PMID: 23704673.
  66. Marcus MD, Wilfley DE, El Ghormli L, et al. Weight change in the management of youth-onset type 2 diabetes: the TODAY clinical trial experience. *Pediatr Obes*. 2017 Aug;12(4):337-45. doi: 10.1111/ijpo.12148. PMID: 27161901.
  67. Jonas DE, Crotty K, Yun JDY, et al. Screening for Prediabetes and Type 2 Diabetes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*. 2021 Aug 24;326(8):744-60. doi: 10.1001/jama.2021.10403. PMID: 34427595.
  68. Vajravelu ME, Lee JM, Shah R, et al. Association between prediabetes diagnosis and body mass index trajectory of overweight and obese adolescents. *Pediatr Diabetes*. 2020 Aug;21(5):743-6. doi: 10.1111/pedi.13028. PMID: 32314478.
  69. Diabetes Canada Clinical Practice Guidelines Expert Committee, Panagiotopoulos C, Hadjiyannakis S, et al. Type 2 diabetes in children and adolescents. *Can J Diabetes*. 2018 Apr;42 Suppl 1:S247-S54. doi: 10.1016/j.jcjd.2017.10.037. PMID: 29650104.
  70. Zeitler P, Fu J, Tandon N, et al. ISPAD clinical practice consensus guidelines 2014. Type 2 diabetes in the child and adolescent. *Pediatr Diabetes*. 2014 Sep;15 Suppl 20:26-46. doi: 10.1111/pedi.12179. PMID: 25182306.
  71. Kapadia C, Zeitler P, Drugs, et al. Hemoglobin A1c measurement for the diagnosis of Type 2 diabetes in children. *Int J Pediatr Endocrinol*. 2012 Dec 20;2012(1):31. doi: 10.1186/1687-9856-2012-31. PMID: 23256825.
  72. Buse JB, Kaufman FR, Linder B, et al. Diabetes screening with hemoglobin A(1c) versus fasting plasma glucose in a multiethnic middle-school cohort. *Diabetes Care*. 2013 Feb;36(2):429-35. doi: 10.2337/dc12-0295. PMID: 23193207.
  73. Galderisi A, Giannini C, Weiss R, et al. Trajectories of changes in glucose tolerance in a multiethnic cohort of obese youths: an observational prospective analysis. *Lancet Child Adolesc Health*. 2018 Oct;2(10):726-35. doi: 10.1016/s2352-4642(18)30235-9. PMID: 30236381.

74. Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. Liraglutide in children and adolescents with type 2 diabetes. *N Engl J Med*. 2019 Aug 15;381(7):637-46. doi: 10.1056/NEJMoa1903822. PMID: 31034184.
75. Postintervention Effects of Varying Treatment Arms on Glycemic Failure and  $\beta$ -Cell Function in the TODAY Trial. *Diabetes Care*. 2021 Jan;44(1):75-80. doi: 10.2337/dc20-0622. PMID: 33290248.
76. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. *Diabetes Care*. 2013 Jun;36(6):1735-41. doi: 10.2337/dc12-2420. PMID: 23704672.
77. Group TS. Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial. *Diabetes Care*. 2013 Jun;36(6):1772-4. doi: 10.2337/dc12-2387. PMID: 23704677.
78. Cali AM, Pierpont BM, Taksali SE, et al. Rosiglitazone improves glucose metabolism in obese adolescents with impaired glucose tolerance: a pilot study. *Obesity (Silver Spring)*. 2011 Jan;19(1):94-9. doi: 10.1038/oby.2010.109. PMID: 20467418.
79. Kaar JL, Schmiede SJ, Drews K, et al. Evaluation of the longitudinal change in health behavior profiles across treatment groups in the TODAY clinical trial. *Pediatric diabetes*. 2020;21(2):224-32. doi: 10.1111/peidi.12976. PMID: CN-02233381.
80. Hitt JM, Velasquez-Mieyer P, Neira C, et al. Factors affecting hemoglobin A1C in the diagnosis of diabetes and prediabetes in youth. *J Pediatr Nurs*. 2016 Sep-Oct;31(5):511-8. doi: 10.1016/j.pedn.2016.03.020. PMID: 27132801.
81. Tester J, Sharma S, Jasik CB, et al. Gender differences in prediabetes and insulin resistance among 1356 obese children in Northern California. *Diabetes Metab Syndr*. 2013 Jul-Sep;7(3):161-5. doi: 10.1016/j.dsx.2013.06.002. PMID: 23953182.
82. Kim MS, Jo DS, Lee DY. Comparison of HbA1c and OGTT for the diagnosis of type 2 diabetes in children at risk of diabetes. *Pediatr Neonatol*. 2019 Aug;60(4):428-34. doi: 10.1016/j.pedneo.2018.11.002. PMID: 30497969.
83. Yoon JS, So CH, Lee HS, et al. Glycated hemoglobin A1c as a screening test for detecting type 2 diabetes mellitus in obese children and adolescents. *J Pediatr Endocrinol Metab*. 2018 Apr 25;31(5):503-6. doi: 10.1515/jpem-2017-0463. PMID: 29652667.
84. Chan CL, Pyle L, Kelsey M, et al. Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemia - 1,5-anhydroglucitol, fructosamine, and glycated albumin. *Pediatr Diabetes*. 2016 May;17(3):206-11. doi: 10.1111/peidi.12258. PMID: 25652226.
85. Galhardo J, Shield J. The role of haemoglobin A1c in screening obese children and adolescents for glucose intolerance and type 2 diabetes. *Acta Med Port*. 2015 May-Jun;28(3):307-15. PMID: 26421782.
86. Brar PC, Mengwall L, Franklin BH, et al. Screening obese children and adolescents for prediabetes and/or type 2 diabetes in pediatric practices: a validation study. *Clin Pediatr (Phila)*. 2014 Jul;53(8):771-6. doi: 10.1177/0009922814528571. PMID: 24671874.
87. Barry E, Roberts S, Oke J, et al. Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions. *BMJ*. 2017 Jan 4;356:i6538. doi: 10.1136/bmj.i6538. PMID: 28052845.
88. Hannon TS, Dugan TM, Saha CK, et al. Effectiveness of Computer Automation for the Diagnosis and Management of Childhood Type 2 Diabetes: A Randomized Clinical Trial. *JAMA Pediatr*. 2017 Apr 1;171(4):327-34. doi: 10.1001/jamapediatrics.2016.4207. PMID: 28192551.


89. Biondich PG, Downs SM, Anand V, et al. Automating the recognition and prioritization of needed preventive services: early results from the CHICA system. *AMIA Annu Symp Proc.* 2005:51-5. PMID: 16779000.
90. Anand V, Biondich PG, Liu G, et al. Child Health Improvement through Computer Automation: the CHICA system. *Stud Health Technol Inform.* 2004;107(Pt 1):187-91. PMID: 15360800.
91. Downs SM, Biondich PG, Anand V, et al. Using Arden Syntax and adaptive turnaround documents to evaluate clinical guidelines. *AMIA Annu Symp Proc.* 2006:214-8. PMID: 17238334.
92. Carroll AE, Biondich PG, Anand V, et al. Targeted screening for pediatric conditions with the CHICA system. *J Am Med Inform Assoc.* 2011 Jul-Aug;18(4):485-90. doi: 10.1136/amiajnl-2011-000088. PMID: 21672910.
93. Anand V, Carroll AE, Biondich PG, et al. Pediatric decision support using adapted Arden Syntax. *Artif Intell Med.* 2018 Nov;92:15-23. doi: 10.1016/j.artmed.2015.09.006. PMID: 26547523.
94. DuBose KD, Cummings DM, Imai S, et al. Development and validation of a tool for assessing glucose impairment in adolescents. *Prev Chronic Dis.* 2012;9:E104. doi: 10.5888/pcd911\_0213. PMID: 22632741.
95. Koopman RJ, Mainous AG, 3rd, Everett CJ, et al. Tool to assess likelihood of fasting glucose impairment (TAG-IT). *Ann Fam Med.* 2008 Nov-Dec;6(6):555-61. doi: 10.1370/afm.913. PMID: 19001309.
96. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8. PMID: 3558716.
97. Gray LJ, Brady EM, Albaina O, et al. Evaluation and refinement of the PRESTART tool for identifying 12-14 year olds at high lifetime risk of developing type 2 diabetes compared to a clinicians assessment of risk: a cross-sectional study. *BMC Endocr Disord.* 2019 Jul 25;19(1):79. doi: 10.1186/s12902-019-0410-3. PMID: 31345191.

**Figure 1. Analytic Framework**



\* Eligible interventions include pharmacotherapy and primary care–relevant counseling focused on healthy diet and nutrition, physical activity, or both.

**Figure 2. Summary of Evidence Search and Selection**



Note: The sum of the number of studies per KQ exceeds the total number of studies because some studies were applicable to multiple KQs.

**Abbreviations:** KQ=key question.



**Table 1. Classification of Diabetes (Adapted From ADA Guidelines)<sup>1</sup>**

<b>Category</b>	<b>Definition/Etiology</b>
Type 1 diabetes	Diabetes due to autoimmune $\beta$ -cell destruction, usually leading to absolute insulin deficiency
Type 2 diabetes	Diabetes due to a progressive loss of $\beta$ -cell insulin secretion frequently on the background of insulin resistance
Gestational diabetes mellitus	Diabetes diagnosed in the second or third trimester of pregnancy that was not clearly overt diabetes before gestation
Diabetes due to other causes	Includes specific types of diabetes attributable to the following: monogenic diabetes syndromes (e.g., maturity-onset diabetes of the young), diseases of the exocrine pancreas (e.g., pancreatitis), and drug- or chemical-induced diabetes (e.g., glucocorticoid use, in the treatment of HIV/AIDS, or after organ transplantation)

**Abbreviations:** ADA=American Diabetes Association; HIV/AIDS=human immunodeficiency virus/acquired immunodeficiency syndrome.

**Table 2. Criteria for the Diagnosis of Type 2 Diabetes and Prediabetes (Adapted From ADA Guidelines)<sup>1</sup>**

Diagnosis	A1c*	Fasting <sup>†</sup> Plasma Glucose	OGTT <sup>‡,§</sup>	Other
Type 2 diabetes	≥6.5% (48.0 mmol/mol) ‡	≥126 mg/dL (7.0 mmol/L)	≥200 mg/dL (11.1 mmol/L)	Random PG ≥200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of hyperglycemia or hyperglycemia crisis
Prediabetes <sup>  </sup>	5.7 to 6.4% (39–47.9 mmol/mol)	IFG: 100 to 125 mg/dL (5.6–6.9 mmol/L)	IGT: 140 to 199 mg/dL (7.8–11.0 mmol/L)	NA

\* The ADA guidelines note this test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.

† Fasting is defined as no caloric intake for at least 8 hours.

‡ Refers to values measured 2 hours post-load on the 75-g OGTT. Per the ADA recommendations, the test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75-gram anhydrous glucose dissolved in water.

§ The ADA guidelines note this test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.

|| ADA guidelines note that for all three tests the risk is continuous, extending below the lower limit of the range and becoming disproportionately greater at higher ends of the range.

**Abbreviations:** A1c=glycated hemoglobin; ADA=American Diabetes Association; DCCT=Diabetes Control and Complications Trial; IFG=impaired fasting glucose; IGT=impaired glucose tolerance; NA=not applicable; NGSP=National Glycohemoglobin Standardization Program; OGTT=oral glucose tolerance test.

**Table 3. Characteristics of Included Randomized Trials of Children and Adolescents With Prediabetes or Type 2 Diabetes (KQs 3, 4, and 5)**

First Author, Year	Participants	Groups, No.	Duration of Followup	Duration of diabetes, Mean (Range or SD), months	Age, Mean (Range or SD), y	No. (%) F	No. (%) Nonwhite	HbA1C Mean (%) (SD)	BMI, Mean (SD) (kg/m <sup>2</sup> )	Quality
Jones, 2002 <sup>63</sup>	Children (10–16 y) with previous or new diagnosis of type 2 diabetes, BMI>50th percentile for age; 44 sites in multiple countries*	G1: Metformin (titrated up to maximum 2,000 mg/day <sup>†</sup> ), 42 G2: Placebo, 40	16 weeks	NR	G1: 13.9 (1.8) G2: 13.6 (1.8)	G1: 30 (71.4) G2: 27 (67.5)	G1: 25 (59.5) G2: 27 (67.5)	G1: 8.3 (1.3) G2: 9.0 (1.4)	G1: 34.2 (10.6) G2: 33.9 (12.7)	Fair
TODAY Study Group, 2007, 2010, 2012, 2013, 2015, 2016 <sup>53, 58-62</sup>	Adolescents who were obese (10–17 y) with type 2 diabetes for <2 years, BMI≥85 <sup>th</sup> percentile for age and sex at 15 clinical centers in the United States	After a run-in of 2 to 6 months <sup>‡</sup> G1: Metformin, 232 G2: Metformin + rosiglitazone 4 mg twice daily, 233 G3: Metformin + lifestyle program, 234	Mean 3.8 y (range 2–6.5 y)	G1: 7.8 (6.0) G2: 8.0 (5.7) G3: 7.6 (5.8)	G1: 14.1 (1.9) G2: 14.1 (2.1) G3: 13.8 (2.0)	G1: NR (63.1) G2: NR (65.7) G3: NR (66.0)	G1: 78.9 G2: 79.8 G3: 80.3	G1: 7.3 (2.2) G2: 7.0 (2.3) G3: 7.1 (2.2)	G1: 35.8 (8.1) G2: 35.0 (7.7) G3: 34.1 (7.1)	Good
Savoie, 2014 <sup>64</sup>	Adolescents who were obese (10–16 y) with BMI>95 <sup>th</sup> percentile and prediabetes (elevated OGTT, 2-h 130–199 mg/dL) from the Yale Pediatric Obesity Clinic	G1: Bright Bodies Healthy Lifestyle Program, <sup>§</sup> 38 G2: standard care, 37	6 months	NA	G1: 12.7 (1.9) G2: 13.2 (1.8)	G1: 26 (68.4) G2: 23 (62.2)	G1: 11 (29.0) G2: 12 (32.4)	G1: 5.7 (0.4) G2: 5.6 (0.4)	G1: 32.1 (5.2) G2: 34.6 (6.8)	Fair

\* Subjects were from the United States (25 sites [n=62]), Russia (6 sites [n=13]), Ukraine (1 site [n=4]), Belarus (1 site [n=2]), and Poland (1 site [n=1]).

<sup>†</sup> Mean final dose of metformin was 1,798 mg/day.

<sup>‡</sup> The run-in involved weaning from nonstudy diabetes medications, initiating metformin at a dose of up to 1,000 mg twice daily, attaining glycemic control with metformin alone (A1c<8.0%), providing standard diabetes education and ensuring the participants' mastery of the material, and confirming adherence.

<sup>§</sup> The program consisted of two 50-minute exercise sessions per week, one weekly weigh-in, and a 40-minute nutrition/behavior modification class. Participants were encouraged to exercise 3 additional days per week and record the duration and type of exercise. The study used raffle tickets for gift cards to motivate participants; tickets could be earned if weight stayed the same or decreased and, in some cases, for returning their weekly exercise log.

**Abbreviations:** BMI=body mass index; G=group; HbA1c=glycated hemoglobin; KQ=key question; NA=not applicable; NR=not reported; OGTT=oral glucose tolerance test; SD=standard deviation; TODAY=Treatment Options for Type 2 Diabetes in Adolescents and Youth.

**Table 4. Results of Trials of Children and Adolescents With Prediabetes or Type 2 Diabetes Reporting Health Outcomes (KQ 3) or Progression From Prediabetes to Type 2 Diabetes (KQ 5)**

First Author, Year	G1 (N) G2 (N)	Progression to Diabetes	Mortality G1 vs. G2; HR (95% CI)	CVD Events G1 vs. G2; HR (95% CI)	Diabetic Ketoacidosis	Chronic Kidney Disease G1 N (%) G2 N (%) HR (95% CI)	Amputations G1 N (%) G2 N (%) HR (95% CI)	Skin Ulcers G1 N (%) G2 N (%) HR (95% CI)	Visual Impairment G1 N (%) G2 N (%) HR (95% CI)	Neuropathy G1 N (%) G2 N (%) HR (95% CI)
Jones, 2002 <sup>63</sup>	G1: 42 G2: 40	NR	NR	NR	G1: 0 G2: 1 (2.5%)	NR	NR	NR	NR	NR
TODAY Study Group, 2007, 2010, 2012, 2013, 2015, 2016 <sup>53, 58-62</sup>	G1: 232 G2: 233 G3: 234	NA	G1: 0 G2: 0 G3: 0	NR	G1: 5 (2.1) G2: 3 (1.3) G3: 3 (1.3) p=0.70	<b>Renal impairment:</b> G1: 0 G2: 1 (0.4) G3: 1 (0.4) p=1.00	NR	NR	NR	NR
Savoie, 2014 <sup>64</sup>	G1: 38 G2: 37	G1: 0 G2: 0	NR	NR	NR	NR	NR	NR	NR	NR

**Abbreviations:** CI=confidence interval; CVD=cardiovascular disease; G=group; HR=hazard ratio; N=number; NA=not applicable; NR=not reported; TODAY=Treatment Options for Type 2 Diabetes in Adolescents and Youth; vs.=versus.

**Table 5. Results of Included Trials of Children and Adolescents With Type 2 Diabetes Reporting Harms/Adverse Events Due to Treatment (KQ 4)**

First Author, Year Trial Name Country	CV Adverse Events G1 N (%) G2 N (%) HR (95% CI)	Hypoglycemic Events G1 N (%) G2 N (%) HR (95% CI)	All-Cause Withdrawals G1 N (%) G2 N (%) HR (95% CI)	Gastrointestinal Adverse Events G1 N (%) G2 N (%) HR (95% CI)	Lactic Acidosis G1 N (%) G2 N (%) HR (95% CI)	Other Adverse Events G1 N (%) G2 N (%) HR (95% CI)
Jones, 2002 <sup>63</sup>	NR	<b>Hypoglycemic events requiring medical attention:</b> G1: 0 G2: 0	G1: 6 (14.3) G2: 4 (10.0)	<b>Abdominal pain</b> G1: NR (25) G2: NR (12)  <b>Nausea/vomiting</b> G1: NR (17) G2: NR (10)	G1: 0 G2: 0	Other adverse events, as reported by the authors (all deemed unrelated to the study drug) G1: 2 (4.7%) (one person became seropositive for hepatitis B and one had severe abdominal pain and diarrhea due to a viral infection) G2: 2 (5.4%) (one had hyperglycemia and one experience problems associated with diabetes and increased liver function enzymes); a third participant had diabetic ketoacidosis but that is covered in <b>Table 4</b>
TODAY Study Group, 2007, 2010, 2012, 2013, 2015, 2016 <sup>53, 58-62</sup>	<b>Heart failure</b> Before primary outcome G1: 0 G2: 0 G3: 0  After primary outcome (out of 319 participants who had the primary outcome of treatment failure) G1: 0 G2: 1 (1.1) G3: 0	<b>Severe hypoglycemia:</b> G1: 1 (0.4) G2: 1 (0.4) G3: 2 (0.8) p=1.00  <b>Mild hypoglycemia:</b> G1: 10 (4.3) G2: 19 (8.2) G3: 8 (3.4) p=0.05  <b>Repeated mild hypoglycemia</b> Before Primary Outcome (out of all 699 participants) G1: 5 (2.1) G2: 16 (6.9) G3: 6 (2.6) p=0.094  After Primary Outcome (out of 319 participants) G1: 4 (3.3) G2: 3 (3.3) G3: 1 (0.9) p=0.029	G1: 15 (6.4) G2: 20 (8.6) G3: 15 (6.4)	<b>GI symptoms</b> Full sample: G1: 129 (55.6) G2: 100 (42.9) G3: 136 (58.1) p=0.002	G1: 1 (0.4) G2: 0 G3: 0 p=0.33	<b>Rash</b> G1: 108 (46.5) G2: 101 (43.3) G3: 95 (40.6) p=0.43  <b>Infection</b> G1: 149 (64.2) G2: 120 (51.5) G3: 151 (64.5) p=0.005  <b>Sprain or fracture</b> G1: 66 (28.4) G2: 53 (22.7) G3: 64 (27.4) p=0.33  <b>Muscle ache or pain</b> G1: 68 (29.3) G2: 53 (22.7) G3: 77 (32.9) p=0.05  <b>Anemia</b> G1: 71 (30.6) G2: 58 (24.8) G3: 52 (22.2) p=0.11

**Table 5. Results of Included Trials of Children and Adolescents With Type 2 Diabetes Reporting Harms/Adverse Events Due to Treatment (KQ 4)**

First Author, Year Trial Name Country	CV Adverse Events	Hypoglycemic Events	All-Cause Withdrawals	Gastrointestinal Adverse Events	Lactic Acidosis	Other Adverse Events
	G1 N (%) G2 N (%) HR (95% CI)	G1 N (%) G2 N (%) HR (95% CI)	G1 N (%) G2 N (%) HR (95% CI)	G1 N (%) G2 N (%) HR (95% CI)	G1 N (%) G2 N (%) HR (95% CI)	
TODAY Study Group, 2007, 2010, 2012, 2013, 2015, 2016 <sup>53</sup> , <sup>58-62</sup> (continued)						Edema G1: 17 (7.3) G2: 17 (7.3) G3: 17 (7.3) p=1.00

**Abbreviations:** CI=confidence interval; CV=cardiovascular; G=group; HR=hazard ratio; KQ=key question; N=number; NR=not reported; TODAY=Treatment Options for Type 2 Diabetes in Adolescents and Youth.

**Table 6. Summary of Evidence on Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents**

<b>Key Question and Topic</b>	<b>No. of Studies (k), No. of Participants (n)</b>	<b>Summary of Findings</b>	<b>Consistency and Precision</b>	<b>Study Quality</b>	<b>Limitations (Including Reporting Bias)</b>	<b>Overall Strength of Evidence</b>	<b>Applicability</b>
KQ 1. Benefits of screening	0, 0	No eligible studies	NA	NA	NA	Insufficient	NA
KQ 2. Harms of screening	0, 0	No eligible studies	NA	NA	NA	Insufficient	NA
KQ 3. Benefits of interventions for screen-detected or recently diagnosed type 2 diabetes and prediabetes	2 RCTs (7 publications), 781 participants	The TODAY study (n=699) reported no significant difference between groups for renal impairment in youths treated with metformin only vs. metformin plus rosiglitazone vs. metformin plus a lifestyle intervention (0 vs. 1 vs. 1, p=1.00) and no difference for DKA (5 vs. 3 vs. 3, p=0.70, respectively). One smaller trial (n=82) reported that 1 adolescent with diabetes in the placebo group developed DKA compared with zero in the metformin group. No eligible studies reported other health outcomes.	Consistency unknown (no 2 studies assessed the same comparisons); imprecise	Good: 1 Fair: 1	Mean followup 3.8 years in TODAY (range 2–6.5 years) likely insufficient to assess health outcomes; followup of 16 weeks in the smaller trial; reporting bias not detected	Insufficient	The TODAY trial enrolled adolescents who were obese (age 10–17 y) with previous or newly diagnosed type 2 diabetes; predominantly nonwhite participants from U.S.; during run-in and prior to randomization, participants had to achieve glycemic control (HbA1c<8%), achieve mastery of diabetes education material, and confirm adherence.

**Table 6. Summary of Evidence on Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents**

Key Question and Topic	No. of Studies (k), No. of Participants (n)	Summary of Findings	Consistency and Precision	Study Quality	Limitations (Including Reporting Bias)	Overall Strength of Evidence	Applicability
KQ 4. Harms of interventions for type 2 diabetes	2 RCTs (7 publications), 781 participants	<p><b>Hypoglycemic events:</b> More youths treated with metformin plus rosiglitazone had repeated mild hypoglycemia than those treated with metformin or metformin plus lifestyle (8.2% vs. 4.3% vs. 3.4%), <math>p=0.05</math>.</p> <p><b>Gastrointestinal adverse events:</b> Higher rates with metformin alone and metformin plus lifestyle intervention than with metformin plus rosiglitazone (55.6% vs. 58.1% vs. 42.9%, <math>p=0.002</math>). Higher rates of abdominal pain (25% vs. 12%, P NR) and nausea or vomiting (17% vs. 10%, P NR) for youths treated with metformin for 16 weeks than with placebo.</p> <p><b>Infection:</b> Lower rates with metformin plus rosiglitazone than with metformin alone or metformin plus a lifestyle intervention (<math>p=0.005</math>).</p> <p><b>Muscle aches or pains:</b> Lower rates with metformin plus rosiglitazone than with metformin alone or metformin plus a lifestyle intervention (<math>p=0.05</math>).</p> <p><b>Heart failure:</b> One participant treated with metformin plus rosiglitazone developed heart failure.</p>	Consistency unknown (no 2 studies used similar measures at similar timepoints for the same comparison); imprecise	Good: 1 Fair: 1	Included studies assessed different comparisons; reporting bias not detected	Low	Youths who were obese ages 10–17 years with previous or newly diagnosed type 2 diabetes; predominantly nonwhite participants from the U.S.
KQ 4. Harms of interventions for prediabetes	0, 0	No eligible studies	NA	NA	NA	Insufficient	NA
KQ 5. Interventions for prediabetes to delay or prevent progression to type 2 diabetes	1 RCT, 75 participants	No participants in the high-contact healthy lifestyle intervention group or the control group developed diabetes over 6 months.	Consistency unknown (single study); imprecise	Fair	Followup duration of 6 months; high attrition; some participants were withdrawn for being started on metformin ( $n=5$ ); reporting bias not detected	Insufficient	Children ages 10–16 years with BMI above the 95 <sup>th</sup> percentile and prediabetes (elevated OGTT, 2-h 130–199 mg/dL) seen in a pediatric obesity clinic; high-contact lifestyle intervention with both diet/nutrition and physical activity/exercise components.



**Table 6. Summary of Evidence on Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents**

Key Question and Topic	No. of Studies (k), No. of Participants (n)	Summary of Findings	Consistency and Precision	Study Quality	Limitations (Including Reporting Bias)	Overall Strength of Evidence	Applicability
KQ 6. Change in health outcomes that results from reduction in diabetes after interventions for prediabetes	0, 0	No eligible studies	NA	NA	NA	Insufficient	NA

**Abbreviations:** BMI=body mass index; KQ=key question; NA=not applicable; NR=not reported; OGTT=oral glucose tolerance test; RCT=randomized, controlled trial; TODAY=Treatment Options for Type 2 Diabetes in Adolescents and Youth.

## Contextual Questions (CQs)

- CQ 1. a. What percentage of children and adolescents with prediabetes progress to type 2 diabetes, remain prediabetic or return to normal glycemia or glucose tolerance (without intervention), and over what time frame?**
- b. What percentage of children and adolescents with type 2 diabetes return to normal glycemia or glucose tolerance or to the prediabetes range (without intervention), and over what time frame?**
- c. How does this differ by baseline hemoglobin (Hb) glycosylated hemoglobin (A1c) level, fasting glucose level, or glucose tolerance?**

Overall, current available studies are limited but suggest that many children and adolescents with prediabetes (22% to 52%) return to normal glycemia or glucose tolerance without intervention over 6 months to 2 years.

A limited number of randomized, controlled trials (RCTs) of prediabetes had control groups that received no intervention, allowing an opportunity to follow those subjects over the course of the study to assess natural history. These studies suggested that a large portion of children and adolescents with prediabetes will remain with prediabetes or revert to normoglycemia over a 2-year period; this pattern appears similar regardless of the method of measuring glycemia or glucose tolerance. The largest of these was the HEALTHY study. This study randomized 21 schools to the control arm, collected baseline metabolic health data on 6<sup>th</sup> graders, and then collected the same data again 2 years later. Of those with prediabetes at baseline (n=128, HgA1c 5.7-6.4), the 2-year followup assessments revealed that 51 (39.8%) had a normal HgA1c, 76 (59.4%) persisted with prediabetes, and 1 (0.8%) progressed to diabetes. By comparison, of those with A1c <5.7 at baseline (n=3,852), 3,761 (97.6%) remained <5.7 at the 2-year followup, 88 (2.3%) progressed to prediabetes, and 3 (0.1%) progressed to diabetes. Of those with an elevated fasting plasma glucose (FPG) at baseline (100-125 mg/dL, n=635), 330 (52%) regressed to <100 mg/dL at followup, 298 (46.9%) remained between 100-125 mg/dL and 7 (1.1%) progressed to FPG greater than or equal to 126 mg/dL. By comparison, of those with baseline FPG <100 mg/dL (n=3,345), 2,774 (82.9%) remained <100 mg/dL at followup, 567 (17%) progressed to 100-125 mg/dL, and 4 (0.1%) progressed to FPG ≥ 126 mg/dL at followup.<sup>72</sup> The placebo arm of a small trial of adolescents ages 10 to 16 years who were obese found that the 22 percent (6 of 21) who had oral glucose tolerance test (OGTT) 2-hour blood glucose greater than or equal to 130 at baseline converted to less than 130 at the 6-month followup without intervention.<sup>64</sup>

No identified prospective cohort studies have followed children with prediabetes or diabetes over time to determine what proportion return to normoglycemia without intervention. Two cohort studies followed youth with prediabetes for 2 years and found that 8 percent to 24 percent progressed to type 2 diabetes, while 45 to 65 percent reverted to normal glucose tolerance, but both studies involved some lifestyle intervention for participants.<sup>7, 73</sup> One of the cohort studies was conducted in an obesity clinic and followed children with prediabetes over 2 years. It provided dietary counseling and evaluation every 5 to 6 months, but it did not have a group who received no intervention. Of 162 adolescents with prediabetes at baseline, 102 (65%) reverted to normal glucose tolerance at 2 years, 44 (27%) had persistent prediabetes, and 13 (8%) progressed to type 2 diabetes.<sup>73</sup> A similar smaller cohort study in the same obesity clinic followed a subset

## Appendix A. Additional Background and Contextual Questions (CQs)

of children and adolescents with prediabetes over 18 to 24 months, providing biannual nutrition and physical activity counseling. It found that of 33 children and adolescents with prediabetes at baseline, 15 (45.5%) reverted to normal glucose tolerance at followup, 10 (30.3%) maintained prediabetes, and 8 (24.2%) progressed to type 2 diabetes.<sup>7</sup>

### **CQ 2. a. Does screening for prediabetes or type 2 diabetes change the intermediate outcomes of HbA1c level, FPG level, 2-hour glucose tolerance test results, subclinical retinopathy, microalbuminuria, or subclinical neuropathy for children and adolescents?**

This review identified no studies for CQ 2a.

### **b. Do interventions for children and adolescents with screen-detected or recently diagnosed type 2 diabetes or prediabetes change the intermediate outcomes of HbA1c level, FPG level, 2-hour glucose tolerance test results, subclinical retinopathy, microalbuminuria, or subclinical neuropathy?**

## Summary

Among those recently diagnosed with type 2 diabetes, metformin improved glycemia, including A1c and FPG levels, compared with placebo in one trial; rosiglitazone combined with metformin improved glycemic control, as measured by A1c <8 percent and/or need for rescue insulin, compared with metformin alone or metformin and lifestyle in one trial, but only while rosiglitazone was being used (i.e., there was no long-term protective effect from prior use); liraglutide combined with metformin resulted in improved glycemia, as measured by A1c and FPG, compared with metformin and placebo in one trial. Among those with prediabetes, lifestyle improved 2-h glucose, but not fasting glucose or A1c, compared with usual care in one trial; data on rosiglitazone were inconclusive because of early trial discontinuation. There was no evidence that metformin combined with rosiglitazone or combined with lifestyle affected microalbuminuria compared with metformin alone in one trial. We found no trials (absence of evidence) demonstrating that interventions for children and adolescents with recently diagnosed type 2 diabetes or prediabetes change subclinical retinopathy or subclinical neuropathy.

## Impact of Interventions on Glycemia in Children/Adolescents with Recently Diagnosed Type 2 Diabetes

Three studies (4 articles) examined the glycemic impact of treating recently diagnosed type 2 diabetes.<sup>53, 63, 74, 75</sup> A double-blind RCT (also included in KQ 4) conducted across 44 sites in the United States, Russia, Ukraine, Belarus, and Poland examined whether screening for type 2 diabetes changed the intermediate outcomes of A1c and FPG.<sup>63</sup> In that trial, Jones et al examined the impact of metformin (titrated up to 2,000 mg/day as tolerated [mean final dose of metformin=1,798 mg]) versus placebo in 82 children ages 10 to 16 years who were previously or newly diagnosed with type 2 diabetes. Some participants may have had a previous diagnosis of type 2 diabetes and taken oral glucose lowering medication previously (but at least 28 days before trial start). The independent Data and Safety Monitoring Board recommended an end to the double-blind period (all participants were switched to open-label metformin) based on 8-week data showing that 70.0 percent of the placebo subjects had required rescue medication for exceeding the predetermined glycemic threshold compared with 15.8 percent of metformin subjects. At the end of double-blind treatment, the adjusted mean FPG had significantly decreased in the metformin group but increased in the placebo group (-2.4 mmol/l [-42.9 mg/dl])

## Appendix A. Additional Background and Contextual Questions (CQs)

vs. +1.2 mmol/l [+21.4 mg/dl];  $p < 0.001$ ). The mean adjusted HbA1c level at the end of the double-blind period was also significantly lower in the metformin group compared with the placebo group (7.5 vs. 8.6%, respectively;  $p < 0.001$ ). The proportion of subjects who met at least one of the American Diabetes Association (ADA) glycemic treatment target levels (FPG  $< 7.0$  mmol/l [ $< 126$  mg/dl] or HbA1c  $< 7.0\%$ ) by their last double-blind treatment visit was 84 percent for the metformin group compared with 22 percent for the placebo group.

In the TODAY trial (described in KQs 3 and 4),<sup>53</sup> 699 adolescents who were obese ages 10 to 17 years and with recent onset type 2 diabetes (mean duration of diagnosed type 2 diabetes=7.8 months) were randomized to metformin, metformin plus rosiglitazone, or metformin plus lifestyle program. The primary outcome was loss of glycemic control, defined as a glycated hemoglobin level of at least 8 percent for 6 months or sustained metabolic decompensation requiring insulin. The authors reported that 51.7 percent (95% CI, 45.3 to 58.2), 38.6 percent (95% CI, 32.4 to 44.9), and 46.6 percent (95% CI, 40.2 to 53.0) of participants experienced loss of glycemic control in the metformin, metformin plus rosiglitazone, and metformin plus lifestyle interventions, respectively. Metformin plus rosiglitazone was associated with a 25.3 percent decrease in the occurrence of the loss of glycemic control compared with metformin alone ( $p = 0.006$ ); the glycemic impact of metformin plus lifestyle intervention did not differ significantly from that of metformin alone or metformin plus rosiglitazone. In TODAY2,<sup>75</sup> a followup study of 572 TODAY participants, rosiglitazone was permanently discontinued in those who had been assigned to that arm. All participants continued receiving metformin monotherapy at the same dose they were taking at the end of TODAY, and add-on insulin therapy was continued or started in participants who had metabolic decompensation during followup. After 36 months, the rate of glycemic failure did not differ among participants who were previously randomized to any of the three TODAY treatment arms (metformin, metformin plus rosiglitazone, or metformin plus lifestyle program). By the end of the 96 months' total observation period (including TODAY and TODAY2), 173 participants (25.6% of the original cohort) remained free of glycemic failure. There were no statistically significant differences by sex or race/ethnicity.

The third study was a double-blind multicenter (25 countries) RCT examining the glycemic impact of metformin plus liraglutide (up to 1.8 mg per day) vs metformin plus placebo in 134 participants aged 10 to 17 years with type 2 diabetes (mean duration 1.9 years).<sup>74</sup> All participants were encouraged to follow a diet and exercise regimen. The authors reported that 23 percent and 15 percent of liraglutide-metformin and metformin only participants, respectively, were also taking basal insulin at baseline; their insulin dosage was reduced by 20 percent at the time of randomization but could be increased back up to the baseline dose (but no higher) after completion of the dose-escalation period. The primary end point was the change from baseline in the A1c level, and secondary end points included change in FPG level. Mean A1c levels at week 26 were reduced from baseline by 0.64 percentage points in the liraglutide group, whereas the levels increased by 0.42 percentage points in the placebo group (estimated treatment difference, -1.06 percentage points [95% CI, -1.65 to -0.46];  $p < 0.001$ ). Moreover, 63.7 percent of the patients in the liraglutide group, as compared with 36.5 percent in the placebo group, attained A1c levels of less than 7.0 percent ( $p < 0.001$ ). Liraglutide was also superior to placebo in reducing FPG levels by 26 weeks (-1.08 mmol/L vs. 0.80 mmol/L).

## Impact of Interventions on Other Intermediate Outcomes in Children/Adolescents with Recently Diagnosed Type 2 Diabetes

The TODAY trial examined the development of microalbuminuria (albumin:creatinine ratio of 30 or more, with albumin measured in milligrams per deciliter and creatinine in grams per deciliter).<sup>76</sup> The prevalence of microalbuminuria increased from 6.3 to 16.6 percent by the end of the study, but the incidence of new cases of microalbuminuria did not differ across treatment arms.

No studies examined subclinical retinopathy or subclinical nephropathy and reported results that were eligible for this report. The TODAY study reported on the prevalence of retinopathy among study participants using retinal images that were taken during the last year of the study, but it did not report data separated by the three study groups nor did it collect baseline data to enable reporting of changes in or incidence of retinopathy.<sup>77</sup>

## Impact of Interventions on Glycemia in Children/Adolescents with Prediabetes

*Lifestyle:* An RCT (described in KQ 5) compared a lifestyle program (Bright Bodies [BB]) with standard clinical care (CC) among 75 racially/ethnically diverse adolescents who were obese (ages 10-16 years) with prediabetes as defined by an elevated OGTT 2-h blood glucose (130-199 mg/dL; using a range that was slightly wider than the current prediabetes criteria of 140 to 199 mg/dL).<sup>64</sup> The BB intervention was family based, tailored for inner-city minority children and their families, and consisted of two 50-min exercise sessions per week, one weekly weigh-in, and a 40-min nutrition/behavior modification class. Participants were encouraged to exercise 3 additional days per week and given guidance on making healthy food choices including low-fat foods of moderate portions. The primary outcomes were change in 2-h blood glucose level and percentage conversion from elevated to nonelevated 2-h blood glucose level (<130 mg/dL) at the 6-month followup. The BB group experienced a greater decrease in 2-h glucose compared with CC (27.2 vs. 10.1 mg/dL; difference=17.1 [95% CI -29.0 to -5.1]; p=0.005). In addition, more participants in the BB experienced conversion to normal 2-h glucose (<130 mg/dL) compared with CC (p=0.003). Fasting glucose and A1c did not differ between groups at 6 months.

*Rosiglitazone.* In a pilot randomized, double-blind, placebo-controlled study, 21 adolescents who were obese (between ages 13 and 18 years) with impaired glucose tolerance (diagnosed via OGTT) received either rosiglitazone (8 mg daily) or placebo over 4 months.<sup>78</sup> Nutritional and exercise recommendations were given to both groups. The study was stopped early because recruitment became difficult due to concerns that had emerged from the literature regarding cardiac complications associated with rosiglitazone. Fifty-eight percent (n=7) in the rosiglitazone group vs. 44 percent (n=4) in the placebo group converted from impaired glucose tolerance (IGT) to normal glucose tolerance (p=0.53). Fasting glucose and A1c were collected during the study but not reported.

### **CQ 3. a. Do interventions for (or does knowledge of) prediabetes change body mass index (BMI), weight, or healthy behaviors?**

In summary, three studies were identified that addressed whether interventions for prediabetes or if knowledge of prediabetes was associated with changes in BMI and weight.<sup>64, 68, 78</sup> No studies were identified that examined changes in healthy behaviors. Included studies compared lifestyle

## Appendix A. Additional Background and Contextual Questions (CQs)

with standard care<sup>64</sup> and rosiglitazone with placebo,<sup>78</sup> and assessed the association of prediabetes identification with BMI.<sup>68</sup> All three studies reported on BMI,<sup>64, 68, 78</sup> and two studies reported on weight.<sup>64, 78</sup> Two of the included studies were RCTs, and one was a cohort study. All three studies were conducted in the United States and included racially diverse samples. Overall, studies reported that lifestyle interventions for children and adolescents with prediabetes improved the intermediate outcomes of weight and BMI compared with controls, rosiglitazone did not reduce weight or BMI compared with placebo, and prediabetes identification was associated with decreases in BMI in adolescents who were obese and overweight.

Two RCTs of prediabetes interventions reported on changes in BMI and weight.<sup>64, 78</sup> One study (described in KQ 5) recruited adolescents from an obesity clinic (n=75) and compared the lifestyle intervention BB with standard care.<sup>64</sup> Participating adolescents (ages 10-16 years) were required to have an elevated OGTT 2-h glucose (130-199 mg/dl), a BMI greater than 95<sup>th</sup> percentile, and a Tanner stage of greater than 2. The final sample included mostly nonwhite (66%) females (70%). At 6 months, participation in BB was associated with a significant decrease in weight (-3.1 kg [95% CI, -5.3 to -0.9]) and BMI (-1.05 kg/m<sup>2</sup> [95% CI, -1.78 to -0.32]; z-score, -0.09 [95% CI, -0.14 to -0.04]) compared with standard care. The second included trial (n=23) compared rosiglitazone with placebo and recruited participants from the same obesity clinic as in the BB study.<sup>78</sup> Participants were between the ages of 13 and 18 years, had IGT or impaired fasting glucose (IFG)-IGT, and were in Tanner stage II-IV with a BMI z-score greater than 2 for age and sex. In the sample of mostly nonwhite (76%) females (57%), the study reported no significant differences in BMI (0.07 vs. -0.016, p=0.757) or weight changes (1.81 vs. 0.61, p=0.541) when comparing rosiglitazone with placebo at posttreatment.

A U.S.-based retrospective cohort study (n=4,184) using data from the Children's Hospital of Philadelphia examined the association between prediabetes identification and BMI.<sup>68</sup> In a sample of children (ages 10 to 18 years) who were overweight or obese (BMI z-score  $\geq 1.04$ ), the study compared differences in BMI z-score before and after available HbA1c tests. Median followup was 9.7 years. Youth were categorized as "screened" if at least 1 HbA1c result was available. Prediabetes was defined as 5.7 percent to 6.4 percent, 39 to 46 mmol/mol, and normal was defined as less than 5.7 percent, less than 39 mmol/mol. Using an adjusted model (adjusting for BMI z-score at HbA1c, age at HbA1c, sex, race, ethnicity, and insurance type), the study reported that children who had an HbA1c in the prediabetes range had a greater decrease in BMI z-score slope than children with a normal HbA1c (pre/post difference of -0.050/y [prediabetes] vs. -0.027 [normal], difference in difference: -0.023/year [95% CI, -0.042 to -0.004]). Children who had an HbA1c in the prediabetes range also had a greater decrease in BMI z-score slope than age-matched "unscreened" children who were obese (difference in difference: -0.031/year [95% CI, -0.042 to -0.021]) adjusting for BMI z-score at HbA1c (or matched age), age, sex, race, ethnicity, and insurance type. Limitations of the study include a lack of any information about whether or how prediabetes diagnosis was conveyed to patients, whether patients were provided counseling or interventions, whether patients changed behaviors as a result of HbA1c testing or prediabetes diagnosis, and reasons for testing (e.g., testing may be more likely for children who were obese who were initiating interventions for their obesity).

### CQ 3. b. Do interventions for (or does knowledge of) type 2 diabetes change BMI, weight, or healthy behaviors?

Two RCTs were identified that examined the association between diabetes interventions and changes in BMI, weight, and healthy behaviors.<sup>18, 53, 63, 65, 66, 79</sup> No studies were identified that examined if knowledge of diabetes was associated with BMI, weight, or healthy behaviors. The two identified trials examined metformin,<sup>18, 53, 63, 65, 66, 79</sup> metformin plus rosiglitazone,<sup>18, 53, 65, 66, 79</sup> and lifestyle intervention.<sup>18, 53, 65, 66, 79</sup> One trial (TODAY) was conducted in the United States,<sup>18, 53, 65, 66, 79</sup> and one trial included sites within multiple countries.<sup>63</sup> Both trials included racially diverse samples. Overall, studies reported that interventions including metformin (e.g., metformin alone, metformin plus lifestyle intervention) were associated with decreases in BMI and weight when compared with active comparators (e.g., metformin plus rosiglitazone); one study reported that metformin was not associated with significant changes compared with control. Studies comparing metformin with metformin plus lifestyle reported significant differences in BMI change and average weight change at shorter followups (e.g., 6 months). Differences between metformin and metformin plus lifestyle were not found for meaningful reductions in weight or when average weight change was examined at longer followups (e.g., 24 months). Studies also reported that interventions that included rosiglitazone (e.g., metformin plus rosiglitazone) were associated with increases in BMI when compared with other active comparators (e.g., metformin alone, metformin plus lifestyle). The findings of the two included trials were mixed. In addition, the TODAY study reported that the combination of metformin plus lifestyle was associated with improved health behaviors compared with metformin plus rosiglitazone for males at 6 months, although data were missing for many participants. Significant differences in health behaviors were not found between other intervention groups (e.g., metformin alone vs. metformin plus lifestyle, metformin alone vs. metformin plus rosiglitazone) among males, and no significant differences were found between groups among females.

One trial<sup>63</sup> conducted in multiple countries included children between the ages 8-16 years with a previous or new diabetes diagnosis. In the sample of mostly nonwhite (63%) females (70%), no significant differences were reported in the mean changes for BMI or weight when comparing metformin with placebo (-0.5 kg/m<sup>2</sup> vs. -0.4 kg/m<sup>2</sup> and -1.5 kg vs. -0.9 kg, respectively) at 16 weeks posttreatment.<sup>63</sup>

The second identified trial was the TODAY study (described in KQ 3).<sup>18, 53, 65, 66, 79</sup> At 6 months, the combination of metformin plus lifestyle was associated with significant decreases in BMI compared with metformin alone (-0.21 vs. 0.35,  $p=0.0201$ ) or in comparison with metformin plus rosiglitazone (-0.21 vs. 0.70,  $p=0.0002$ ). At 24 months, significant differences in BMI were reported between metformin plus rosiglitazone compared with metformin alone (2.93 vs. 1.57;  $p<0.0001$ ) and when comparing metformin plus rosiglitazone with metformin plus lifestyle (2.93 vs. 1.52,  $p<0.001$ ).

For average change in percentage overweight (defined as BMI minus BMI at the 50th percentile for age and sex, divided by BMI at the 50th percentile), the TODAY study reported that both metformin alone (-1.42 percentage points) and metformin plus lifestyle (-3.64 percentage points) were associated with significant decreases. The study also reported that metformin plus rosiglitazone was associated with a significant increase in percentage overweight (0.81

## Appendix A. Additional Background and Contextual Questions (CQs)

percentage points). The overall comparison and the comparison across all three groups were significant for this outcome at 6 months ( $p < 0.001$ ). At 24 months, differences between metformin plus rosiglitazone compared with metformin alone (0.89 percentage points vs. -4.42 percentage points), and metformin plus rosiglitazone compared with metformin plus lifestyle (0.89 percentage points vs. -5.02 percentage points) remained statistically significant ( $p < 0.001$ ). The differences between metformin and metformin and lifestyle were no longer significant at 24 months.<sup>18, 53, 65, 66, 79</sup>

The TODAY study also reported on the proportion of children with a meaningful reduction ( $\geq 7$  percentage points) in percentage overweight posttreatment. A higher proportion of children in the metformin plus lifestyle group had a meaningful reduction in overweight participants compared with metformin plus rosiglitazone (31.2% vs. 16.7%,  $p < 0.001$ ) at 6 months. The study did not report any significant differences when comparing metformin plus lifestyle versus metformin alone (31.2% vs. 24.3%,  $p = \text{NS}$ ).<sup>18, 53, 65, 66, 79</sup>

In addition, the TODAY study reported on the association between interventions and health behaviors.<sup>79</sup> However, the results for these outcomes may have a high risk of bias because of missing data (with data missing for 36% to 41% of participants, depending on the time point). At 6 months, males in the metformin plus lifestyle group were more likely to improve their eating habits and sedentary lifestyles compared with males in the metformin plus rosiglitazone group (50% vs. 26%,  $p = 0.01$ ). No significant differences were found between metformin plus lifestyle and metformin plus rosiglitazone at 24 months. Also, no significant differences were found between metformin plus lifestyle and metformin alone or between metformin alone and metformin plus rosiglitazone at 6 or 24 months. No significant differences in health behaviors were reported for females at 6 or 24 months across the three intervention groups.<sup>79</sup>

### **CQ 4. What is the frequency of agreement among screening tests (HbA1c level, FPG level, and 2-hour glucose tolerance test) for prediabetes and type 2 diabetes?**

We focused on studies from very high HDI countries with at least 100 participants that reported relevant outcomes and used (at least some) data collected within the past 10 years. Studies were required to report frequency of agreement between at least two of the relevant tests and to use current criteria for diagnosis of prediabetes or type 2 diabetes (based on the ADA guidelines); we excluded studies that used older criteria. We included eight articles (**Appendix A Table 2**). Of those eight, one compared A1c and OGTT,<sup>80</sup> two compared A1c and FPG,<sup>72, 81</sup> and five compared the results of all three tests (A1c, FPG, and OGTT).<sup>82-86</sup> Sample sizes ranged from 117 to 3,980. Five of the studies were conducted in the United States. The studies typically enrolled youths who were obese and overweight. Many of the studies reported relatively large differences in the proportion of youths diagnosed with prediabetes or diabetes when using different tests.<sup>72, 80, 81, 84, 86</sup> For example, a study of 902 predominantly black youths conducted in the United States reported that prediabetes prevalence was 54.3 percent based on A1c compared with only 5.6 percent when using OGTT, and a study of 149 predominately Hispanic youths reported a diabetes or prediabetes (combined) prevalence of 48 percent based on A1c compared with 12 percent based on FPG and 16 percent based on OGTT.<sup>80, 86</sup>

These findings are consistent with evidence in adults. Further, elevations in A1c, FPG, and OGTT results may represent somewhat different metabolic states. The 2021 evidence review for



## Appendix A. Additional Background and Contextual Questions (CQs)

the USPSTF on screening for prediabetes and diabetes in adults summarized a systematic review on the prevalence of prediabetes that would be identified by various screening tests.<sup>87</sup> The review identified five studies (with a total of 17,108 adults) that showed generally low agreement between HbA1c, fasting plasma glucose, and 2-hour glucose tolerance test.<sup>87</sup> For example, using ADA criteria, the prevalence of prediabetes by any test was 54 percent.<sup>87</sup> Of those, 25 percent had isolated IFG, 6 percent isolated IGT, 22 percent isolated HbA1c criteria, 7 percent IFG and IGT, 27 percent IFG and HbA1c criteria, 4 percent IGT and HbA1c criteria, and 9 percent had all three.<sup>87</sup>

### **CQ 5. Are there risk assessment tools that are feasible for use in primary care settings, accurately predict the risk of prediabetes or type 2 diabetes for children and adolescents, and have been externally validated in U.S. populations?**

We found two risk assessment tools for predicting risk of type 2 diabetes or prediabetes that have been validated in U.S. children or adolescents. Hannon and colleagues conducted a cluster-randomized clinical trial (published in 2017) to study the feasibility and effectiveness of a computerized clinical decision support system called Child Health Improvement Through Computer Automation (CHICA).<sup>88-93</sup> The risk assessment tool compiled relevant inputs from the parent section of a previsit questionnaire (family history, race/ethnicity), the clinic staff prescreening form (patient height and weight), and a physician worksheet (signs and symptoms of insulin resistance or conditions associated with insulin resistance). CHICA analyzes these inputs and identifies those at "high risk for type 2 diabetes" using the ADA guidelines from 2000 (i.e., if they had BMI  $\geq$ 85<sup>th</sup> percentile and two or more of the following risk factors: a family history of type 2 diabetes in a first- or second-degree relative, black race, Hispanic ethnicity, maternal history of diabetes or gestational diabetes, and signs of or conditions associated with insulin resistance) (the article did not provide additional details about what signs or conditions were considered as associated with insulin resistance). If high risk, it recommended screening for type 2 diabetes using FPG and HbA1c where prediabetes was defined as FPG 95 to 125 mg/dL and HbA1c 5.7 to 6.5 percent, and diabetes as FPG greater than 125 mg/dL and HbA1c greater than 6.5 percent. Children age 10 years or older (n=1,369) attending four primary care clinics in Indiana were included. The primary outcome was the percentage of youths identified with documented risk factors for type 2 diabetes. The authors found that the screening rate was significantly higher after using the tool, but the authors noted that using the tool did not lead to more patients being diagnosed with prediabetes or type 2 diabetes (although the study was not designed or powered for that outcome). The authors found that when using FPG, 33.3 percent of control patients screened and 22.2 percent of intervention patients had FPG in the prediabetes range, and none were in the diabetes range. When using HbA1c, 31.2 percent of control patients and 20.6 percent of intervention patients had levels in the prediabetes range, and only one patient in the intervention group was diagnosed with diabetes.

DuBose and colleagues developed an adapted version of the adult risk assessment tool called Tool for Assessing Glucose Impairment (TAG-IT) for an adolescent population (published in 2012) and named it Tool for Assessing Glucose Impairment among Adolescents (TAG-IT-A).<sup>94, 95</sup> They used data from a national U.S. sample from the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey (NHANES) from 1999 to 2008. To develop TAG-IT-A, the authors followed the development process of TAG-IT. They used multiple regression to calculate the association of individual patient factors (age, race, sex, BMI,

## Appendix A. Additional Background and Contextual Questions (CQs)

resting heart rate, hypertension diagnosis [measured resting blood pressure or physician diagnosis]) and fasting blood glucose and FPG greater than or equal to 100 mg/dL, defined as IFG. They then used regression to calculate the association of the group of significant factors with FPG level and calculated weighted scores for each factor to create a TAG-IT-A scoring system. The scoring system involves each predictive factor being given a score, modeled after the Charlson Comorbidity Index.<sup>96</sup> Odds ratios (ORs) from 1.0 to 1.19 were assigned 0 points, ORs from 1.2 to 1.49 were assigned 1 point, ORs from 1.5 to 2.49 were assigned 2 points, etc. The score from each factor is added together to create a final score, and as scores increased from 3 or higher, the authors reported that sensitivity of TAG-IT-A improved. The authors found that there was a positive and significant relationship between FPG and age (ages 12-14 years), sex (male), BMI (obese), and resting heart rate ( $\geq 70$  beats per minute), which are the four components that create the TAG-IT-A score. TAG-IT-A score was predictive of IFG with an area under the receiver operating curve (AUC)=0.61 (confidence interval not reported), indicating inadequate discrimination. Although the AUC was lower than it was found for the original TAG-IT tool, it was thought that TAG-IT-A may not be as predictive in adolescents because other variables that are not captured may be important, such as aerobic fitness, pubertal development, and physical activity levels.

We identified one additional tool that has not been studied in the United States but was studied in a European pediatric population. Gray and colleagues conducted an accuracy evaluation (published in 2019) of a previously developed risk prediction tool called PRESTART, comparing it with a reference standard of clinician assessment of whether the participant was high or low risk of developing type 2 diabetes in their lifetime.<sup>97</sup> Aside from stating that two clinicians independently judged each participant, with a third adjudicating if needed, no additional details are provided about how lifetime risk status was established. The authors recruited 636 adolescents age 12 to 14 years from five European countries (Germany, Greece, Portugal, Spain, and the United Kingdom). They found that participants were high risk if they were overweight/obese and had at least one other risk factor from among the following: high waist circumference, family history of diabetes, parental obesity, not breast fed, high sugar intake, high screen time, low physical activity, and low fruit and vegetable intake. The AUC when comparing PRESTART and clinician assessment was 0.74 (95% CI, 0.71 to 0.78).

**Appendix A Table 1. Screening Recommendations of Other Groups**

Organization, Year	Screening Recommendation	Risk Factors Considered	Frequency of Screening
American Diabetes Association, 2020 <sup>47</sup>	Screen children after onset of puberty or age 10 years who are overweight or obese and have one or more additional risk factors with FPG or 2-h PG after 75-g OGTT, or an A1c	Puberty; age (after 10 years); overweight (BMI $\geq$ 85 <sup>th</sup> percentile) or obese (BMI $\geq$ 95 <sup>th</sup> percentile); additional risk factors include maternal history of diabetes or GDM during the child's gestation, family history of type 2 diabetes in first- or second-degree relative, race/ethnicity (Native American, African American, Latino, Asian American, Pacific Islander), or signs of insulin resistance or conditions associated with insulin resistance (acanthosis nigricans, hypertension, dyslipidemia, polycystic ovary syndrome, or small-for-gestational-age birth weight)	Repeat screening every 3 years or more frequently if BMI is increasing
Diabetes Canada, 2018 <sup>69</sup>	Screen nonpubertal children with at least three risk factors and pubertal children with at least two risk factors with a combination of A1c and a FPG test or a random PG test	Obesity (BMI >95 <sup>th</sup> percentile for age and gender), member of a high-risk ethnic group (e.g., aboriginal, African, Asian, Hispanic, or South Asian descent), family history of type 2 diabetes or exposure to hyperglycemia in utero and symptoms of insulin resistance (including acanthosis nigricans, hypertension, dyslipidemia, NAFLD)	Repeat screening every 2 years in nonpubertal children with $\geq$ 3 risk factors and in pubertal children $\geq$ 2 risk factors, in children with IFG or impaired glucose tolerance, in children with use of atypical antipsychotic medications, and in children with PCOS
International Society for Pediatric and Adolescent Diabetes, 2014 <sup>70</sup>	Screen children and adolescents using American Diabetes Association criteria including using a FPG test, a 2-h postchallenge glucose test, or a hemoglobin A1c	NR	Does not specify, but supporting the American Diabetes Association criteria implies every 3 years or more frequent if BMI is increasing
National Institute for Health and Care Excellence (NICE), 2015 <sup>52</sup>	Does not have a true screening recommendation, but they state to "think about the possibility of type 2 diabetes in children and young people with suspected diabetes"	Family history of type 2 diabetes, obese at presentation, are of black or Asian family origin, have no insulin requirement or an insulin requirement of less than 0.5 units/kg body weight/day after the partial remission phase, and demonstrate evidence of insulin resistance	NR
Pediatric Endocrine Society (PES) Drugs and Therapeutics Committee, 2012 <sup>71</sup>	Screen children who are asymptomatic or minimally symptomatic and at risk with HbA1c test	HbA1c is unreliable in those with sickle-cell carrier status	NR

**Abbreviations:** BMI=body mass index; FPG=fasting plasma glucose; GDM=gestational diabetes mellitus; IFG=impaired fasting glucose; HbA1c=glycated hemoglobin; NAFLD=non-alcoholic fatty liver disease; NICE=National Institute for Health and Care Excellence; NR=not reported; OGTT=oral glucose tolerance test; PCOS=polycystic ovary syndrome; PES=Pediatric Endocrine Society; PG=2-h plasma glucose.

**Appendix A Table 2. Studies That Compared Agreement Among Screening Tests, by Comparison**

Author, Year	Comparison	N	Age, Mean (range)	Country	Race and Ethnicity	Main Results
Hitt et al., 2016 <sup>80</sup>	A1c and OGTT	902	11.6 (2 to 18 years)	U.S.	70% black	Diabetes prevalence: based on A1c was 2.9% (n=26) vs. 1.7% (n=15) based on OGTT Prediabetes prevalence: based on A1c was 54.3% (n=491) vs. 5.6% (n=51) based on OGTT
Buse et al., 2013 <sup>72</sup> HEALTHY	A1c and FPG	3,980	11 (10 to 14 years)	U.S.	91.5% white	3.2% had A1c 5.7%-6.4%; 16.0% had IFG. Of those with A1c 5.7% to 6.4% (128 participants), 63.3% had normal fasting glucose (<100) and 36.7% had IFG. Of those with normal A1c (<5.7%) (3,852 participants), 84.7% had normal fasting glucose and 15.3% had IFG
Tester et al., 2013 <sup>81</sup>	A1c and FPG	1,356	11 (2 to 19 years)	U.S.	14% black 49% Hispanic	Prediabetes prevalence was 20.7% based on A1c vs. 7.8% based on IFG
Kim et al., 2019 <sup>82</sup>	A1c, FPG, and OGTT	190	12.6 (NR)	South Korea	NR	Diabetes prevalence: based on A1c was 22.1% (n=42) vs. 21.1% (n=40) based on OGTT Prediabetes prevalence: based on A1c was 21.6% (n=41) vs. 17.4% (n=33) based on OGTT Diagnostic sensitivity (for diabetes) was lower for FPG (63.8%) than for A1c (89.4%) or OGTT (85.1%)
Yoon et al., 2018 <sup>83</sup>	A1c, FPG, and OGTT	236	10.4 (NR)	South Korea	NR	Diabetes prevalence: 17% (n=39) based on OGTT. Prediabetes prevalence: 22% (n=52) based on OGTT. Using ADA cutoffs, A1c had sensitivity of 87.2% and specificity of 98.5% for detecting diabetes and FPG had 66.7% and 99.0%, respectively (compared with OGTT reference standard)
Chan et al., 2016 <sup>84</sup>	A1c, FPG, and OGTT	117	14.1 (10 to 18 years)	U.S.	22% white 17% black 59% Hispanic	About half of the participants met criteria for prediabetes or diabetes based on either OGTT (40.2%) or HbA1c (51.3%), but only 9% met FPG criteria for prediabetes or diabetes
Galhardo and Shield, 2015 <sup>85</sup>	A1c, FPG, and OGTT	266	12.3 (8.9 to 17.6 years)	Portugal	90% white	Diabetes prevalence: 1 (0.4%) based on A1c vs 0 (0%) based on OGTT Prediabetes prevalence: 32 (12%) based on A1c vs. 13 (4.9%) based on OGTT A1c had AUC 0.59 (95% CI 0.40 to 0.78) and FPG had AUC 0.76 (95% CI 0.66 to 0.87) using OGTT as the reference standard
Brar et al., 2014 <sup>86</sup>	A1c, FPG, and OGTT	149	13.0 to 13.8 (NR)	U.S.	71% Hispanic	Prediabetes or type 2 diabetes prevalence: 71 (48%) based on A1c vs 18 (12%) based on FPG vs. 24 (16%) based on OGTT

**Abbreviations:** ADA=American Diabetes Association; AUC=area under the curve; CI=confidence interval; FPG=fasting plasma glucose; IFG=impaired fasting glucose; NR=not reported; OGTT=oral glucose tolerance test.

## Appendix B1. Original Literature Search Strategies

### PubMed Screening, 8/3/2020

Search Number	Query	Filters	Results
1	"Diabetes Mellitus, Type 2"[Mesh] OR "Glucose Tolerance"[Mesh] OR "glucose tolerance"[All Fields] OR "impaired glucose tolerance"[All Fields] OR dysglycemia[tiab] OR IGT OR "impaired fasting glucose" OR IFG OR "Glucose Intolerance"[MeSH] OR "glucose intolerance"[All Fields] OR "Prediabetic State"[MeSH] OR "prediabetic state"[All Fields] OR prediabet* OR "pre diabetes"[All Fields] OR "diabetes mellitus type 2"[All Fields] OR "type 2 diabetes mellitus"[All Fields]		213,359
2	"Blood Glucose"[Mesh] OR "blood glucose"[tiab] OR "Glucose Tolerance Test"[Mesh] OR OGTT[tiab] OR "glucose tolerance test"[ti] OR "Glycated Hemoglobin A"[Mesh] OR "hemoglobin A1c" OR HbA1c OR "fasting plasma glucose"[tiab] OR "oral glucose tolerance"[tiab]		253,967
3	#1 AND #2		97,474
4	"Mass Screening"[Mesh] OR screen*[tiab]		796,716
5	#3 AND #4		6,429
6	#5 NOT (gestation* OR Pregnancy[Mesh])		4,708
7	#5 NOT (gestation* OR Pregnancy[Mesh])	English	4,331
8	#5 NOT (gestation* OR Pregnancy[Mesh])	English, Child: birth-18 years	698
9	adolescen*[tiab] OR boys[tiab] OR child*[tiab] OR children[tiab] OR girls[tiab] OR pediatric[tiab] OR paediatric*[tiab] OR teen[tiab] OR teens[tiab] OR teenage[tiab] OR teenaged[tiab] OR teenager*[tiab] OR toddler*[tiab]		1,766,063
10	#7 AND #9		345
11	#8 OR #10		759
12	(#11 AND humans[mesh:noexp]) OR (#11 NOT animals[mesh:noexp])		758
13	("review"[Publication Type] AND "systematic"[tiab]) OR "systematic review"[All Fields] OR ("review literature as topic"[MeSH] AND "systematic"[tiab]) OR "meta-analysis"[Publication Type] OR "meta-analysis as topic"[MeSH Terms] OR "meta-analysis"[All Fields] OR "meta synthesis"[ti] OR "systematic literature review"[ti] OR "this systematic review"[tw] OR "cochrane database syst rev"[ta]		323,325
14	#12 AND #13		<b>11</b>
15	"controlled clinical trial"[publication type] OR "Randomized Controlled Trial"[Publication Type] OR "Single-Blind Method"[MeSH] OR "Double-Blind Method"[MeSH] OR "Random Allocation"[MeSH] OR (controlled[tiab] AND trial[tiab]) OR groups [tiab] OR placebo [tiab] OR randomised [tiab] OR randomized [tiab] OR randomly [tiab] OR trial [tiab]		3,141,667
16	#12 AND #15		<b>206</b>
17	#12 AND "Case-Control Studies"[MeSH]		74
18	"Cohort Studies"Mesh] OR "Epidemiologic Studies"[Mesh] OR "Follow-up Studies"[Mesh] OR "prospective cohort" OR "prospective studies"[MeSH] OR (prospective*[All Fields] AND cohort[All Fields] AND (study[All Fields] OR studies[All Fields]))		2,550,540
19	#12 AND #18		284
20	"Evaluation Study"[pt] OR "Comparative Study"[pt]		2,062,504
21	#12 AND #20		70
22	#17 OR #19 OR #21		<b>324</b>

**Appendix B1. Original Literature Search Strategies**

**PubMed Interventions, 8/3/2020**

Search Number	Query	Filters	Results
1	"Diabetes Mellitus, Type 2"[Mesh] OR "Glucose Tolerance"[Mesh] OR "glucose tolerance"[All Fields] OR "impaired glucose tolerance"[All Fields] OR dysglycemia[tiab] OR IGT OR "impaired fasting glucose" OR IFG OR "Glucose Intolerance"[MeSH] OR "glucose intolerance"[All Fields] OR "Prediabetic State"[MeSH] OR "prediabetic state"[All Fields] OR prediabet* OR "pre diabetes"[All Fields] OR "diabetes mellitus type 2"[All Fields] OR "type 2 diabetes mellitus"[All Fields]		213,359
2	Actos[tiab] OR Albiglutide[tiab] OR Amaryl[tiab] OR Biguanides[Mesh] OR Biguanides[tiab] OR Bydureon[tiab] OR Byetta[tiab] OR DiaBeta[tiab] OR "Dipeptidyl-Peptidase IV Inhibitors"[Mesh] OR "Dipeptidyl-Peptidase IV Inhibitors"[Pharmacological Action] OR "Dipeptidyl peptidase IV inhibitor"[tiab] OR "Dipeptidyl peptidase IV inhibitors"[tiab] OR dulaglutide[Supplementary Concept] OR dulaglutide[tiab] OR exenatide[Supplementary Concept] OR Exenatide[tiab] OR Fortamet[tiab] OR Gliclazide[Mesh] OR Gliclazide[tiab] OR glimepiride[tiab] OR Glipizide[Mesh] OR glipizide[tiab] OR "GLP-1 receptor agonist"[tiab] OR "GLP-1 receptor agonists"[tiab] OR "Glucagon-like peptide-1 receptor agonist"[tiab] OR "Glucagon-like peptide-1 receptor agonists"[tiab] OR Glucophage[tiab] OR Glucotrol[tiab] OR "Glucotrol XL"[tiab] OR Glumetza[tiab] OR Glyburide[Mesh] OR glyburide[tiab] OR "Glynase PresTab"[tiab] OR Linagliptin[Mesh] OR Linagliptin[tiab] OR Liraglutide[Mesh] OR liraglutide[tiab] OR lixisenatide[Supplementary Concept] OR lixisenatide[tiab] OR Lyxumia[tiab] OR Meglitinides[tiab] OR Metformin[Mesh] OR Metformin[tiab] OR Micronase[tiab] OR nateglinide[Supplementary Concept] OR Nateglinide[tiab] OR Ozempic[tiab] OR pioglitazone[Supplementary Concept] OR Pioglitazone[tiab] OR Prandin[tiab] OR Repaglinide[tiab] OR rosiglitazone[Supplementary Concept] OR Rosiglitazone[tiab] OR Saxagliptin[tiab] OR semaglutide[Supplementary Concept] OR semaglutide[tiab] OR Sitagliptin[tiab] OR "Sitagliptin Phosphate"[Mesh] OR "Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination"[Mesh] OR "Sulfonylurea Compounds"[Mesh] OR Starlix[tiab] OR Sulfonylureas[tiab] OR Tanzeum[tiab] OR Thiazolidinediones[Mesh] OR Thiazolidinediones[tiab] OR Tolazamide[Mesh] OR Tolazamide[tiab] OR Tolbutamide[Mesh] OR tolbutamide[tiab] OR Trulicity[tiab] OR TZDs[tiab] OR Victoza[tiab] OR vildagliptin[Supplementary Concept] OR vildagliptin[tiab]		78,684
3	#1 AND #2		23,456

## Appendix B1. Original Literature Search Strategies

Search Number	Query	Filters	Results
4	advice[tiab] OR "Behavior Therapy"[Mesh] OR "behavior therapy"[tiab] OR (behavior*[tiab] AND therap*[tiab]) OR (behavior*[tiab] AND chang*[tiab]) OR (behavior*[tiab] AND modification*[tiab]) OR "Caloric Restriction"[Mesh] OR ((child*[tiab] AND parent*[tiab]) and therap*[tiab]) OR Counseling[Mesh] OR counsel*[tiab] OR "cognitive behavior"[tiab] OR "cognitive behavioral"[tiab] OR "cognitive therap*[tiab] OR CBT[tij] OR "Diabetes Prevention Program"[tiab] OR "Diabetes Prevention Programme"[tiab] OR DPP[tiab] OR ("Diabetes Prevention"[tiab] AND (program*[tiab] OR stud*[tiab] OR trial*[tiab])) OR diet[tij] OR "Diet, Carbohydrate-Restricted"[Mesh] OR "Diet, Fat-Restricted"[Mesh] OR "Diet, Mediterranean"[Mesh] OR "Diet, Reducing"[Mesh] OR "Diet Therapy"[Mesh] OR dietary[tij] OR "Directive Counseling"[Mesh] OR Exercise[Mesh] OR exercise[tij] OR "Exercise Therapy"[Mesh] OR "family intervention*[tiab] OR "family therap*[tiab] OR "Feedback, Psychological"[Mesh] OR "group therap*[tiab] OR "Health Behavior"[Majr] OR "health behavior"[tiab] OR "health behaviors"[tiab] OR "health behavioral"[tiab] "health behaviours"[tiab] OR "health behaviour"[tiab] OR "Health Education"[Mesh] OR "Health Education as Topic"[Mesh] OR "health education"[tiab] OR "Health Promotion"[Majr] OR "health promotion"[tiab] OR "Life Style"[Mesh] OR lifestyle[tiab] OR "life style"[tiab] OR "Lifestyle Intervention"[Mesh] OR "Motivational Interviewing"[Mesh] OR "motivational interviewing"[tiab] OR "non pharmacologic intervention"[tiab] OR "nonpharmacologic intervention"[tiab] OR "parent* intervention*[tiab] OR "Patient Education as Topic"[Mesh] OR "patient education"[tiab] OR "physical activity"[tij] OR "physically active"[tij] OR "psychological feedback"[tiab] OR "Risk Reduction Behavior"[Mesh] OR "Risk Reduction Behavior"[tiab] OR "Weight Loss"[Mesh] OR "Weight Reduction Programs"[Mesh]		507,576
5	#1 AND #4		19,500
6	#3 OR #5		41,039
7	(#6 AND Humans[Mesh:NOEXP]) OR (#6 NOT Animals[Mesh:NOEXP])		38,332
8	(#6 AND Humans[Mesh:NOEXP]) OR (#6 NOT Animals[Mesh:NOEXP])	English	34,717
9	(#6 AND Humans[Mesh:NOEXP]) OR (#6 NOT Animals[Mesh:NOEXP])	English, Child: birth-18 years	2,985
10	adolescen*[tiab] OR boys[tiab] OR child*[tiab] OR children[tiab] OR girls[tiab] OR pediatric[tiab] OR paediatric*[tiab] OR teen[tiab] OR teens[tiab] OR teenage[tiab] OR teenaged[tiab] OR teenager*[tiab] OR toddler*[tiab]		1,766,063
11	#8 AND #10		1,507
12	#9 OR #11		3,429
13	address[pt] OR "autobiography"[pt] OR "bibliography"[pt] OR "biography"[pt] OR "case report"[tw] OR "case reports"[tw] OR "case series"[tw] OR "comment"[pt] OR "comment on"[All Fields] OR congress[pt] OR "cross-sectional"[tw] OR "dictionary"[pt] OR "directory"[pt] OR "editorial"[pt] OR "festschrift"[pt] OR "historical article"[pt] OR "interview"[pt] OR lecture[pt] OR "legal case"[pt] OR "legislation"[pt] OR letter[pt] OR "news"[pt] OR "newspaper article"[pt] OR "patient education handout"[pt] OR "periodical index"[pt] OR "retrospective cohort"[tw] OR ("Animals"[Mesh] NOT "Humans"[Mesh]) OR rats[tw] OR cow[tw] OR cows[tw] OR chicken[tw] OR chickens[tw] OR horse[tw] OR horses[tw] OR mice[tw] OR mouse[tw] OR bovine[tw] OR sheep OR ovine OR murine OR murinae		10,840,629
14	#12 NOT #13		2,846

## Appendix B1. Original Literature Search Strategies

Search Number	Query	Filters	Results
15	#14 NOT (gestation* OR Pregnancy[Mesh])		2,500
16	"controlled clinical trial"[publication type] OR "Randomized Controlled Trial"[Publication Type] OR "Single-Blind Method"[MeSH] OR "Double-Blind Method"[MeSH] OR "Random Allocation"[MeSH] OR (controlled[tiab] AND trial[tiab]) OR groups [tiab] OR placebo [tiab] OR randomised [tiab] OR randomized [tiab] OR randomly [tiab] OR trial [tiab]		3,141,667
17	#15 AND #16		999
18	("review"[Publication Type] AND "systematic"[tiab]) OR "systematic review"[All Fields] OR ("review literature as topic"[MeSH] AND "systematic"[tiab]) OR "meta-analysis"[Publication Type] OR "meta-analysis as topic"[MeSH Terms] OR "meta-analysis"[All Fields] OR "meta synthesis"[ti] OR "systematic literature review"[ti] OR "this systematic review"[tw] OR "cochrane database syst rev"[ta]		323,325
19	#15 AND #18		76
20	#15 AND "Case-Control Studies"[MeSH]		188
21	#15 AND ("Cohort Studies"[Mesh:NOEXP] OR "Epidemiologic Studies"[Mesh] OR "Follow-up Studies"[Mesh] OR "prospective cohort" OR "prospective studies"[MeSH] OR (prospective*[All Fields] AND cohort[All Fields] AND (study[All Fields] OR studies[All Fields])))		519
22	#15 AND ("Evaluation Study"[pt] OR "Comparative Study"[pt])		252

### Cochrane Library Screening, 8/3/2020

ID	Search	Hits
#1	[mh "Diabetes Mellitus, Type 2"] OR [mh "Glucose Tolerance"] OR "glucose tolerance" OR "impaired glucose tolerance" OR dysglycemia:ti,ab OR IGT OR "impaired fasting glucose" OR IFG OR [mh "Glucose Intolerance"] OR "glucose intolerance" OR [mh "Prediabetic State"] OR "prediabetic state" OR prediabet* OR "pre diabetes" OR "diabetes mellitus type 2" OR "type 2 diabetes mellitus"	34233
#2	[mh "Blood Glucose"] OR "blood glucose":ti,ab OR [mh "Glucose Tolerance Test"] OR OGTT:ti,ab OR "glucose tolerance test":ti OR [mh "Glycated Hemoglobin A"] OR "hemoglobin A1c" OR HbA1c OR "fasting plasma glucose":ti,ab OR "oral glucose tolerance":ti,ab	45778
#3	#1 AND #2	19244
#4	[mh "Mass Screening"] OR screen*:ti,ab	67390
#5	#3 AND #4	1702
#6	#5 NOT (gestation* OR [mh Pregnancy])	1521
#7	adolescen*:ti,ab,kw OR boys:ti,ab,kw OR child*:ti,ab,kw OR children:ti,ab,kw OR girls:ti,ab,kw OR pediatric:ti,ab,kw OR paediatric*:ti,ab,kw OR teen:ti,ab,kw OR teens:ti,ab,kw OR teenage:ti,ab,kw OR teenaged:ti,ab,kw OR teenager*:ti,ab,kw OR toddler*:ti,ab,kw	248461
#8	#6 AND #7	197



## Appendix B1. Original Literature Search Strategies

### Cochrane Library Interventions, 8/3/2020

ID	Search	Hits
#1	[mh "Diabetes Mellitus, Type 2"] OR [mh "Glucose Tolerance"] OR "glucose tolerance" OR "impaired glucose tolerance" OR dysglycemia:ti,ab OR IGT OR "impaired fasting glucose" OR IFG OR [mh "Glucose Intolerance"] OR "glucose intolerance" OR [mh "Prediabetic State"] OR "prediabetic state" OR prediabet* OR "pre diabetes" OR "diabetes mellitus type 2" OR "type 2 diabetes mellitus"	34233
#2	Actos:ti,ab OR Albiglutide:ti,ab OR Amaryl:ti,ab OR [mh Biguanides] OR Biguanides:ti,ab OR Bydureon:ti,ab OR Byetta:ti,ab OR DiaBeta:ti,ab OR [mh "Dipeptidyl-Peptidase IV Inhibitors"] OR "Dipeptidyl peptidase IV inhibitor":ti,ab OR "Dipeptidyl peptidase IV inhibitors":ti,ab OR dulaglutide:ti,ab OR Exenatide:ti,ab OR Fortamet:ti,ab OR [mh Gliclazide] OR Gliclazide:ti,ab OR gimepiride:ti,ab OR [mh Glipizide] OR glipizide:ti,ab OR "GLP-1 receptor agonist":ti,ab OR "GLP-1 receptor agonists":ti,ab OR "Glucagon-like peptide-1 receptor agonist":ti,ab OR "Glucagon-like peptide-1 receptor agonists":ti,ab OR Glucophage:ti,ab OR Glucotrol:ti,ab OR "Glucotrol XL":ti,ab OR Glumetza:ti,ab OR [mh Glyburide] OR glyburide:ti,ab OR "Glynase PresTab":ti,ab OR [mh Linagliptin] OR Linagliptin:ti,ab OR [mh Liraglutide] OR liraglutide:ti,ab OR lixisenatide:ti,ab OR Lyxumia:ti,ab OR Meglitinides:ti,ab OR [mh Metformin] OR Metformin:ti,ab OR Micronase:ti,ab OR Nateglinide:ti,ab OR Ozempic:ti,ab OR Pioglitazone:ti,ab OR Prandin:ti,ab OR Repaglinide:ti,ab OR Rosiglitazone:ti,ab OR Saxagliptin:ti,ab OR semaglutide:ti,ab OR Sitagliptin:ti,ab OR [mh "Sitagliptin Phosphate"] OR [mh "Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination"] OR [mh "Sulfonylurea Compounds"] OR Starlix:ti,ab OR Sulfonylureas:ti,ab OR Tanzeum:ti,ab OR [mh Thiazolidinediones] OR Thiazolidinediones:ti,ab OR [mh Tolazamide] OR Tolazamide:ti,ab OR [mh Tolbutamide] OR tolbutamide:ti,ab OR Trulicity:ti,ab OR TZDs:ti,ab OR Victoza:ti,ab OR vildagliptin:ti,ab	21765
#3	#1 AND #2	9227
#4	advice:ti,ab OR [mh "Behavior Therapy"] OR "behavior therapy":ti,ab OR (behavior*:ti,ab AND therap*:ti,ab) OR (behavior*:ti,ab AND chang*:ti,ab) OR (behavior*:ti,ab AND modification*:ti,ab) OR [mh "Caloric Restriction"] OR ((child*:ti,ab AND parent*:ti,ab) and therap*:ti,ab) OR [mh Counseling] OR counsel*:ti,ab OR "cognitive behavior":ti,ab OR "cognitive behavioral":ti,ab OR "cognitive therap*":ti,ab OR CBT:ti OR "Diabetes Prevention Program":ti,ab OR "Diabetes Prevention Programme":ti,ab OR DPP:ti,ab OR ("Diabetes Prevention":ti,ab AND (program*:ti,ab OR stud*:ti,ab OR trial*:ti,ab)) OR diet:ti OR [mh "Diet, Carbohydrate-Restricted"] OR [mh "Diet, Fat-Restricted"] OR [mh "Diet, Mediterranean"] OR [mh "Diet, Reducing"] OR [mh "Diet Therapy"] OR dietary:ti OR [mh "Directive Counseling"] OR [mh Exercise] OR exercise:ti OR [mh "Exercise Therapy"] OR "family intervention":ti,ab OR "family therap*":ti,ab OR [mh "Feedback, Psychological"] OR "group therap*":ti,ab OR [mh ^"Health Behavior"] OR "health behavior":ti,ab OR "health behaviors":ti,ab OR "health behavioral":ti,ab OR "health behaviours":ti,ab OR "health behaviour":ti,ab OR [mh "Health Education"] OR [mh "Health Education as Topic"] OR "health education":ti,ab OR [mh ^"Health Promotion"] OR "health promotion":ti,ab OR [mh "Life Style"] OR lifestyle:ti,ab OR "life style":ti,ab OR [mh "Lifestyle Intervention"] OR [mh "Motivational Interviewing"] OR "motivational interviewing":ti,ab OR "non pharmacologic intervention":ti,ab OR "nonpharmacologic intervention":ti,ab OR "parent* intervention*":ti,ab OR [mh "Patient Education as Topic"] OR "patient education":ti,ab OR "physical activity":ti OR "physically active":ti OR "psychological feedback":ti,ab OR [mh "Risk Reduction Behavior"] OR "Risk Reduction Behavior":ti,ab OR [mh "Weight Loss"] OR [mh "Weight Reduction Programs"]	181889
#5	#1 AND #4	8940
#6	#3 OR #5	16313
#7	#6 NOT ([mh animals] NOT [mh humans])	16313
#8	adolescen*:ti,ab,kw OR boys:ti,ab,kw OR child*:ti,ab,kw OR children:ti,ab,kw OR girls:ti,ab,kw OR pediatric:ti,ab,kw OR paediatric*:ti,ab,kw OR teen:ti,ab,kw OR teens:ti,ab,kw OR teenage:ti,ab,kw OR teenaged:ti,ab,kw OR teenager*:ti,ab,kw OR toddler*:ti,ab,kw	248461
#9	#7 AND #8	1360
#10	#9 NOT (gestation* OR [mh Pregnancy])	1162

**Appendix B1. Original Literature Search Strategies**

**PubMed Interventions Addendum #1, 8/4/2020**

Search Number	Query	Filters	Results
1	"Diabetes Mellitus, Type 2"[Mesh] OR "Glucose Tolerance"[Mesh] OR "glucose tolerance"[All Fields] OR "impaired glucose tolerance"[All Fields] OR dysglycemia[tiab] OR IGT OR "impaired fasting glucose" OR IFG OR "Glucose Intolerance"[MeSH] OR "glucose intolerance"[All Fields] OR "Prediabetic State"[MeSH] OR "prediabetic state"[All Fields] OR prediabet* OR "pre diabetes"[All Fields] OR "diabetes mellitus type 2"[All Fields] OR "type 2 diabetes mellitus"[All Fields]		213,453
2	advice[tiab] OR "Behavior Therapy"[Mesh] OR "behavior therapy"[tiab] OR (behavior*[tiab] AND therap*[tiab]) OR (behavior*[tiab] AND chang*[tiab]) OR (behavior*[tiab] AND modification*[tiab]) OR "Caloric Restriction"[Mesh] OR ((child*[tiab] AND parent*[tiab]) and therap*[tiab]) OR Counseling[Mesh] OR counsel*[tiab] OR "cognitive behavior"[tiab] OR "cognitive behavioral"[tiab] OR "cognitive therap*"[tiab] OR CBT[ti] OR "Diabetes Prevention Program"[tiab] OR "Diabetes Prevention Programme"[tiab] OR DPP[tiab] OR ("Diabetes Prevention"[tiab] AND (program*[tiab] OR stud*[tiab] OR trial*[tiab])) OR diet[ti] OR "Diet, Carbohydrate-Restricted"[Mesh] OR "Diet, Fat-Restricted"[Mesh] OR "Diet, Mediterranean"[Mesh] OR "Diet, Reducing"[Mesh] OR "Diet Therapy"[Mesh] OR dietary[ti] OR "Directive Counseling"[Mesh] OR Exercise[Mesh] OR exercise[ti] OR "Exercise Therapy"[Mesh] OR "family intervention*"[tiab] OR "family therap*"[tiab] OR "Feedback, Psychological"[Mesh] OR "group therap*"[tiab] OR "Health Behavior"[Majr] OR "health behavior"[tiab] OR "health behaviors"[tiab] OR "health behavioral"[tiab] OR "health behaviours"[tiab] OR "health behaviour"[tiab] OR "Health Education"[Mesh] OR "Health Education as Topic"[Mesh] OR "health education"[tiab] OR "Health Promotion"[Majr] OR "health promotion"[tiab] OR "Life Style"[Mesh] OR lifestyle[tiab] OR "life style"[tiab] OR "Lifestyle Intervention"[Mesh] OR "Motivational Interviewing"[Mesh] OR "motivational interviewing"[tiab] OR "non pharmacologic intervention"[tiab] OR "nonpharmacologic intervention"[tiab] OR "parent* intervention*"[tiab] OR "Patient Education as Topic"[Mesh] OR "patient education"[tiab] OR "physical activity"[ti] OR "physically active"[ti] OR "psychological feedback"[tiab] OR "Risk Reduction Behavior"[Mesh] OR "Risk Reduction Behavior"[tiab] OR "Weight Loss"[Mesh] OR "Weight Reduction Programs"[Mesh]		1,475,119
3	#1 AND #2		37,820
4	(#3 AND Humans[Mesh:NOEXP]) OR (#3 NOT Animals[Mesh:NOEXP])		33,767
5	(#3 AND Humans[Mesh:NOEXP]) OR (#3 NOT Animals[Mesh:NOEXP])	English	31,056
6	(#3 AND Humans[Mesh:NOEXP]) OR (#3 NOT Animals[Mesh:NOEXP])	English, Child: birth-18 years	3,077
7	adolescen*[tiab] OR boys[tiab] OR child*[tiab] OR children[tiab] OR girls[tiab] OR pediatric[tiab] OR paediatric*[tiab] OR teen[tiab] OR teens[tiab] OR teenage[tiab] OR teenaged[tiab] OR teenager*[tiab] OR toddler*[tiab]		1,766,520
8	#5 AND #7		1,778
9	#6 OR #8		3,617
10	address[pt] OR "autobiography"[pt] OR "bibliography"[pt] OR "biography"[pt] OR "case report"[tw] OR "case reports"[tw] OR "case series"[tw] OR "comment"[pt] OR "comment on"[All Fields] OR congress[pt] OR "cross-sectional"[tw] OR "dictionary"[pt] OR "directory"[pt] OR "editorial"[pt] OR "festschrift"[pt] OR "historical article"[pt] OR "interview"[pt] OR lecture[pt] OR "legal case"[pt] OR "legislation"[pt] OR letter[pt] OR "news"[pt] OR "newspaper article"[pt] OR "patient education handout"[pt] OR "periodical index"[pt] OR "retrospective cohort"[tw] OR ("Animals"[Mesh] NOT "Humans"[Mesh]) OR rats[tw] OR cow[tw] OR cows[tw] OR chicken[tw] OR chickens[tw] OR horse[tw] OR horses[tw] OR mice[tw] OR mouse[tw] OR bovine[tw] OR sheep OR ovine OR murine OR murinae		10,842,788

## Appendix B1. Original Literature Search Strategies

Search Number	Query	Filters	Results
11	#9 NOT #10		2,978
12	#11 NOT (gestation* OR Pregnancy[Mesh])		2,547
13	("review"[Publication Type] AND "systematic"[tiab]) OR "systematic review"[All Fields] OR ("review literature as topic"[MeSH] AND "systematic"[tiab]) OR "meta-analysis"[Publication Type] OR "meta-analysis as topic"[MeSH Terms] OR "meta-analysis"[All Fields] OR "meta synthesis"[ti] OR "systematic literature review"[ti] OR "this systematic review"[tw] OR "cochrane database syst rev"[ta]		323,538
14	#12 AND #13		88
15	"controlled clinical trial"[publication type] OR "Randomized Controlled Trial"[Publication Type] OR "Single-Blind Method"[MeSH] OR "Double-Blind Method"[MeSH] OR "Random Allocation"[MeSH] OR (controlled[tiab] AND trial[tiab]) OR groups [tiab] OR placebo [tiab] OR randomised [tiab] OR randomized [tiab] OR randomly [tiab] OR trial [tiab]		3,142,672
16	#12 AND #15		918
17	#12 AND "Case-Control Studies"[MeSH]		165
18	#12 AND ("Cohort Studies"[Mesh:NOEXP] OR "Epidemiologic Studies"[Mesh] OR "Follow-up Studies"[Mesh] OR "prospective cohort" OR "prospective studies"[MeSH] OR (prospective*[All Fields] AND cohort[All Fields] AND (study[All Fields] OR studies[All Fields])))		496
19	#12 AND ("Evaluation Study"[pt] OR "Comparative Study"[pt])		224

## Cochrane Library Interventions Addendum #1, 8/4/2020

ID	Search	Hits
#1	[mh "Diabetes Mellitus, Type 2"] OR [mh "Glucose Tolerance"] OR "glucose tolerance" OR "impaired glucose tolerance" OR dysglycemia:ti,ab OR IGT OR "impaired fasting glucose" OR IFG OR [mh "Glucose Intolerance"] OR "glucose intolerance" OR [mh "Prediabetic State"] OR "prediabetic state" OR prediabet* OR "pre diabetes" OR "diabetes mellitus type 2" OR "type 2 diabetes mellitus"	34233
#2	advice:ti,ab OR [mh "Behavior Therapy"] OR "behavior therapy":ti,ab OR (behavior*:ti,ab AND therap*:ti,ab) OR (behavior*:ti,ab AND chang*:ti,ab) OR (behavior*:ti,ab AND modification*:ti,ab) OR [mh "Caloric Restriction"] OR ((child*:ti,ab AND parent*:ti,ab) and therap*:ti,ab) OR [mh Counseling] OR counsel*:ti,ab OR "cognitive behavior":ti,ab OR "cognitive behavioral":ti,ab OR "cognitive therap*":ti,ab OR CBT:ti OR "Diabetes Prevention Program":ti,ab OR "Diabetes Prevention Programme":ti,ab OR DPP:ti,ab OR ("Diabetes Prevention":ti,ab AND (program*:ti,ab OR stud*:ti,ab OR trial*:ti,ab)) OR diet:ti OR [mh "Diet, Carbohydrate-Restricted"] OR [mh "Diet, Fat-Restricted"] OR [mh "Diet, Mediterranean"] OR [mh "Diet, Reducing"] OR [mh "Diet Therapy"] OR dietary:ti OR [mh "Directive Counseling"] OR [mh Exercise] OR exercise:ti OR [mh "Exercise Therapy"] OR "family intervention*":ti,ab OR "family therap*":ti,ab OR [mh "Feedback, Psychological"] OR "group therap*":ti,ab OR [mh ^"Health Behavior"] OR "health behavior":ti,ab OR "health behaviors":ti,ab OR "health behavioral":ti,ab OR "health behaviours":ti,ab OR "health behaviour":ti,ab OR [mh "Health Education"] OR [mh "Health Education as Topic"] OR "health education":ti,ab OR [mh ^"Health Promotion"] OR "health promotion":ti,ab OR [mh "Life Style"] OR lifestyle:ti,ab OR "life style":ti,ab OR [mh "Lifestyle Intervention"] OR [mh "Motivational Interviewing"] OR "motivational interviewing":ti,ab OR "non pharmacologic intervention":ti,ab OR "nonpharmacologic intervention":ti,ab OR "parent* intervention*":ti,ab OR [mh "Patient Education as Topic"] OR "patient education":ti,ab OR "physical activity":ti OR "physically active":ti OR "psychological feedback":ti,ab OR [mh "Risk Reduction Behavior"] OR "Risk Reduction Behavior":ti,ab OR [mh "Weight Loss"] OR [mh "Weight Reduction Programs"]	181924
#3	#1 AND #2	8941
#4	#3 NOT (([mh animals] NOT [mh humans]))	8941
#5	adolescen*:ti,ab,kw OR boys:ti,ab,kw OR child*:ti,ab,kw OR children:ti,ab,kw OR girls:ti,ab,kw OR pediatric:ti,ab,kw OR paediatric*:ti,ab,kw OR teen:ti,ab,kw OR teens:ti,ab,kw OR teenage:ti,ab,kw OR teenaged:ti,ab,kw OR teenager*:ti,ab,kw OR toddler*:ti,ab,kw	248464
#6	#4 AND #5	844

## Appendix B1. Original Literature Search Strategies

ID	Search	Hits
#7	#6 NOT (gestation* OR [mh Pregnancy])	700

### PubMed Interventions Addendum #2, 8/19/2020

Search Number	Query	Filters	Results
1	"Diabetes Mellitus, Type 2"[Mesh] OR "Glucose Tolerance"[Mesh] OR "Glucose Intolerance"[MeSH] OR "Prediabetic State"[MeSH]		143,540
2	("diabetes mellitus type 2"[All Fields] OR dysglycemia[tiab] OR "glucose tolerance"[All Fields] OR "glucose intolerance"[All Fields] OR IGT OR "impaired fasting glucose" OR IFG OR "impaired glucose tolerance"[All Fields] OR "prediabetic state"[All Fields] OR prediabet* OR "pre diabetes"[All Fields] OR "type 2 diabetes mellitus"[All Fields]) NOT (Medline[sb])		17,008
3	#1 OR #2		160,548
5	#3 NOT ("Diabetes Mellitus, Type 1"[Mesh] OR "diabetes mellitus type 1" OR "type 1 diabetes")		143,845
6	(hypoglycemic agents[mh] OR "Hypoglycemic Agents" [Pharmacological Action]) OR ("hypoglycemic agent*" [tiab] NOT Medline[sb])		259,681
7	#5 AND #6		41,304
8	(Insulin[Mesh] OR "Insulin, Long-Acting"[Mesh] OR "Insulin, Isophane"[Mesh] OR "Insulin Glargine"[Mesh]) OR (insulin[tiab] NOT medline[sb])		219,909
9	#5 AND #8		28,029
10	#7 OR #9		47,259
11	(#10 AND Humans[Mesh:NOEXP]) OR (#10 NOT Animals[Mesh:NOEXP])		42,806
12	(#10 AND Humans[Mesh:NOEXP]) OR (#10 NOT Animals[Mesh:NOEXP])	English	39,189
13	(#10 AND Humans[Mesh:NOEXP]) OR (#10 NOT Animals[Mesh:NOEXP])	English, Child: birth-18 years	1,942
14	(adolescen*[tiab] OR boys[tiab] OR child*[tiab] OR children[tiab] OR girls[tiab] OR pediatric[tiab] OR paediatric*[tiab] OR teen[tiab] OR teens[tiab] OR teenage[tiab] OR teenaged[tiab] OR teenager*[tiab] OR toddler*[tiab]) NOT Medline[sb]		203,552
15	#12 AND #14		305
16	#13 OR #15		2,247
17	address[pt] OR "autobiography"[pt] OR "bibliography"[pt] OR "biography"[pt] OR "case report"[tw] OR "case reports"[tw] OR "case series"[tw] OR "comment"[pt] OR "comment on"[All Fields] OR congress[pt] OR "cross-sectional"[tw] OR "dictionary"[pt] OR "directory"[pt] OR "editorial"[pt] OR "festschrift"[pt] OR "historical article"[pt] OR "interview"[pt] OR lecture[pt] OR "legal case"[pt] OR "legislation"[pt] OR letter[pt] OR "news"[pt] OR "newspaper article"[pt] OR "patient education handout"[pt] OR "periodical index"[pt] OR "retrospective cohort"[tw] OR ("Animals"[Mesh] NOT "Humans"[Mesh]) OR rats[tw] OR cow[tw] OR cows[tw] OR chicken[tw] OR chickens[tw] OR horse[tw] OR horses[tw] OR mice[tw] OR mouse[tw] OR bovine[tw] OR sheep OR ovine OR murine OR murinae		10,860,747
18	#16 NOT #17		1,767
19	#15 NOT (gestation* OR Pregnancy[Mesh])		265

## Appendix B1. Original Literature Search Strategies

Search Number	Query	Filters	Results
20	"controlled clinical trial"[publication type] OR "Randomized Controlled Trial"[Publication Type] OR "Single-Blind Method"[MeSH] OR "Double-Blind Method"[MeSH] OR "Random Allocation"[MeSH] OR (controlled[tiab] AND trial[tiab]) OR groups [tiab] OR placebo [tiab] OR randomised [tiab] OR randomized [tiab] OR randomly [tiab] OR trial [tiab]		3,151,828
21	#19 AND #20		<b>77</b>
22	("review"[Publication Type] AND "systematic"[tiab]) OR "systematic review"[All Fields] OR ("review literature as topic"[MeSH] AND "systematic"[tiab]) OR "meta-analysis"[Publication Type] OR "meta-analysis as topic"[MeSH Terms] OR "meta-analysis"[All Fields] OR "meta synthesis"[ti] OR "systematic literature review"[ti] OR "this systematic review"[tw] OR "cochrane database syst rev"[ta]		325,513
23	#19 AND #22		<b>10</b>
24	#19 AND "Case-Control Studies"[MeSH]		0
25	#19 AND ("Cohort Studies"[Mesh:NOEXP] OR "Epidemiologic Studies"[Mesh] OR "Follow-up Studies"[Mesh] OR "prospective cohort" OR "prospective studies"[MeSH] OR (prospective*[All Fields] AND cohort[All Fields] AND (study[All Fields] OR studies[All Fields])))		<b>7</b>
26	#19 AND ("Evaluation Study"[pt] OR "Comparative Study"[pt])		0

### Cochrane Library Interventions Addendum #2, 8/20/2020

ID	Search	Hits
#1	[mh "Diabetes Mellitus, Type 2"] OR [mh "Glucose Tolerance"] OR "glucose tolerance" OR "impaired glucose tolerance" OR dysglycemia:ti,ab OR IGT OR "impaired fasting glucose" OR IFG OR [mh "Glucose Intolerance"] OR "glucose intolerance" OR [mh "Prediabetic State"] OR "prediabetic state" OR prediabet* OR "pre diabetes" OR "diabetes mellitus type 2" OR "type 2 diabetes mellitus"	34234
#2	#1 NOT ([mh "Diabetes Mellitus, Type 1"] OR "diabetes mellitus type 1":ti,ab,kw OR "type 1 diabetes":ti,ab,kw)	33099
#3	[mh "hypoglycemic agents"] OR "hypoglycemic agent*":ti,ab,kw	8175
#4	#2 AND #3	5220
#5	[mh Insulin] OR [mh "Insulin, Long-Acting"] OR [mh "Insulin, Isophane"] OR [mh "Insulin Glargine"] OR insulin:ti,ab,kw	58978
#6	#2 AND #5	18697
#7	#4 OR #6	20183
#8	adolescen*:ti,ab,kw OR boys:ti,ab,kw OR child*:ti,ab,kw OR children:ti,ab,kw OR girls:ti,ab,kw OR pediatric:ti,ab,kw OR paediatric*:ti,ab,kw OR teen:ti,ab,kw OR teens:ti,ab,kw OR teenage:ti,ab,kw OR teenaged:ti,ab,kw OR teenager*:ti,ab,kw OR toddler*:ti,ab,kw	248470
#9	#7 AND #8	1492
#10	#9 NOT (gestation* OR [mh Pregnancy])	<b>1322</b>

### PubMed Interventions Addendum #3, 5/3/2021

Search Number	Query	Filters	Results
1	"Diabetes Mellitus, Type 2"[Mesh] OR "Glucose Intolerance"[MeSH] OR "Prediabetic State"[MeSH]		150,744
2	("diabetes mellitus type 2"[All Fields] OR dysglycemia[tiab] OR "glucose tolerance"[All Fields] OR "glucose intolerance"[All Fields] OR IGT OR "impaired fasting glucose" OR IFG OR "impaired glucose tolerance"[All Fields] OR "prediabetic state"[All Fields] OR prediabet* OR "pre diabetes"[All Fields] OR "type 2 diabetes mellitus"[All Fields]) NOT (Medline[sb])		18,860
3	#1 OR #2		169,604

## Appendix B1. Original Literature Search Strategies

Search Number	Query	Filters	Results
4	#3 NOT ("Diabetes Mellitus, Type 1"[Mesh] OR "diabetes mellitus type 1" OR "type 1 diabetes")		152,347
5	(hypoglycemic agents[mh] OR "Hypoglycemic Agents" [Pharmacological Action]) OR ("hypoglycemic agent*" [tiab] NOT Medline[sb])		266,210
6	#4 AND #5		43,303
7	(Insulin[Mesh] OR "Insulin, Long-Acting"[Mesh] OR "Insulin, Isophane"[Mesh] OR "Insulin Glargine"[Mesh]) OR (insulin [tiab] NOT medline[sb])		225,745
8	#4 AND #7		29,218
9	#6 OR #8		49,756
10	(#9 AND Humans[Mesh:NOEXP]) OR (#9 NOT Animals[Mesh:NOEXP])		45,102
11	(#9 AND Humans[Mesh:NOEXP]) OR (#9 NOT Animals[Mesh:NOEXP])	English	41,438
12	(#9 AND Humans[Mesh:NOEXP]) OR (#9 NOT Animals[Mesh:NOEXP])	English, Child: birth-18 years	2,019
13	#11 AND ((adolescen* [tiab] OR boys [tiab] OR child* [tiab] OR children [tiab] OR girls [tiab] OR pediatric [tiab] OR paediatric [tiab] OR teen [tiab] OR teens [tiab] OR teenage [tiab] OR teenaged [tiab] OR teenager* [tiab] OR toddler* [tiab]) NOT Medline[sb])		316
14	#12 NOT #13		2,019
15	address [pt] OR "autobiography" [pt] OR "bibliography" [pt] OR "biography" [pt] OR "case report" [tw] OR "case reports" [tw] OR "case series" [tw] OR "comment" [pt] OR "comment on" [All Fields] OR congress [pt] OR "cross-sectional" [tw] OR "dictionary" [pt] OR "directory" [pt] OR "editorial" [pt] OR "festschrift" [pt] OR "historical article" [pt] OR "interview" [pt] OR lecture [pt] OR "legal case" [pt] OR "legislation" [pt] OR letter [pt] OR "news" [pt] OR "newspaper article" [pt] OR "patient education handout" [pt] OR "periodical index" [pt] OR "retrospective cohort" [tw] OR ("Animals" [Mesh] NOT "Humans" [Mesh]) OR rats [tw] OR cow [tw] OR cows [tw] OR chicken [tw] OR chickens [tw] OR horse [tw] OR horses [tw] OR mice [tw] OR mouse [tw] OR bovine [tw] OR sheep OR ovine OR murine OR murinae		11,199,555
16	#14 NOT #15		1,608
17	#16 NOT (gestation* OR Pregnancy [Mesh])		1,461
18	"controlled clinical trial" [publication type] OR "Randomized Controlled Trial" [Publication Type] OR "Single-Blind Method" [MeSH] OR "Double-Blind Method" [MeSH] OR "Random Allocation" [MeSH] OR (controlled [tiab] AND trial [tiab]) OR groups [tiab] OR placebo [tiab] OR randomised [tiab] OR randomized [tiab] OR randomly [tiab] OR trial [tiab]		3,313,682
19	#17 AND #18		712
20	("review" [Publication Type] AND "systematic" [tiab]) OR "systematic review" [All Fields] OR ("review literature as topic" [MeSH] AND "systematic" [tiab]) OR "meta-analysis" [Publication Type] OR "meta-analysis as topic" [MeSH Terms] OR "meta-analysis" [All Fields] OR "meta synthesis" [ti] OR "systematic literature review" [ti] OR "this systematic review" [tw] OR "cochrane database syst rev" [ta]		362,198
21	#17 AND #20		32
22	#17 AND "Case-Control Studies" [MeSH]		176
23	#17 AND ("Cohort Studies" [Mesh:NOEXP] OR "Epidemiologic Studies" [Mesh] OR "Follow-up Studies" [Mesh] OR "prospective cohort" OR "prospective studies" [MeSH] OR (prospective* [All Fields] AND cohort [All Fields] AND (study [All Fields] OR studies [All Fields])))		397
24	#17 AND ("Evaluation Study" [pt] OR "Comparative Study" [pt])		198

## Appendix B1. Original Literature Search Strategies

### PubMed Screening, 5/3/2021

Search Number	Query	Filters	Results
1	"Diabetes Mellitus, Type 2"[Mesh] OR "glucose tolerance"[All Fields] OR "impaired glucose tolerance"[All Fields] OR dysglycemia[tiab] OR IGT OR "impaired fasting glucose" OR IFG OR "Glucose Intolerance"[MeSH] OR "glucose intolerance"[All Fields] OR "Prediabetic State"[MeSH] OR "prediabetic state"[All Fields] OR prediabet* OR "pre diabetes"[All Fields] OR "diabetes mellitus type 2"[All Fields] OR "type 2 diabetes mellitus"[All Fields]		224,878
2	"Blood Glucose"[Mesh] OR "blood glucose"[tiab] OR "Glucose Tolerance Test"[Mesh] OR OGTT[tiab] OR "glucose tolerance test"[ti] OR "Glycated Hemoglobin A"[Mesh] OR "hemoglobin A1c" OR HbA1c OR "fasting plasma glucose"[tiab] OR "oral glucose tolerance"[tiab]		264,030
3	#1 AND #2		101,723
4	#3 NOT ("Diabetes Mellitus, Type 1"[Mesh] OR "diabetes mellitus type 1" OR "type 1 diabetes")		94,239
5	#4 AND ("Mass Screening"[Mesh] OR screen*[tiab])		6,345
6	#5 NOT (gestation* OR Pregnancy[Mesh])		4,617
7	#5 NOT (gestation* OR Pregnancy[Mesh])	English	4,272
8	#5 NOT (gestation* OR Pregnancy[Mesh])	English, Child: birth-18 years	605
9	adolescen*[tiab] OR boys[tiab] OR child*[tiab] OR children[tiab] OR girls[tiab] OR pediatric[tiab] OR paediatric*[tiab] OR teen[tiab] OR teens[tiab] OR teenage[tiab] OR teenaged[tiab] OR teenager*[tiab] OR toddler*[tiab]		1,850,962
10	#7 AND #9		301
11	#8 OR #10		665
12	(#11 AND Humans[mesh:noexp]) OR (#11 NOT Animals[mesh:noexp])		664
13	(#11 AND Humans[mesh:noexp]) OR (#11 NOT Animals[mesh:noexp])	from 2019/8/3 - 3000/12/12	60
14	("review"[Publication Type] AND "systematic"[tiab]) OR "systematic review"[All Fields] OR ("review literature as topic"[MeSH] AND "systematic"[tiab]) OR "meta-analysis"[Publication Type] OR "meta-analysis as topic"[MeSH Terms] OR "meta-analysis"[All Fields] OR "meta synthesis"[ti] OR "systematic literature review"[ti] OR "this systematic review"[tw] OR "cochrane database syst rev"[ta]		362,198
15	#13 AND #14		2
16	"controlled clinical trial"[publication type] OR "Randomized Controlled Trial"[Publication Type] OR "Single-Blind Method"[MeSH] OR "Double-Blind Method"[MeSH] OR "Random Allocation"[MeSH] OR (controlled[tiab] AND trial[tiab]) OR groups [tiab] OR placebo [tiab] OR randomised [tiab] OR randomized [tiab] OR randomly [tiab] OR trial [tiab]		3,313,682
17	#13 AND #16		19
18	#13 AND "Case-Control Studies"[MeSH]		5
19	"Cohort Studies"[Mesh] OR "Epidemiologic Studies"[Mesh] OR "Follow-up Studies"[Mesh] OR "prospective cohort" OR "prospective studies"[MeSH] OR (prospective*[All Fields] AND cohort[All Fields] AND (study[All Fields] OR studies[All Fields]))		2,694,511
20	#13 AND #19		21
21	"Evaluation Study"[pt] OR "Comparative Study"[pt]		2,087,906
22	#13 AND #21		0

## Appendix B1. Original Literature Search Strategies

### PubMed Interventions, 5/3/2021

Search Number	Query	Filters	Results
1	"Diabetes Mellitus, Type 2"[Mesh] OR "Glucose Intolerance"[MeSH] OR "Prediabetic State"[MeSH]		150,744
2	("diabetes mellitus type 2"[All Fields] OR dysglycemia[tiab] OR "glucose tolerance"[All Fields] OR "glucose intolerance"[All Fields] OR IGT OR "impaired fasting glucose" OR IFG OR "impaired glucose tolerance"[All Fields] OR "prediabetic state"[All Fields] OR prediabet* OR "pre diabetes"[All Fields] OR "type 2 diabetes mellitus"[All Fields]) NOT (Medline[sb])		18,860
3	#1 OR #2		169,604
4	#3 NOT ("Diabetes Mellitus, Type 1"[Mesh] OR "diabetes mellitus type 1" OR "type 1 diabetes")		152,347
5	(hypoglycemic agents[mh] OR "Hypoglycemic Agents" [Pharmacological Action]) OR ("hypoglycemic agent"[tiab] NOT Medline[sb])		266,210
6	#4 AND #5		43,303
7	(Insulin[Mesh] OR "Insulin, Long-Acting"[Mesh] OR "Insulin, Isophane"[Mesh] OR "Insulin Glargine"[Mesh]) OR (insulin[tiab] NOT medline[sb])		225,745
8	#4 AND #7		29,218
9	Actos[tiab] OR Albiglutide[tiab] OR Amaryl[tiab] OR Biguanides[Mesh] OR Biguanides[tiab] OR Bydureon[tiab] OR Byetta[tiab] OR DiaBeta[tiab] OR "Dipeptidyl-Peptidase IV Inhibitors"[Mesh] OR "Dipeptidyl-Peptidase IV Inhibitors"[Pharmacological Action] OR "Dipeptidyl peptidase IV inhibitor"[tiab] OR "Dipeptidyl peptidase IV inhibitors"[tiab] OR dulaglutide[Supplementary Concept] OR dulaglutide[tiab] OR exenatide[Supplementary Concept] OR Exenatide[tiab] OR Fortamet[tiab] OR Gliclazide[Mesh] OR Gliclazide[tiab] OR glimepiride[tiab] OR Glipizide[Mesh] OR glipizide[tiab] OR "GLP-1 receptor agonist"[tiab] OR "GLP-1 receptor agonists"[tiab] OR "Glucagon-like peptide-1 receptor agonist"[tiab] OR "Glucagon-like peptide-1 receptor agonists"[tiab] OR Glucophage[tiab] OR Glucotrol[tiab] OR "Glucotrol XL"[tiab] OR Glumetza[tiab] OR Glyburide[Mesh] OR glyburide[tiab] OR "Glynase PresTab"[tiab] OR Linagliptin[Mesh] OR Linagliptin[tiab] OR Liraglutide[Mesh] OR liraglutide[tiab] OR lixisenatide[Supplementary Concept] OR lixisenatide[tiab] OR Lyxumia[tiab] OR Meglitinides[tiab] OR Metformin[Mesh] OR Metformin[tiab] OR Micronase[tiab] OR nateglinide[Supplementary Concept] OR Nateglinide[tiab] OR Ozempic[tiab] OR pioglitazone[Supplementary Concept] OR Pioglitazone[tiab] OR Prandin[tiab] OR Repaglinide[tiab] OR rosiglitazone[Supplementary Concept] OR Rosiglitazone[tiab] OR Saxagliptin[tiab] OR semaglutide[Supplementary Concept] OR semaglutide[tiab] OR Sitagliptin[tiab] OR "Sitagliptin Phosphate"[Mesh] OR "Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination"[Mesh] OR "Sulfonylurea Compounds"[Mesh] OR Starlix[tiab] OR Sulfonylureas[tiab] OR Tanzeum[tiab] OR Thiazolidinediones[Mesh] OR Thiazolidinediones[tiab] OR Tolazamide[Mesh] OR Tolazamide[tiab] OR Tolbutamide[Mesh] OR tolbutamide[tiab] OR Trulicity[tiab] OR TZDs[tiab] OR Victoza[tiab] OR vildagliptin[Supplementary Concept] OR vildagliptin[tiab]		82,627
10	#4 AND #9		20,543



## Appendix B1. Original Literature Search Strategies

Search Number	Query	Filters	Results
11	advice[tiab] OR "Behavior Therapy"[Mesh] OR "behavior therapy"[tiab] OR (behavior*[tiab] AND therap*[tiab]) OR (behavior*[tiab] AND chang*[tiab]) OR (behavior*[tiab] AND modification*[tiab]) OR "Caloric Restriction"[Mesh] OR ((child*[tiab] AND parent*[tiab]) and therap*[tiab]) OR Counseling[Mesh] OR counsel*[tiab] OR "cognitive behavior"[tiab] OR "cognitive behavioral"[tiab] OR "cognitive therap*"[tiab] OR CBT[ti] OR "Diabetes Prevention Program"[tiab] OR "Diabetes Prevention Programme"[tiab] OR DPP[tiab] OR ("Diabetes Prevention"[tiab] AND (program*[tiab] OR stud*[tiab] OR trial*[tiab])) OR diet[ti] OR "Diet, Carbohydrate-Restricted"[Mesh] OR "Diet, Fat-Restricted"[Mesh] OR "Diet, Mediterranean"[Mesh] OR "Diet, Reducing"[Mesh] OR "Diet Therapy"[Mesh] OR dietary[ti] OR "Directive Counseling"[Mesh] OR Exercise[Mesh] OR exercise[ti] OR "Exercise Therapy"[Mesh] OR "family intervention*"[tiab] OR "family therap*"[tiab] OR "Feedback, Psychological"[Mesh] OR "group therap*"[tiab] OR "Health Behavior"[Majr] OR "health behavior"[tiab] OR "health behaviors"[tiab] OR "health behavioral"[tiab] OR "health behaviours"[tiab] OR "health behaviour"[tiab] OR "Health Education"[Mesh] OR "health education"[tiab] OR "Health Promotion"[Majr] OR "health promotion"[tiab] OR "Life Style"[Mesh] OR lifestyle[tiab] OR "life style"[tiab] OR "Motivational Interviewing"[Mesh] OR "motivational interviewing"[tiab] OR "non pharmacologic intervention"[tiab] OR "nonpharmacologic intervention"[tiab] OR "parent* intervention*"[tiab] OR "Patient Education as Topic"[Mesh] OR "patient education"[tiab] OR "physical activity"[ti] OR "physically active"[ti] OR "psychological feedback"[tiab] OR "Risk Reduction Behavior"[Mesh] OR "Risk Reduction Behavior"[tiab] OR "Weight Loss"[Mesh] OR "Weight Reduction Programs"[Mesh]		1,544,095
12	#4 AND #11		30,288
13	#6 OR #8 OR #10 OR #12		72,197
14	(#13 AND Humans[Mesh:NOEXP]) OR (#13 NOT Animals[Mesh:NOEXP])		66,506
15	(#13 AND Humans[Mesh:NOEXP]) OR (#13 NOT Animals[Mesh:NOEXP])	English	61,430
16	(#13 AND Humans[Mesh:NOEXP]) OR (#13 NOT Animals[Mesh:NOEXP])	Child: birth-18 years	3,828
17	(adolescen*[tiab] OR boys[tiab] OR child*[tiab] OR children[tiab] OR girls[tiab] OR pediatric[tiab] OR paediatric*[tiab] OR teen[tiab] OR teens[tiab] OR teenage[tiab] OR teenaged[tiab] OR teenager*[tiab] OR toddler*[tiab]) NOT Medline[sb]		225,420
18	#14 AND #17		436
19	#16 OR #18		4,264
20	address[pt] OR "autobiography"[pt] OR "bibliography"[pt] OR "biography"[pt] OR "case report"[tw] OR "case reports"[tw] OR "case series"[tw] OR "comment on"[All Fields] OR congress[pt] OR "cross-sectional"[tw] OR "dictionary"[pt] OR "directory"[pt] OR "editorial"[pt] OR "festschrift"[pt] OR "historical article"[pt] OR "interview"[pt] OR lecture[pt] OR "legal case"[pt] OR "legislation"[pt] OR letter[pt] OR "news"[pt] OR "newspaper article"[pt] OR "patient education handout"[pt] OR "periodical index"[pt] OR "retrospective cohort"[tw] OR ("Animals"[Mesh] NOT "Humans"[Mesh]) OR rats[tw] OR cow[tw] OR cows[tw] OR chicken[tw] OR chickens[tw] OR horse[tw] OR horses[tw] OR mice[tw] OR mouse[tw] OR bovine[tw] OR sheep OR ovine OR murine OR murinae		11,199,555
21	#19 NOT #20		3,636
22	#21 NOT (gestation* OR Pregnancy[Mesh])		3,009
23	#21 NOT (gestation* OR Pregnancy[Mesh])	from 2019/8/3 - 3000/12/12	316

## Appendix B1. Original Literature Search Strategies

Search Number	Query	Filters	Results
24	"controlled clinical trial"[publication type] OR "Randomized Controlled Trial"[Publication Type] OR "Single-Blind Method"[MeSH] OR "Double-Blind Method"[MeSH] OR "Random Allocation"[MeSH] OR (controlled[tiab] AND trial[tiab]) OR groups [tiab] OR placebo [tiab] OR randomised [tiab] OR randomized [tiab] OR randomly [tiab] OR trial [tiab]		3,313,682
25	#23 AND #24		139
26	("review"[Publication Type] AND "systematic"[tiab]) OR "systematic review"[All Fields] OR ("review literature as topic"[MeSH] AND "systematic"[tiab]) OR "meta-analysis"[Publication Type] OR "meta-analysis as topic"[MeSH Terms] OR "meta-analysis"[All Fields] OR "meta synthesis"[ti] OR "systematic literature review"[ti] OR "this systematic review"[tw] OR "cochrane database syst rev"[ta]		362,198
27	#23 AND #26		16
28	#23 AND "Case-Control Studies"[MeSH]		24
29	#23 AND ("Cohort Studies"[Mesh:NOEXP] OR "Epidemiologic Studies"[Mesh] OR "Follow-up Studies"[Mesh] OR "prospective cohort" OR "prospective studies"[MeSH] OR (prospective*[All Fields] AND cohort[All Fields] AND (study[All Fields] OR studies[All Fields])))		71
30	#23 AND ("Evaluation Study"[pt] OR "Comparative Study"[pt])		11

## Cochrane Library Screening, 5/3/2021

ID	Search	Hits
#1	[mh "Diabetes Mellitus, Type 2"] OR "glucose tolerance" OR "impaired glucose tolerance" OR dysglycemia:ti,ab OR IGT OR "impaired fasting glucose" OR IFG OR [mh "Glucose Intolerance"] OR "glucose intolerance" OR [mh "Prediabetic State"] OR "prediabetic state" OR prediabet* OR "pre diabetes" OR "diabetes mellitus type 2" OR "type 2 diabetes mellitus"	36248
#2	[mh "Blood Glucose"] OR "blood glucose":ti,ab OR [mh "Glucose Tolerance Test"] OR OGTT:ti,ab OR "glucose tolerance test":ti OR [mh "Glycated Hemoglobin A"] OR "hemoglobin A1c" OR HbA1c OR "fasting plasma glucose":ti,ab OR "oral glucose tolerance":ti,ab	48756
#3	#1 AND #2	20381
#4	[mh "Mass Screening"] OR screen*:ti,ab	73937
#5	#3 AND #4	1840
#6	#5 NOT (gestation* OR [mh Pregnancy])	1645
#7	adolescen*:ti,ab,kw OR boys:ti,ab,kw OR child*:ti,ab,kw OR children:ti,ab,kw OR girls:ti,ab,kw OR infant*:ti,ab,kw OR pediatric:ti,ab,kw OR paediatric*:ti,ab,kw OR teen:ti,ab,kw OR teens:ti,ab,kw OR teenage:ti,ab,kw OR teenaged:ti,ab,kw OR teenager*:ti,ab,kw OR toddler*:ti,ab,kw	289615
#8	#6 AND #7	213
#9	#8 with Cochrane Library publication date Between Aug 2019 and Dec 2021	41
#10	#9 NOT ([mh "Diabetes Mellitus, Type 1"] OR "diabetes mellitus type 1":ti,ab,kw OR "type 1 diabetes":ti,ab,kw)	38

## Appendix B1. Original Literature Search Strategies

### Cochrane Library Interventions, 5/3/2021

ID	Search	Hits
#1	[mh "Diabetes Mellitus, Type 2"] OR "glucose tolerance" OR "impaired glucose tolerance" OR dysglycemia:ti,ab OR IGT OR "impaired fasting glucose" OR IFG OR [mh "Glucose Intolerance"] OR "glucose intolerance" OR [mh "Prediabetic State"] OR "prediabetic state" OR prediabet* OR "pre diabetes" OR "diabetes mellitus type 2" OR "type 2 diabetes mellitus"	36248
#2	#1 NOT ([mh "Diabetes Mellitus, Type 1"] OR "diabetes mellitus type 1":ti,ab,kw OR "type 1 diabetes":ti,ab,kw)	35092
#3	Actos:ti,ab OR Albiglutide:ti,ab OR Amaryl:ti,ab OR [mh Biguanides] OR Biguanides:ti,ab OR Bydureon:ti,ab OR Byetta:ti,ab OR DiaBeta:ti,ab OR [mh "Dipeptidyl-Peptidase IV Inhibitors"] OR "Dipeptidyl peptidase IV inhibitor":ti,ab OR "Dipeptidyl peptidase IV inhibitors":ti,ab OR dulaglutide:ti,ab OR Exenatide:ti,ab OR Fortamet:ti,ab OR [mh Gliclazide] OR Gliclazide:ti,ab OR glimepiride:ti,ab OR [mh Glipizide] OR glipizide:ti,ab OR "GLP-1 receptor agonist":ti,ab OR "GLP-1 receptor agonists":ti,ab OR "Glucagon-like peptide-1 receptor agonist":ti,ab OR "Glucagon-like peptide-1 receptor agonists":ti,ab OR Glucophage:ti,ab OR Glucotrol:ti,ab OR "Glucotrol XL":ti,ab OR Glumetza:ti,ab OR [mh Glyburide] OR glyburide:ti,ab OR "Glynase PresTab":ti,ab OR [mh Linagliptin] OR Linagliptin:ti,ab OR [mh Liraglutide] OR liraglutide:ti,ab OR lixisenatide:ti,ab OR Lyxumia:ti,ab OR Meglitinides:ti,ab OR [mh Metformin] OR Metformin:ti,ab OR Micronase:ti,ab OR Nateglinide:ti,ab OR Ozempic:ti,ab OR Pioglitazone:ti,ab OR Prandin:ti,ab OR Repaglinide:ti,ab OR Rosiglitazone:ti,ab OR Saxagliptin:ti,ab OR semaglutide:ti,ab OR Sitagliptin:ti,ab OR [mh "Sitagliptin Phosphate"] OR [mh "Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination"] OR [mh "Sulfonylurea Compounds"] OR Starlix:ti,ab OR Sulfonylureas:ti,ab OR Tanzeum:ti,ab OR [mh Thiazolidinediones] OR Thiazolidinediones:ti,ab OR [mh Tolazamide] OR Tolazamide:ti,ab OR [mh Tolbutamide] OR tolbutamide:ti,ab OR Trulicity:ti,ab OR TZDs:ti,ab OR Victoza:ti,ab OR vildagliptin:ti,ab	22966
#4	#2 AND #3	9584
#5	#2 AND ([mh "hypoglycemic agents"] OR "hypoglycemic agent*":ti,ab,kw)	5438
#6	#2 AND ([mh Insulin] OR [mh "Insulin, Long-Acting"] OR [mh "Insulin, Isophane"] OR [mh "Insulin Glargine"] OR insulin:ti,ab,kw)	19860
#7	#4 OR #5 OR #6	23813
#8	advice:ti,ab OR [mh "Behavior Therapy"] OR "behavior therapy":ti,ab OR (behavior*:ti,ab AND therap*:ti,ab) OR (behavior*:ti,ab AND chang*:ti,ab) OR (behavior*:ti,ab AND modification*:ti,ab) OR [mh "Caloric Restriction"] OR ((child*:ti,ab AND parent*:ti,ab) AND therap*:ti,ab) OR [mh Counseling] OR counsel*:ti,ab OR "cognitive behavior":ti,ab OR "cognitive behavioral":ti,ab OR "cognitive therap*":ti,ab OR CBT:ti OR "Diabetes Prevention Program":ti,ab OR "Diabetes Prevention Programme":ti,ab OR DPP:ti,ab OR ("Diabetes Prevention":ti,ab AND (program*:ti,ab OR stud*:ti,ab OR trial*:ti,ab)) OR diet:ti OR [mh "Diet, Carbohydrate-Restricted"] OR [mh "Diet, Fat-Restricted"] OR [mh "Diet, Mediterranean"] OR [mh "Diet, Reducing"] OR [mh "Diet Therapy"] OR dietary:ti OR [mh "Directive Counseling"] OR [mh Exercise] OR exercise:ti OR [mh "Exercise Therapy"] OR "family intervention*":ti,ab OR "family therap*":ti,ab OR [mh "Feedback, Psychological"] OR "group therap*":ti,ab OR [mh "Health Behavior"] OR "health behavior":ti,ab OR "health behaviors":ti,ab OR "health behavioral":ti,ab OR "health behaviours":ti,ab OR "health behaviour":ti,ab OR [mh "Health Education"] OR "health education":ti,ab OR [mh "Health Promotion"] OR "health promotion":ti,ab OR [mh "Life Style"] OR lifestyle:ti,ab OR "life style":ti,ab OR [mh "Motivational Interviewing"] OR "motivational interviewing":ti,ab OR "non pharmacologic intervention":ti,ab OR "nonpharmacologic intervention":ti,ab OR "parent* intervention*":ti,ab OR [mh "Patient Education as Topic"] OR "patient education":ti,ab OR "physical activity":ti OR "physically active":ti OR "psychological feedback":ti,ab OR [mh "Risk Reduction Behavior"] OR "Risk Reduction Behavior":ti,ab OR [mh "Weight Loss"] OR [mh "Weight Reduction Programs"]	195053
#9	#1 AND #8	9525
#10	#7 OR #9	27598
#11	#10 NOT (gestation* OR [mh Pregnancy])	26684
#12	#11 NOT ([mh animals] NOT [mh humans])	26684
#13	adolescen*:ti,ab,kw OR boys:ti,ab,kw OR child*:ti,ab,kw OR children:ti,ab,kw OR girls:ti,ab,kw OR infant*:ti,ab,kw OR pediatric:ti,ab,kw OR paediatric*:ti,ab,kw OR teen:ti,ab,kw OR teens:ti,ab,kw OR teenage:ti,ab,kw OR teenaged:ti,ab,kw OR teenager*:ti,ab,kw OR toddler*:ti,ab,kw	289615
#14	#12 AND #13	1771
#15	#14 with Cochrane Library publication date from Aug 2019 to Dec 2021	267 (3 are reviews)
#16	#15 with Publication Year from 2019 to 2021, in Trials	182

## Appendix B1. Original Literature Search Strategies

ClinicalTrials.gov, 5/3/2021

### Screening (40 results)

Condition box: ("Diabetes Mellitus, Type 2" OR "Glucose Tolerance" OR "impaired glucose tolerance" OR IGT OR "impaired fasting glucose" OR IFG OR "Glucose Intolerance" OR "Prediabetic State" OR prediabet\* OR "pre diabetes" OR "diabetes mellitus type 2" OR "type 2 diabetes mellitus")

AND

Other terms box: ("blood glucose" OR OGTT OR "glucose tolerance test" OR "Glycated Hemoglobin A" OR "hemoglobin A1c" OR HbA1c OR "fasting plasma glucose" OR "HbA(1c)" OR HbA1 OR HbA1c OR "HbA 1c" OR "glycosylated hemoglobin" OR "glycated hemoglobin" OR "oral glucose tolerance") AND (screen\* OR screening)

Used child limits Age Group Child (birth-17)

Expert search: (("blood glucose" OR OGTT OR "glucose tolerance test" OR "Glycated Hemoglobin A" OR "hemoglobin A1c" OR HbA1c OR "fasting plasma glucose" OR "HbA(1c)" OR HbA1 OR HbA1c OR "HbA 1c" OR "glycosylated hemoglobin" OR "glycated hemoglobin" OR "oral glucose tolerance") AND (screen\* OR screening)) AND AREA[ConditionSearch] ("Diabetes Mellitus, Type 2" OR "Glucose Tolerance" OR "impaired glucose tolerance" OR IGT OR "impaired fasting glucose" OR IFG OR "Glucose Intolerance" OR "Prediabetic State" OR prediabet\* OR "pre diabetes" OR "diabetes mellitus type 2" OR "type 2 diabetes mellitus") AND AREA[StdAge] EXPAND[Term] COVER[FullMatch] "Child"

### Interventions (integrates terms for hypoglycemic agents and insulin)

A. Pharmacologic Interventions (322 results)

Condition box: ("Diabetes Mellitus, Type 2" OR "Glucose Tolerance" OR "impaired glucose tolerance" OR IGT OR "impaired fasting glucose" OR IFG OR "glucose Intolerance" OR "Prediabetic State" OR prediabet\* OR "pre diabetes" OR "diabetes mellitus type 2" OR "type 2 diabetes mellitus")

AND

Intervention/treatment box: (Actos OR Albiglutide OR Amaryl OR Biguanides OR Bydureon OR Byetta OR DiaBeta OR "Dipeptidyl-Peptidase IV Inhibitors" OR "Dipeptidyl peptidase IV inhibitor" OR dulaglutide OR Exenatide OR Fortamet OR Gliclazide OR glimepiride OR Glipizide OR "GLP-1 receptor agonist" OR "GLP-1 receptor agonists" OR "Glucagon-like peptide-1 receptor agonist" OR "Glucagon-like peptide-1 receptor agonists" OR Glucophage OR Glucotrol OR Glumetza OR Glyburide OR "Glynase PresTab" hypoglycemic agent\* OR "hypoglycemic agents" OR insulin OR Linagliptin OR Liraglutide OR lixisenatide OR Lyxumia OR Meglitinides OR Metformin OR Micronase OR Ozempic OR Pioglitazone OR Prandin OR Repaglinide OR Rosiglitazone OR Saxagliptin OR semaglutide OR Sitagliptin OR "Sulfonylurea

## Appendix B1. Original Literature Search Strategies

Compounds" OR Starlix OR Sulfonylureas OR Tanzeum OR Thiazolidinediones OR Tolazamide OR Tolbutamide OR Trulicity OR TZDs OR Victoza OR vildagliptin)

Used child limits Age Group Child (birth-17)

In Expert Search box: AREA[ConditionSearch] ("Diabetes Mellitus, Type 2" OR "Glucose Tolerance" OR "impaired glucose tolerance" OR IGT OR "impaired fasting glucose" OR IFG OR "glucose Intolerance" OR "Prediabetic State" OR prediabet\* OR "pre diabetes" OR "diabetes mellitus type 2" OR "type 2 diabetes mellitus") AND AREA[InterventionSearch] (Actos OR Albiglutide OR Amaryl OR Biguanides OR Bydureon OR Byetta OR DiaBeta OR "Dipeptidyl-Peptidase IV Inhibitors" OR "Dipeptidyl peptidase IV inhibitor" OR dulaglutide OR Exenatide OR Fortamet OR Gliclazide OR glimepiride OR Glipizide OR "GLP-1 receptor agonist" OR "GLP-1 receptor agonists" OR "Glucagon-like peptide-1 receptor agonist" OR "Glucagon-like peptide-1 receptor agonists" OR Glucophage OR Glucotrol OR Glumetza OR Glyburide OR "Glynase PresTab" hypoglycemic agent\* OR "hypoglycemic agents" OR insulin OR Linagliptin OR Liraglutide OR lixisenatide OR Lyxumia OR Meglitinides OR Metformin OR Micronase OR Ozempic OR Pioglitazone OR Prandin OR Repaglinide OR Rosiglitazone OR Saxagliptin OR semaglutide OR Sitagliptin OR "Sulfonylurea Compounds" OR Starlix OR Sulfonylureas OR Tanzeum OR Thiazolidinediones OR Tolazamide OR Tolbutamide OR Trulicity OR TZDs OR Victoza OR vildagliptin) AND AREA[StdAge] EXPAND[Term] COVER[FullMatch] "Child"

### B. Non-pharmacologic interventions (186 results)

Condition box: ("Diabetes Mellitus, Type 2" OR "Glucose Tolerance" OR "impaired glucose tolerance" OR IGT OR "impaired fasting glucose" OR IFG OR "glucose Intolerance" OR "Prediabetic State" OR prediabet\* OR "pre diabetes" OR "diabetes mellitus type 2" OR "type 2 diabetes mellitus")

AND

Non-Pharmacological Interventions in Treatment/Interventions box: (advice OR "Behavior Therapy" OR (behavior\* AND therap\*) OR (behavior\* AND chang\*) OR (behavior\* AND modification\*) OR "Caloric Restriction" OR ((child\* AND parent\*) and therap\*) OR counsel\* OR "cognitive behavior" OR "cognitive behavioral" OR "cognitive therap\*" OR CBT OR "Diabetes Prevention Program" OR "Diabetes Prevention Programme" OR DPP OR ("Diabetes Prevention" AND (program\* OR stud\* OR trial\*)) OR diet OR dietary OR Exercise OR "family intervention\*" OR "family therap\*" OR "Feedback, Psychological" OR "group therap\*" OR "Health Behavior" OR "health behaviors" OR "health behavioral" OR "health behaviours" OR "health behaviour" OR "health behavioural" OR "Health Education" OR "Health Education as Topic" OR "health education" OR "Health Promotion" OR "health promotion" OR "Life Style" OR lifestyle OR "life style" OR "Lifestyle Intervention" OR "Motivational Interviewing" OR "motivational interviewing" OR "non pharmacologic intervention" OR "nonpharmacologic intervention" OR "parent\* intervention\*" OR "patient education" OR "physical activity" OR "physically active" OR "psychological feedback" OR "Risk Reduction Behavior" OR "Risk Reduction Behavior" OR "Weight Loss" OR "Weight Reduction Programs")

## Appendix B1. Original Literature Search Strategies

Used child limits Age Group Child (birth-17)

In Expert Search box: AREA[ConditionSearch] ("Diabetes Mellitus, Type 2" OR "Glucose Tolerance" OR "impaired glucose tolerance" OR IGT OR "impaired fasting glucose" OR IFG OR "glucose Intolerance" OR "Prediabetic State" OR prediabet\* OR "pre diabetes" OR "diabetes mellitus type 2" OR "type 2 diabetes mellitus") AND AREA[InterventionSearch] (advice OR "Behavior Therapy" OR (behavior\* AND therap\*) OR (behavior\* AND chang\*) OR (behavior\* AND modification\*) OR "Caloric Restriction" OR ((child\* AND parent\*) and therap\*) OR counsel\* OR "cognitive behavior" OR "cognitive behavioral" OR "cognitive therap\*" OR CBT OR "Diabetes Prevention Program" OR "Diabetes Prevention Programme" OR DPP OR ("Diabetes Prevention" AND (program\* OR stud\* OR trial\*)) OR diet OR dietary OR Exercise OR "family intervention\*" OR "family therap\*" OR "Feedback, Psychological" OR "group therap\*" OR "Health Behavior" OR "health behaviors" OR "health behavioral" OR "health behaviours" OR "health behaviour" OR "health behavioural" OR "Health Education" OR "Health Education as Topic" OR "health education" OR "Health Promotion" OR "health promotion" OR "Life Style" OR lifestyle OR "life style" OR "Lifestyle Intervention" OR "Motivational Interviewing" OR "motivational interviewing" OR "non pharmacologic intervention" OR "nonpharmacologic intervention" OR "parent\* intervention\*" OR "patient education" OR "physical activity" OR "physically active" OR "psychological feedback" OR "Risk Reduction Behavior" OR "Risk Reduction Behavior" OR "Weight Loss" OR "Weight Reduction Programs") AND AREA[StdAge] EXPAND[Term] COVER[FullMatch] "Child"

## Appendix B2. Eligibility Criteria

	<b>Include</b>	<b>Exclude</b>
Populations	<p><b>All KQs:</b> Studies of people younger than age 18; studies of participants without obvious symptoms of diabetes (e.g., for KQ 1, studies of unselected populations that may include some participants with unrecognized symptoms of diabetes such as fatigue); nonpregnant women with a history of gestational diabetes (if they are &gt;1 year postpartum); studies that substantially overlap this age range (e.g., ages 14–65 years) will be included if results for younger participants are reported separately. At least 50 percent of the study population must meet the review eligibility criteria or results must be reported separately for the population eligible for the review.</p> <p><b>KQs 1, 2:</b> Asymptomatic, nonpregnant children and adolescents</p> <p><b>KQs 3:</b> Asymptomatic, nonpregnant children and adolescents with screen-detected prediabetes or type 2 diabetes (3a and 3b) or with recently diagnosed type 2 diabetes (3c); studies of people with Maturity Onset Diabetes of the Young (MODY) are also eligible.</p> <p><b>KQ 4:</b> Asymptomatic, nonpregnant children and adolescents with screen-detected prediabetes or type 2 diabetes; nonpregnant children and adolescents with recently diagnosed type 2 diabetes; studies of people with MODY are also eligible.</p> <p><b>KQs 5–6:</b> Asymptomatic, nonpregnant children and adolescents with screen-detected prediabetes</p> <p><b>Specific populations:</b> Studies that examine whether effectiveness of screening or intervention differs based on age, sex, race/ethnicity, BMI, sexual maturity rating, age of menarche, and socioeconomic status will be examined.</p>	<p><b>KQs 1–6:</b> Studies limited to or predominately comprising adults or pregnant women; persons with symptomatic prediabetes or type 2 diabetes (e.g., weight loss, polyuria, blurred vision, headache); persons with a recent hospitalization; persons taking antipsychotics or glucocorticoids; persons with known cardiovascular disease or severe chronic kidney disease; persons living in an institution; other persons with medical conditions limiting their applicability to primary care–based populations (e.g., those with acute illness)</p> <p><b>KQ 3c:</b> Studies limited to or predominately comprising persons who have had diabetes for more than 1 year or with more advanced diabetes (e.g., persons already taking insulin or other medications; persons with proliferative retinopathy, nephropathy)</p>
Screening	<p><b>KQs 1, 2:</b> Screening (targeted or universal) for prediabetes<sup>a</sup> or diabetes; tests include hemoglobin A1c, FPG, and the OGTT</p>	<p>All other tests, such as genetic testing for the risk of prediabetes or diabetes or testing for autoantibodies, which may be used for further evaluation after a diabetes diagnosis (e.g., to assess for type 1 or type 2 diabetes)</p>
Interventions	<p><b>KQs 3–6:</b> Primary care–relevant behavioral counseling or pharmacotherapy interventions for glycemic control. Behavioral counseling interventions can be provided alone or as part of a larger multicomponent intervention on diet and nutrition, physical activity, sedentary behavior, or a combination thereof, including but not limited to assessment with feedback, advice, collaborative goal setting, assistance, exercise prescriptions (referral to exercise facility or program), or arrangement of further contacts. Interventions may be delivered via face-to-face contact, telephone, print materials, or technology (e.g., computer based, text messages, remote video feed) and can be delivered by a number of potential interventionists, including but not limited to clinicians, nurses, exercise specialists, dietitians, nutritionists, and behavioral health specialists.</p> <p>Dietary counseling may involve:</p>	<ul style="list-style-type: none"> <li>• Counseling interventions aimed at depression</li> <li>• Prenatal or postnatal dietary counseling</li> <li>• Counseling interventions with components that are not feasible for implementation in healthcare settings (e.g., occupational/worksite-, church-, or school-based interventions conducted within existing social networks)</li> <li>• Social marketing (e.g., media campaigns)</li> <li>• Policy (e.g., local or state public/health policy)</li> <li>• Stress management interventions (e.g., meditation, yoga, tai chi)</li> <li>• Use of incentives (e.g., paying persons to lose weight)</li> <li>• Supervised exercise with the goal of assessing effects of exercise</li> </ul>

## Appendix B2. Eligibility Criteria

	<b>Include</b>	<b>Exclude</b>
	<ul style="list-style-type: none"> <li>Increased consumption of fruits, vegetables, whole grains, fat-free or low-fat dairy, and/or lean proteins</li> <li>Limited consumption of sodium, saturated fat, trans fat, and/or sugar-sweetened food and beverages</li> </ul> <p>Physical activity counseling may involve:</p> <ul style="list-style-type: none"> <li>Aerobic activities that involve repeated use of large muscles, such as walking, cycling, and swimming</li> <li>Resistance training designed to improve physical strength</li> <li>Reduction of sedentary behaviors</li> <li>Optional or access to guided physical activity or exercise classes</li> </ul> <p>Limited guided physical activity (i.e., 1 to 2 sessions) or provision of food samples is allowed if intention is to teach or demonstrate healthy lifestyle principles</p>	<ul style="list-style-type: none"> <li>Dietary counseling solely focused on increasing intake of specific vitamins, micronutrients, herbal supplements, spices (e.g., ginger, cinnamon), or antioxidants through dietary change or supplementation, or counseling on alcohol</li> <li>Surgery</li> </ul>
Comparisons	<p><b>KQs 1, 2:</b> No screening or alternative screening strategies</p> <p><b>KQ 3a:</b> Comparison based on timing; sooner vs. later intervention (i.e., starting intervention upon detection by screening vs. starting later based on clinical diagnosis); clinical diagnosis refers to any approach based on development of symptoms (e.g., polyuria, polydipsia, paresthesia, vision changes) or monitoring of biomarkers (e.g., increase in hemoglobin A1c above a certain threshold)</p> <p><b>KQs 3b, 3c:</b> No intervention, placebo, usual care (can include minimal intervention), different treatment targets (e.g., glucose or blood pressure targets), wait-list, or attention control (for lifestyle interventions)</p> <p><b>KQ 4:</b> All comparisons eligible for KQ 3</p> <p><b>KQs 5–6:</b> Sooner vs. later intervention, no intervention, placebo, usual care, wait-list, or attention control (for lifestyle interventions)</p>	Comparative effectiveness (head-to-head) trials of medications or behavioral counseling without another eligible control group
Outcomes	<p><b>KQs 1, 3, 6:</b> Mortality, cardiovascular morbidity (including myocardial infarction, stroke, congestive heart failure), chronic kidney disease, amputation, skin ulcers, visual impairment (including blindness), periodontitis (including tooth loss), moderate to severe neuropathy, and quality of life</p> <p><b>KQ 2:</b> Labeling, anxiety, harms from false-positive results, burden, inconvenience, depression, and unnecessary testing and treatment</p> <p><b>KQ 4:</b> Serious side effects from treatment, including gastrointestinal side effects, mortality, myocardial infarction, stroke, cancer, and hypoglycemic events requiring medical attention; burden and inconvenience</p> <p><b>KQ 5:</b> Development of type 2 diabetes</p>	<b>KQs 1, 3, 5, 6:</b> Studies with less than 6 months of followup
Study Designs	<p><b>All KQs:</b> Controlled clinical trials</p> <p><b>KQs 2, 4:</b> Controlled prospective cohort studies and case-control studies are also eligible</p>	Modeling studies, systematic reviews, <sup>b</sup> case series, case reports, uncontrolled observational studies, retrospective cohort



## Appendix B2. Eligibility Criteria

	Include	Exclude
	<b>KQ 6:</b> Controlled prospective cohort studies are also eligible	studies, editorials, and all other study designs not mentioned
Settings	Studies conducted in or recruited from primary care settings or settings otherwise applicable to primary care, including school-based health centers and other community settings that provide primary care or are referable from primary care (i.e., screening/interventions that could feasibly be implemented in or referred from primary care)	Settings not generalizable to primary care (e.g., inpatient hospital units, emergency departments, nursing home and other institutional settings, school-based curricula or programs that are not referable from primary care, occupational settings)
Countries	Studies conducted in countries categorized as “Very High” on the Human Development Index in the 2019 Human Development Report (as defined by the United Nations Development Programme)	Studies conducted in countries that are categorized as lower than “Very High” on the Human Development Index in the 2019 Human Development Report
Language	English	Languages other than English
Study Quality	Good or Fair	Poor (according to design-specific USPSTF criteria)

<sup>a</sup> Prediabetes includes individuals who meet criteria for IFG, IGT, and those with an A1c from 5.7 to 6.4 percent.

<sup>b</sup> Systematic reviews were excluded from the evidence review. However, separate searches were conducted to identify relevant systematic reviews, and the citations of all studies included in those systematic reviews were reviewed to ensure that the database searches have captured all relevant primary studies.

**Abbreviations:** A1c=glycated hemoglobin; BMI=body mass index; FPG=fasting plasma glucose; IFG=impaired fasting glucose; IGT=impaired glucose tolerance; KQ=key question; MODY=Maturity Onset Diabetes of the Young; OGTT=oral glucose tolerance test; USPSTF=U.S. Preventive Services Task Force.

## Randomized, Controlled Trials and Cohort Studies

### Criteria

- Initial assembly of comparable groups
- Randomized, controlled trials (RCTs)—adequate randomization, including concealment and whether potential confounders were distributed equally among groups; cohort studies—consideration of potential confounders with either restriction or measurement for adjustment in the analysis; consideration of inception cohorts
- Maintenance of comparable groups (includes attrition, crossovers, adherence, and contamination)
- Important differential loss to followup or overall high loss to followup
- Measurements that are equal, reliable, and valid (includes masking of outcome assessment)
- Clear definition of interventions
- Important outcomes considered
- Analysis: Adjustment for potential confounders for cohort studies or intention-to-treat analysis for RCTs; for cluster RCTs, correction for correlation coefficient

### Definition of Ratings Based on Above Criteria

**Good:** Meets all criteria: Comparable groups are assembled initially and maintained throughout the study (followup  $\geq 80\%$ ); reliable and valid measurement instruments are used and applied equally to the groups; interventions are spelled out clearly; important outcomes are considered; and appropriate attention is given to confounders in analysis. In addition, intention-to-treat analysis is used for RCTs.

**Fair:** Studies will be graded “fair” if any or all of the following problems occur without the important limitations noted in the “poor” category below: Generally comparable groups are assembled initially, but some question remains on whether some (although not major) differences occurred in followup; measurement instruments are acceptable (although not the best) and generally applied equally; some but not all important outcomes are considered; and some but not all potential confounders are accounted for. Intention-to-treat analysis is lacking for RCTs.

**Poor:** Studies will be graded “poor” if any of the following major limitations exist: Groups assembled initially are not close to being comparable or maintained throughout the study; unreliable or invalid measurement instruments are used or not applied equally among groups (including not masking outcome assessment); and key confounders are given little or no attention. Intention-to-treat analysis is lacking for RCTs.

Source: U.S. Preventive Services Task Force. U.S. Preventive Services Task Force, Procedure Manual, Appendix VI. Rockville, MD: U.S. Preventive Services Task Force; 2015<sup>56</sup>

## Diagnostic Accuracy Studies

### Criteria:

- Screening test relevant, available for primary care, and adequately described
- Credible reference standard, performed regardless of test results
- Reference standard interpreted independently of screening test
- Indeterminate results handled in a reasonable manner
- Spectrum of patients included in study
- Sample size
- Reliable screening test

### Definition of Ratings Based on Above Criteria:

**Good:** Evaluates relevant available screening test; uses a credible reference standard; interprets reference standard independently of screening test; assesses reliability of test; has few or handles indeterminate results in a reasonable manner; includes large number (greater than 100) of broad-spectrum patients with and without disease.

**Fair:** Evaluates relevant available screening test; uses reasonable although not best standard; interprets reference standard independent of screening test; has moderate sample size (50 to 100 subjects) and a “medium” spectrum of patients.

**Poor:** Has a fatal flaw, such as uses inappropriate reference standard; improperly administers screening test; biased ascertainment of reference standard; has very small sample size or very narrow selected spectrum of patients.

Source: U.S. Preventive Services Task Force. U.S. Preventive Services Task Force, Procedure Manual, Appendix VI. Rockville, MD: U.S. Preventive Services Task Force; 2015<sup>56</sup>

## Appendix C. Excluded Articles

- X1: Non-English
- X2: Ineligible Population
- X3: Ineligible Screening
- X4: Ineligible Treatment
- X5: Ineligible Comparison
- X6: Ineligible Outcome
- X7: Ineligible Setting
- X8: Ineligible Study Design
- X9: Ineligible Country
- X10: Abstract Only

1. Metformin: new indication. Useful for some children with type 2 diabetes. *Prescrire Int.* 2007 Apr;16(88):50-2. PMID: 17458042. Exclusion Code: X8.
2. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. *Diabetes Care.* 2013 Jun;36(6):1735-41. doi: 10.2337/dc12-2420. PMID: 23704672. Exclusion Code: X6.
3. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and  $\beta$ -cell function in TODAY. *Diabetes Care.* 2013 Jun;36(6):1749-57. doi: 10.2337/dc12-2393. PMID: 23704674. Exclusion Code: X6.
4. Treatment effects on measures of body composition in the TODAY clinical trial. *Diabetes Care.* 2013 Jun;36(6):1742-8. doi: 10.2337/dc12-2534. PMID: 23704673. Exclusion Code: X6.
5. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. *Diabetes Care.* 2013 Jun;36(6):1758-64. doi: 10.2337/dc12-2388. PMID: 23704675. Exclusion Code: X6.
6. Restoring Insulin Secretion (RISE): design of studies of  $\beta$ -cell preservation in prediabetes and early type 2 diabetes across the life span. *Diabetes Care.* 2014;37(3):780-8. doi: 10.2337/dc13-1879. PMID: 24194506. Exclusion Code: X6.
7. Effects of a community-based diabetes prevention program for obese latino youth. *Diabetes.* 2017;Conference: 77th Scientific Sessions of the American Diabetes Association, ADA 2017. United States. 66(pp A369) PMID: CN-01471124. Exclusion Code: X2.
8. Impact of insulin and metformin versus metformin alone on  $\beta$ -cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. *Diabetes Care.* 2018 Aug;41(8):1717-25. doi: 10.2337/dc18-0787. PMID: 29941500. Exclusion Code: X5.
9. Effects of treatment of impaired glucose tolerance or recently diagnosed type 2 diabetes with metformin alone or in combination with insulin glargine on  $\beta$ -cell function: comparison of responses in youth and adults. *Diabetes.* 2019 Aug;68(8):1670-80. doi: 10.2337/db19-0299. PMID: 31178433. Exclusion Code: X6.
10. DIABRISK-SL trial: further consideration of age and impact of imputations. *BMC medicine.* 2019;17(1)doi: 10.1186/s12916-019-1361-2. PMID: CN-02002832. Exclusion Code: X8.
11. Reducing the incidence of predictors of cardio-metabolic disease and dysglycaemia with lifestyle modification in at-risk persons-results of further analyses of DIABRISK-SL in those below 18 years of age. *BMC medicine.* 2019;17(1)doi: 10.1186/s12916-019-1398-2. PMID: CN-02092627. Exclusion Code: X2.
12. Effects of treatment of impaired glucose tolerance or recently diagnosed type 2 diabetes with metformin alone or in

## Appendix C. Excluded Articles

- combination with insulin glargine on  $\hat{I}^2$ -cell function: comparison of responses in youth and adults: the RISE consortium. *Diabetes*. 2019;68(8):1670-80. doi: 10.2337/db19-0299. PMID: CN-02011190. Exclusion Code: X5.
13. Postintervention Effects of Varying Treatment Arms on Glycemic Failure and  $\beta$ -Cell Function in the TODAY Trial. *Diabetes Care*. 2021 Jan;44(1):75-80. doi: 10.2337/dc20-0622. PMID: 33290248. Exclusion Code: X6.
  14. Abdella K, McReelis KD, Strungaru MH. Diabetic retinopathy screening in a Canadian community pediatric diabetes clinic. *Can J Ophthalmol*. 2019 Feb;54(1):27-32. doi: 10.1016/j.jcjo.2018.03.012. PMID: 30851771. Exclusion Code: X2.
  15. Abdella NA, Mojiminiyi OA. Clinical applications of adiponectin measurements in type 2 diabetes mellitus: screening, diagnosis, and marker of diabetes control. *Dis Markers*. 2018;2018:5187940. doi: 10.1155/2018/5187940. PMID: 30069271. Exclusion Code: X2.
  16. Abegg MR, Nandagopal R, Brown RJ, et al. Partners for better health in adolescents with type 2 diabetes ("Buddy study")-an update. *Diabetes*. 2012;61:A615-A6. doi: 10.2337/db12-2323-2568. PMID: CN-01032289. Exclusion Code: X10.
  17. Abrams P, Levitt Katz LE, Moore RH, et al. Threshold for improvement in insulin sensitivity with adolescent weight loss. *J Pediatr*. 2013 Sep;163(3):785-90. doi: 10.1016/j.jpeds.2013.04.003. PMID: 23706362. Exclusion Code: X2.
  18. Addy C, Tatosian D, Hou XS, et al. Effects of age, gender and obesity on the single dose pharmacokinetics (PK) of omarigliptin, a novel once-weekly dipeptidyl peptidase- 4 (DPP-4) inhibitor. *Diabetes*. 2013;62:A301. doi: 10.2337/db13-859-1394. PMID: CN-01065264. Exclusion Code: X2.
  19. Aguilar C, Reza A, García JE, et al. Biguanide related lactic acidosis: incidence and risk factors. *Arch Med Res*. 1992 Spring;23(1):19-24. PMID: 1308787. Exclusion Code: X2.
  20. Ahrens MJ, Thompson DL. Effect of emulin on blood glucose in type 2 diabetics. *Journal of medicinal food*. 2013;16(3):211-5. doi: 10.1089/jmf.2012.0069. PMID: CN-00877198. Exclusion Code: X2.
  21. Al Amiri E, Abdullatif M, Abdulle A, et al. The prevalence, risk factors, and screening measure for prediabetes and diabetes among Emirati overweight/obese children and adolescents. *BMC Public Health*. 2015 Dec 24;15:1298. doi: 10.1186/s12889-015-2649-6. PMID: 26704130. Exclusion Code: X8.
  22. Al Khalifah R, Thabane L, Tarnopolsky MA, et al. The prognosis for glycemic status among children and youth with obesity 2 years after entering a weight management program. *Pediatr Diabetes*. 2018 Aug;19(5):874-81. doi: 10.1111/pedi.12675. PMID: 29577539. Exclusion Code: X5.
  23. Al-Rubeaan K, Al-Manaa H, Khoja T, et al. The Saudi Abnormal Glucose Metabolism and Diabetes Impact Study (SAUDI-DM). *Ann Saudi Med*. 2014 Nov-Dec;34(6):465-75. doi: 10.5144/0256-4947.2014.465. PMID: 25971818. Exclusion Code: X8.
  24. Amed S, Islam N, Sutherland J, et al. Incidence and prevalence trends of youth-onset type 2 diabetes in a cohort of Canadian youth: 2002-2013. *Pediatr Diabetes*. 2018 Jun;19(4):630-6. doi: 10.1111/pedi.12631. PMID: 29280255. Exclusion Code: X8.
  25. Apovian CM, Bergenstal RM, Cuddihy RM, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. *Am J Med*. 2010 May;123(5):468.e9-17. doi: 10.1016/j.amjmed.2009.11.019. PMID: 20399326. Exclusion Code: X2.
  26. Arky RA, Abramson EA. Insulin response to glucose in the presence of

## Appendix C. Excluded Articles

- oral hypoglycemics. *Ann N Y Acad Sci.* 1968 Mar 26;148(3):768-77. doi: 10.1111/j.1749-6632.1968.tb27749.x. PMID: 5241475. Exclusion Code: X2.
27. Arslanian S, El Ghormli L, Bacha F, et al. Adiponectin, insulin sensitivity,  $\beta$ -cell function, and racial/ethnic disparity in treatment failure rates in TODAY. *Diabetes Care.* 2017 Jan;40(1):85-93. doi: 10.2337/dc16-0455. PMID: 27803118. Exclusion Code: X6.
28. Arslanian S, El Ghormli L, Haymond MH, et al. Beta cell function and insulin sensitivity in obese youth with maturity onset diabetes of youth mutations vs type 2 diabetes in TODAY: Longitudinal observations and glycemic failure. *Pediatr Diabetes.* 2020 Jun;21(4):575-85. doi: 10.1111/pedi.12998. PMID: 32064729. Exclusion Code: X5.
29. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. *Diabetes Care.* 2006 Dec;29(12):2632-7. doi: 10.2337/dc06-0703. PMID: 17130196. Exclusion Code: X2.
30. Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. *J Pediatr Endocrinol Metab.* 2008 Apr;21(4):339-48. doi: 10.1515/jpem.2008.21.4.339. PMID: 18556965. Exclusion Code: X6.
31. Babamoto KS, Sey KA, Camilleri AJ, et al. Improving diabetes care and health measures among hispanics using community health workers: results from a randomized controlled trial. *Health Educ Behav.* 2009 Feb;36(1):113-26. doi: 10.1177/1090198108325911. PMID: 19188371. Exclusion Code: X2.
32. Bacha F, El Ghormli L, Arslanian S, et al. Predictors of response to insulin therapy in youth with poorly-controlled type 2 diabetes in the TODAY trial. *Pediatr Diabetes.* 2019 Nov;20(7):871-9. doi: 10.1111/pedi.12906. PMID: 31418516. Exclusion Code: X2.
33. Bacha F, Gungor N, Lee S, et al. Indices of insulin secretion during a liquid mixed-meal test in obese youth with diabetes. *J Pediatr.* 2013 May;162(5):924-9. doi: 10.1016/j.jpeds.2012.11.037. PMID: 23290511. Exclusion Code: X5.
34. Bacha F, Pyle L, Nadeau K, et al. Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study. *Pediatr Diabetes.* 2012 Aug;13(5):376-83. doi: 10.1111/j.1399-5448.2011.00841.x. PMID: 22332798. Exclusion Code: X8.
35. Bahillo-Curienes MP, Hermoso-López F, Martínez-Sopena MJ, et al. Prevalence of insulin resistance and impaired glucose tolerance in a sample of obese Spanish children and adolescents. *Endocrine.* 2012 Apr;41(2):289-95. doi: 10.1007/s12020-011-9540-8. PMID: 21964644. Exclusion Code: X8.
36. Bantle JP, Laine DC, Thomas JW. Metabolic effects of dietary fructose and sucrose in types I and II diabetic subjects. *JAMA.* 1986;256(23):3241-6. PMID: CN-00045554. Exclusion Code: X2.
37. Barnes NS, White PC, Hutchison MR. Time to failure of oral therapy in children with type 2 diabetes: a single center retrospective chart review. *Pediatr Diabetes.* 2012 Nov;13(7):578-82. doi: 10.1111/j.1399-5448.2012.00873.x. PMID: 22646303. Exclusion Code: X5.
38. Barnett AH, Charbonnel B, Li J, et al. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. *Clin Drug Investig.* 2013 Oct;33(10):707-17. doi: 10.1007/s40261-013-0107-8. PMID: 23949898. Exclusion Code: X2.
39. Barnett AH, Patel S, Harper R, et al. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is

## Appendix C. Excluded Articles

- inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. *Diabetes Obes Metab.* 2012 Dec;14(12):1145-54. doi: 10.1111/dom.12011. PMID: 22974280. Exclusion Code: X2.
40. Barreiro-Ribeiro F, Vasques AC, da Silva CC, et al. Hypertriglyceridemic waist phenotype indicates insulin resistance in adolescents according to the clamp technique in the BRAMS Study. *Child Obes.* 2016 Dec;12(6):446-54. doi: 10.1089/chi.2016.0180. PMID: 27627113. Exclusion Code: X6.
41. Bashier AMK, Hussain AKB, Alawadi F, et al. Impact of optimum diabetes care on the safety of fasting in Ramadan in adult patients with type 2 diabetes mellitus on insulin therapy. *Diabetes Res Clin Pract.* 2019 Apr;150:301-7. doi: 10.1016/j.diabres.2019.01.037. PMID: 30768940. Exclusion Code: X2.
42. Bays HE, Goldberg RB, Truitt KE, et al. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. *Arch Intern Med.* 2008 Oct 13;168(18):1975-83. doi: 10.1001/archinte.168.18.1975. PMID: 18852398. Exclusion Code: X2.
43. Bazelier MT, de Vries F, Vestergaard P, et al. Use of thiazolidinediones and risk of bladder cancer: disease or drugs? *Curr Drug Saf.* 2013 Nov;8(5):364-70. doi: 10.2174/15748863113086660069. PMID: 24215315. Exclusion Code: X2.
44. Benavides S, Striet J, Germak J, et al. Efficacy and safety of hypoglycemic drugs in children with type 2 diabetes mellitus. *Pharmacotherapy.* 2005 Jun;25(6):803-9. doi: 10.1592/phco.2005.25.6.803. PMID: 15927898. Exclusion Code: X8.
45. Bergman A, Tan B, Somayaji VR, et al. A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus. *Diabetes Res Clin Pract.* 2017 Apr;126:95-104. doi: 10.1016/j.diabres.2017.01.019. PMID: 28237861. Exclusion Code: X2.
46. Berkowitz RI, Marcus MD, Anderson BJ, et al. Adherence to a lifestyle program for youth with type 2 diabetes and its association with treatment outcome in the TODAY clinical trial. *Pediatr Diabetes.* 2018 Mar;19(2):191-8. doi: 10.1111/pedi.12555. PMID: 28664624. Exclusion Code: X8.
47. Bernardita Prado A, Veronica Gaete P, Francisca Corona H, et al. Metabolic effect of metformin in obese adolescents at risk of diabetes mellitus type 2. *Revista chilena de pediatria.* 2012;83(1):48-57. doi: 10.4067/S0370-41062012000100006. PMID: CN-01017731. Exclusion Code: X1.
48. Berry DC, Gonzales C, Montano NP, et al. Rationale, design, and methodology for the healthy mothers-healthy children study: a randomized controlled trial. *BMC Nutr.* 2019;5:58. doi: 10.1186/s40795-019-0322-7. PMID: 32153971. Exclusion Code: X2.
49. Bhagyanathan M, Dhayanithy D, Parambath VA, et al. Acanthosis nigricans: a screening test for insulin resistance - an important risk factor for diabetes mellitus type-2. *J Family Med Prim Care.* 2017 Jan-Mar;6(1):43-6. doi: 10.4103/2249-4863.214961. PMID: 29026747. Exclusion Code: X8.
50. Bhisitkul DM, Vinik AI, Morrow AL, et al. Prediabetic markers in children with stress hyperglycemia. *Arch Pediatr Adolesc Med.* 1996 Sep;150(9):936-41. doi: 10.1001/archpedi.1996.02170340050010. PMID: 8790124. Exclusion Code: X3.
51. Bizino MB, Jazet IM, Westenberg JJM, et al. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. *Cardiovasc Diabetol.* 2019 Apr 30;18(1):55. doi: 10.1186/s12933-019-0857-6. PMID: 31039778. Exclusion Code: X2.
52. Bjornstad P, Nehus E, El Ghormli L, et al. Insulin sensitivity and diabetic

## Appendix C. Excluded Articles

- kidney disease in children and adolescents with type 2 diabetes: an observational analysis of data from the TODAY clinical trial. *Am J Kidney Dis*. 2018 Jan;71(1):65-74. doi: 10.1053/j.ajkd.2017.07.015. PMID: 29157731. Exclusion Code: X6.
53. Blackett PR, Taylor T, Russell D, et al. Lipoprotein changes in relation to body mass index in Native American adolescents. *Pediatric research*. 1996;40(1):77-81. doi: 10.1203/00006450-199607000-00014. PMID: CN-00129817. Exclusion Code: X4.
54. Bouchard C. Individual differences in the response to regular exercise. *Int J Obes Relat Metab Disord*. 1995 Oct;19 Suppl 4:S5-8. PMID: 8581095. Exclusion Code: X8.
55. Boucher AB, Adesanya EA, Owei I, et al. Dietary habits and leisure-time physical activity in relation to adiposity, dyslipidemia, and incident dysglycemia in the pathobiology of prediabetes in a biracial cohort study. *Metabolism*. 2015 Sep;64(9):1060-7. doi: 10.1016/j.metabol.2015.05.015. PMID: 26116207. Exclusion Code: X2.
56. Bourn DM, Mann JI, McSkimming BJ, et al. Impaired glucose tolerance and NIDDM: does a lifestyle intervention program have an effect? *Diabetes Care*. 1994 Nov;17(11):1311-9. doi: 10.2337/diacare.17.11.1311. PMID: 7821173. Exclusion Code: X2.
57. Bradshaw B. The role of the family in managing therapy in minority children with type 2 diabetes mellitus. *J Pediatr Endocrinol Metab*. 2002 Apr;15 Suppl 1:547-51. PMID: 12017230. Exclusion Code: X6.
58. Brar PC, Mengwall L, Franklin BH, et al. Screening obese children and adolescents for prediabetes and/or type 2 diabetes in pediatric practices: a validation study. *Clin Pediatr (Phila)*. 2014 Jul;53(8):771-6. doi: 10.1177/0009922814528571. PMID: 24671874. Exclusion Code: X8.
59. Broadney MM, Belcher B, Berrigan D, et al. Effects of interrupting sedentary behavior with short bouts of moderate physical activity on glucose tolerance in overweight children: a randomized, crossover trial. *Diabetes*. 2017;66:A365-. PMID: CN-01756063. Exclusion Code: X6.
60. Broadney MM, Belcher BR, Berrigan DA, et al. Effects of interrupting sedentary behavior with short bouts of moderate physical activity on glucose tolerance in children with overweight and obesity: a randomized crossover trial. *Diabetes Care*. 2018 Oct;41(10):2220-8. doi: 10.2337/dc18-0774. PMID: 30082324. Exclusion Code: X4.
61. Brown B, Noonan C, Harris KJ, et al. Developing and piloting the Journey to Native Youth Health program in Northern Plains Indian communities. *Diabetes Educ*. 2013 Jan-Feb;39(1):109-18. doi: 10.1177/0145721712465343. PMID: 23150531. Exclusion Code: X6.
62. Brufani C, Fintini D, Ciampalini P, et al. Pre-diabetes in Italian obese children and youngsters. *J Endocrinol Invest*. 2011 Oct;34(9):e275-80. doi: 10.3275/7798. PMID: 21666412. Exclusion Code: X4.
63. Bryrup T, Thomsen CW, Kern T, et al. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study. *Diabetologia*. 2019 Jun;62(6):1024-35. doi: 10.1007/s00125-019-4848-7. PMID: 30904939. Exclusion Code: X2.
64. Burgert TS, Duran EJ, Goldberg-Gell R, et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. *Pediatr Diabetes*. 2008 Dec;9(6):567-76. doi: 10.1111/j.1399-5448.2008.00434.x. PMID: 18761646. Exclusion Code: X2.
65. Burkeholder JN, Pickens JM, Womack WN. Oral glucose tolerance test in siblings of children with diabetes mellitus. *Diabetes*. 1967 Mar;16(3):156-



## Appendix C. Excluded Articles

60. doi: 10.2337/diab.16.3.156. PMID: 6019594. Exclusion Code: X8.
66. Buse JB, DeFronzo RA, Rosenstock J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. *Diabetes Care*. 2016 Feb;39(2):198-205. doi: 10.2337/dc15-0488. PMID: 26285584. Exclusion Code: X2.
67. Buse JB, Kaufman FR, Linder B, et al. Diabetes screening with hemoglobin A(1c) versus fasting plasma glucose in a multiethnic middle-school cohort. *Diabetes Care*. 2013 Feb;36(2):429-35. doi: 10.2337/dc12-0295. PMID: 23193207. Exclusion Code: X8.
68. Cali AM, Pierpont BM, Taksali SE, et al. Rosiglitazone improves glucose metabolism in obese adolescents with impaired glucose tolerance: a pilot study. *Obesity (Silver Spring)*. 2011 Jan;19(1):94-9. doi: 10.1038/oby.2010.109. PMID: 20467418. Exclusion Code: X6.
69. Campbell EM, Redman S, Moffitt PS, et al. The relative effectiveness of educational and behavioral instruction programs for patients with NIDDM: a randomized trial. *Diabetes Educ*. 1996 Jul-Aug;22(4):379-86. doi: 10.1177/014572179602200412. PMID: 8846745. Exclusion Code: X2.
70. Candler TP, Mahmoud O, Lynn RM, et al. Treatment adherence and BMI reduction are key predictors of HbA1c 1 year after diagnosis of childhood type 2 diabetes in the United Kingdom. *Pediatr Diabetes*. 2018 Dec;19(8):1393-9. doi: 10.1111/pedi.12761. PMID: 30175430. Exclusion Code: X8.
71. Caprio S. Treatment of impaired glucose tolerance in childhood. *Nature clinical practice endocrinology and metabolism*. 2008;4(6):320-1. doi: 10.1038/ncpendmet0815. PMID: CN-01757313. Exclusion Code: X8.
72. Carrel AL. Randomised trial of exercise dose in children reduces diabetes risk (as measured by insulin resistance) in both 20-min and 40-min doses. *Evidence-based medicine*. 2013;18(4):147-8. doi: 10.1136/eb-2012-101092. PMID: CN-00917731. Exclusion Code: X2.
73. Castells S. Management of hyperglycemia in minority children with type 2 diabetes mellitus. *J Pediatr Endocrinol Metab*. 2002 Apr;15 Suppl 1:531-40. PMID: 12017228. Exclusion Code: X5.
74. Cha E, Paul S, Braxter BJ, et al. Dietary behaviors and glucose metabolism in young adults at risk for type 2 diabetes. *Diabetes Educ*. 2018 Apr;44(2):158-67. doi: 10.1177/0145721718756057. PMID: 29495910. Exclusion Code: X2.
75. Chadwick JQ, Van Buren DJ, Morales E, et al. Structure to utilize interventionists' implementation experiences of a family-based behavioral weight management program to enhance the dissemination of the standardized intervention: The TODAY study. *Clin Trials*. 2017 Aug;14(4):406-12. doi: 10.1177/1740774517707727. PMID: 28486851. Exclusion Code: X6.
76. Chambers RA, Rosenstock S, Neault N, et al. A home-visiting diabetes prevention and management program for American Indian Youth: The Together on Diabetes Trial. *Diabetes Educ*. 2015 Dec;41(6):729-47. doi: 10.1177/0145721715608953. PMID: 26450222. Exclusion Code: X5.
77. Chan CL, McFann K, Newnes L, et al. Hemoglobin A1c assay variations and implications for diabetes screening in obese youth. *Pediatr Diabetes*. 2014 Dec;15(8):557-63. doi: 10.1111/pedi.12132. PMID: 24636682. Exclusion Code: X8.
78. Chan CL, Pyle L, Kelsey M, et al. Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemia - 1,5-anhydroglucitol, fructosamine, and glycated albumin. *Pediatr Diabetes*. 2016 May;17(3):206-11. doi: 10.1111/pedi.12258. PMID: 25652226. Exclusion Code: X3.

## Appendix C. Excluded Articles

79. Chan CL, Pyle L, Newnes L, et al. Continuous glucose monitoring and its relationship to hemoglobin A1c and oral glucose tolerance testing in obese and prediabetic youth. *J Clin Endocrinol Metab.* 2015 Mar;100(3):902-10. doi: 10.1210/jc.2014-3612. PMID: 25532041. Exclusion Code: X8.
80. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. *Diabetes Care.* 2006 Dec;29(12):2638-43. doi: 10.2337/dc06-0706. PMID: 17130197. Exclusion Code: X2.
81. Chaudhari P, Vallarino C, Law EH, et al. Evaluation of patients with type 2 diabetes mellitus receiving treatment during the pre-diabetes period: Is early treatment associated with improved outcomes? *Diabetes Res Clin Pract.* 2016 Dec;122:162-9. doi: 10.1016/j.diabres.2016.10.020. PMID: 27865163. Exclusion Code: X2.
82. Chen J, Guo H, Yuan S, et al. Efficacy of urinary glucose for diabetes screening: a reconsideration. *Acta Diabetol.* 2019 Jan;56(1):45-53. doi: 10.1007/s00592-018-1212-1. PMID: 30159749. Exclusion Code: X8.
83. Cheskin LJ, Mitchell AM, Jhaveri AD, et al. Efficacy of meal replacements versus a standard food-based diet for weight loss in type 2 diabetes: a controlled clinical trial. *Diabetes Educ.* 2008 Jan-Feb;34(1):118-27. doi: 10.1177/0145721707312463. PMID: 18267998. Exclusion Code: X2.
84. Chitnis SD, Han Y, Yamaguchi M, et al. Population pharmacokinetic modeling and noncompartmental analysis demonstrated bioequivalence between metformin component of metformin/vildagliptin fixed-dose combination products and metformin immediate-release tablet sourced from various countries. *Clin Pharmacol Drug Dev.* 2016 Jan;5(1):40-51. doi: 10.1002/cpdd.191. PMID: 27119577. Exclusion Code: X2.
85. Choi SH, Lim S, Hong ES, et al. PROPIT: A PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome. *Clin Endocrinol (Oxf).* 2015 May;82(5):670-7. doi: 10.1111/cen.12580. PMID: 25109606. Exclusion Code: X2.
86. Choi YS, Klaric JS, Beltran TH. Prediction of insulin resistance with anthropometric and clinical laboratory measures in nondiabetic teenagers. *Metab Syndr Relat Disord.* 2019 Feb;17(1):37-45. doi: 10.1089/met.2018.0072. PMID: 30394863. Exclusion Code: X3.
87. Chou HS, Palmer JP, Jones AR, et al. Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. *Diabetes Obes Metab.* 2008 Aug;10(8):626-37. doi: 10.1111/j.1463-1326.2007.00753.x. PMID: 17645558. Exclusion Code: X2.
88. Christensen ML, Meibohm B, Capparelli EV, et al. Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. *J Clin Pharmacol.* 2005 Oct;45(10):1137-44. doi: 10.1177/0091270005279578. PMID: 16172178. Exclusion Code: X5.
89. Clarson CL, Brown HK, De Jesus S, et al. Effects of a Comprehensive, Intensive Lifestyle Intervention Combined with Metformin Extended Release in Obese Adolescents. *Int Sch Res Notices.* 2014;2014:659410. doi: 10.1155/2014/659410. PMID: 27433488. Exclusion Code: X6.
90. Clarson CL, Mahmud FH, Baker JE, et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. *Endocrine.* 2009 Aug;36(1):141-6. doi: 10.1007/s12020-009-9196-9. PMID: 19387874. Exclusion Code: X2.

## Appendix C. Excluded Articles

91. Conwell LS, Batch JA. Oral glucose tolerance test in children and adolescents: positives and pitfalls. *J Paediatr Child Health*. 2004 Nov;40(11):620-6. doi: 10.1111/j.1440-1754.2004.00487.x. PMID: 15469531. Exclusion Code: X8.
92. Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. *J Clin Endocrinol Metab*. 2011 Jan;96(1):159-67. doi: 10.1210/jc.2010-1642. PMID: 20962021. Exclusion Code: X6.
93. Craft S, Tripputi M, Edelstein S, et al. Associations between  $\beta$ -cell function and cognitive measures following treatment in youth with impaired glucose tolerance (IGT) or recently diagnosed type 2 diabetes (T2d). *Diabetes*. 2020;69doi: 10.2337/db20-1268-P. PMID: CN-02203727. Exclusion Code: X5.
94. Czech M, Rdzanek E, Pawęska J, et al. Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis. *BMC Endocr Disord*. 2015 Oct 12;15:57. doi: 10.1186/s12902-015-0052-z. PMID: 26458540. Exclusion Code: X8.
95. Daaboul JJ, Siverstein JH. The management of type 2 diabetes in children and adolescents. *Minerva Pediatr*. 2004 Jun;56(3):255-64. PMID: 15252375. Exclusion Code: X8.
96. Dangardt F, Chen Y, Gronowitz E, et al. High physiological omega-3 Fatty Acid supplementation affects muscle Fatty Acid composition and glucose and insulin homeostasis in obese adolescents. *J Nutr Metab*. 2012;2012:395757. doi: 10.1155/2012/395757. PMID: 22523671. Exclusion Code: X2.
97. d'Annunzio G, Vanelli M, Pistorio A, et al. Insulin resistance and secretion indexes in healthy Italian children and adolescents: a multicentre study. *Acta Biomed*. 2009 Apr;80(1):21-8. PMID: 19705616. Exclusion Code: X2.
98. Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. *Diabetes Care*. 2016 Feb;39(2):222-30. doi: 10.2337/dc14-2883. PMID: 26681713. Exclusion Code: X2.
99. Davis CL, Pollock NK, Waller JL, et al. Exercise dose and diabetes risk in overweight and obese children: a randomized controlled trial. *Jama*. 2012 Sep 19;308(11):1103-12. doi: 10.1001/2012.jama.10762. PMID: 22990269. Exclusion Code: X2.
100. Davis JN, Gyllenhammer LE, Vanni AA, et al. Startup circuit training program reduces metabolic risk in Latino adolescents. *Med Sci Sports Exerc*. 2011 Nov;43(11):2195-203. doi: 10.1249/MSS.0b013e31821f5d4e. PMID: 21502883. Exclusion Code: X2.
101. Davis JN, Kelly LA, Lane CJ, et al. Randomized control trial to improve adiposity and insulin resistance in overweight Latino adolescents. *Obesity (silver spring, md.)*. 2009;17(8):1542-8. doi: 10.1038/oby.2009.19. PMID: CN-00720224. Exclusion Code: X2.
102. Davis JN, Tung A, Chak SS, et al. Aerobic and strength training reduces adiposity in overweight Latina adolescents. *Med Sci Sports Exerc*. 2009 Jul;41(7):1494-503. doi: 10.1249/MSS.0b013e31819b6aea. PMID: 19516150. Exclusion Code: X2.
103. Davis JN, Ventura EE, Tung A, et al. Effects of a randomized maintenance intervention on adiposity and metabolic risk factors in overweight minority adolescents. *Pediatr Obes*. 2012 Feb;7(1):16-27. doi: 10.1111/j.2047-6310.2011.00002.x. PMID: 22434736. Exclusion Code: X2.
104. de Moraes MM, Mediano MFF, de Souza RAG, et al. Discouraging soft drink consumption reduces blood glucose and cholesterol of Brazilian elementary students: Secondary analysis of a randomized controlled trial. *Prev*

## Appendix C. Excluded Articles

- Med.* 2017 Jul;100:223-8. doi: 10.1016/j.yjmed.2017.04.035. PMID: 28457714. Exclusion Code: X4.
105. DeBar LL, Schneider M, Ford EG, et al. Social marketing-based communications to integrate and support the HEALTHY study intervention. *Int J Obes (Lond)*. 2009 Aug;33 Suppl 4(Suppl 4):S52-9. doi: 10.1038/ijo.2009.117. PMID: 19623190. Exclusion Code: X6.
106. DeBoer MD, Gurka MJ. Low sensitivity of the metabolic syndrome to identify adolescents with impaired glucose tolerance: an analysis of NHANES 1999-2010. *Cardiovasc Diabetol*. 2014 Apr 23;13:83. doi: 10.1186/1475-2840-13-83. PMID: 24755002. Exclusion Code: X6.
107. DeBoer MD, Gurka MJ, Morrison JA, et al. Inter-relationships between the severity of metabolic syndrome, insulin and adiponectin and their relationship to future type 2 diabetes and cardiovascular disease. *Int J Obes (Lond)*. 2016 Sep;40(9):1353-9. doi: 10.1038/ijo.2016.81. PMID: 27133621. Exclusion Code: X2.
108. Deehan EC, Colin-Ramirez E, Triador L, et al. Efficacy of metformin and fermentable fiber combination therapy in adolescents with severe obesity and insulin resistance: study protocol for a double-blind randomized controlled trial. *Trials*. 2021 Feb 17;22(1):148. doi: 10.1186/s13063-021-05060-8. PMID: 33596993. Exclusion Code: X5.
109. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. *Diabetes Care*. 2009 Sep;32(9):1649-55. doi: 10.2337/dc08-1984. PMID: 19478198. Exclusion Code: X2.
110. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of  $\beta$ -cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. *Diabetes Obes Metab*. 2011 Mar;13(3):258-67. doi: 10.1111/j.1463-1326.2010.01350.x. PMID: 21205122. Exclusion Code: X2.
111. Delahanty L, Kriska A, Edelstein S, et al. Self-reported dietary intake of youth with recent onset of type 2 diabetes: results from the TODAY study. *J Acad Nutr Diet*. 2013 Mar;113(3):431-9. doi: 10.1016/j.jand.2012.11.015. PMID: 23438494. Exclusion Code: X6.
112. Deschamps I, Heptner W, Desjeux JF, et al. Effects of diet on insulin and gastric inhibitory polypeptide levels in obese children. *Pediatr Res*. 1980 Apr;14(4 Pt 1):300-3. doi: 10.1203/00006450-198004000-00008. PMID: 6990366. Exclusion Code: X8.
113. Dhaliwal R, Shepherd JA, El Ghormli L, et al. Changes in visceral and subcutaneous fat in youth with type 2 diabetes in the TODAY Study. *Diabetes Care*. 2019 Aug;42(8):1549-59. doi: 10.2337/dc18-1935. PMID: 31167889. Exclusion Code: X6.
114. Di Bonito P, Pacifico L, Chiesa C, et al. Impaired fasting glucose and impaired glucose tolerance in children and adolescents with overweight/obesity. *J Endocrinol Invest*. 2017 Apr;40(4):409-16. doi: 10.1007/s40618-016-0576-8. PMID: 27854028. Exclusion Code: X4.
115. Diaz-Zavala RG, Esparza-Romero J, Moya-Camarena SY, et al. Improvement of insulin sensitivity after an intensive lifestyle program for youth's weight management in the primary care. *Archivos latinoamericanos de nutricion*. 2012;62(3):258-66. PMID: CN-01048157. Exclusion Code: X1.
116. Dobson R, Whittaker R, Jiang Y, et al. Effectiveness of text message based, diabetes self management support programme (SMS4BG): two arm, parallel randomised controlled trial. *Bmj*. 2018 May 17;361:k1959. doi: 10.1136/bmj.k1959. PMID: 29773539. Exclusion Code: X2.
117. Dolan LM, Bean J, D'Alessio D, et al. Frequency of abnormal carbohydrate metabolism and diabetes in a population-based screening of adolescents. *J Pediatr*. 2005

## Appendix C. Excluded Articles

- Jun;146(6):751-8. doi: 10.1016/j.jpeds.2005.01.045. PMID: 15973311. Exclusion Code: X8.
118. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. *Diabetes Obes Metab*. 2011 Jun;13(6):559-66. doi: 10.1111/j.1463-1326.2011.01376.x. PMID: 21320263. Exclusion Code: X2.
119. Dorenbos E, Drummen M, Adam T, et al. Effect of a high protein/low glycaemic index diet on insulin resistance in adolescents with overweight/obesity—A PREVIEW randomized clinical trial. *Pediatric obesity*. 2020doi: 10.1111/ijpo.12702. PMID: CN-02139974. Exclusion Code: X5.
120. Dorenbos E, Drummen M, Rijks J, et al. PREVIEW (Prevention of Diabetes Through Lifestyle Intervention and Population Studies in Europe and Around the World) study in children aged 10 to 17 years: Design, methods and baseline results. *Diabetes Obes Metab*. 2018 May;20(5):1096-101. doi: 10.1111/dom.13216. PMID: 29322617. Exclusion Code: X5.
121. Dreyfus JG, Lutsey PL, Huxley R, et al. Age at menarche and risk of type 2 diabetes among African-American and white women in the Atherosclerosis Risk in Communities (ARIC) study. *Diabetologia*. 2012 Sep;55(9):2371-80. doi: 10.1007/s00125-012-2616-z. PMID: 22760786. Exclusion Code: X5.
122. Duncan S, Stewart T, McPhee J, et al. Efficacy of a compulsory homework programme for increasing physical activity and improving nutrition in children: a cluster randomised controlled trial. *International journal of behavioral nutrition and physical activity*. 2019;16(1):N.PAG. doi: 10.1186/s12966-019-0840-3. PMID: CN-02117475. Exclusion Code: X7.
123. Edwards NM, Daniels SR, Claytor RP, et al. Physical activity is independently associated with multiple measures of arterial stiffness in adolescents and young adults. *Metabolism*. 2012 Jun;61(6):869-72. doi: 10.1016/j.metabol.2011.10.016. PMID: 22153839. Exclusion Code: X8.
124. Ehrlich RM, Martin JM. Early diabetes mellitus in children. *Metabolism*. 1973 Feb;22(2):391-2. doi: 10.1016/0026-0495(73)90197-2. PMID: 4687967. Exclusion Code: X5.
125. Eisenmann JC, DuBose KD, Donnelly JE. Fatness, fitness, and insulin sensitivity among 7- to 9-year-old children. *Obesity (Silver Spring)*. 2007 Aug;15(8):2135-44. doi: 10.1038/oby.2007.254. PMID: 17712133. Exclusion Code: X4.
126. Elder DA, Hornung LN, Herbers PM, et al. Rapid deterioration of insulin secretion in obese adolescents preceding the onset of type 2 diabetes. *J Pediatr*. 2015 Mar;166(3):672-8. doi: 10.1016/j.jpeds.2014.11.029. PMID: 25557969. Exclusion Code: X4.
127. Elks CE, Ong KK, Scott RA, et al. Age at menarche and type 2 diabetes risk: the EPIC-InterAct study. *Diabetes Care*. 2013 Nov;36(11):3526-34. doi: 10.2337/dc13-0446. PMID: 24159179. Exclusion Code: X4.
128. Emerson P, Van Haeften TW, Pimenta W, et al. Different pathophysiology of impaired glucose tolerance in first-degree relatives of individuals with type 2 diabetes mellitus. *Metabolism*. 2009 May;58(5):602-7. doi: 10.1016/j.metabol.2008.12.004. PMID: 19375581. Exclusion Code: X2.
129. Eppens MC, Craig ME, Cusumano J, et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. *Diabetes Care*. 2006 Jun;29(6):1300-6. doi: 10.2337/dc05-2470. PMID: 16732012. Exclusion Code: X8.
130. Escudero-Carretero MJ, Prieto-Rodríguez M, Fernández-Fernández I, et al. Expectations held by type 1 and 2 diabetes mellitus patients and their relatives: the importance of facilitating the health-care process. *Health Expect*. 2007 Dec;10(4):337-49. doi:

## Appendix C. Excluded Articles

- 10.1111/j.1369-7625.2007.00452.x.  
PMID: 17986070. Exclusion Code: X8.
131. Esposito K, Chiodini P, Bellastella G, et al. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. *Diabetes Obes Metab.* 2012 Mar;14(3):228-33. doi: 10.1111/j.1463-1326.2011.01512.x. PMID: 21958121. Exclusion Code: X8.
132. Fajans SS, Herman WH, Oral EA. Insufficient sensitivity of hemoglobin A<sub>1c</sub> determination in diagnosis or screening of early diabetic states. *Metabolism.* 2011 Jan;60(1):86-91. doi: 10.1016/j.metabol.2010.06.017. PMID: 20723948. Exclusion Code: X2.
133. Farabi SS, Carley DW, Smith D, et al. Impact of exercise on diurnal and nocturnal markers of glycaemic variability and oxidative stress in obese individuals with type 2 diabetes or impaired glucose tolerance. *Diabetes & vascular disease research.* 2015;12(5):381-5. doi: 10.1177/1479164115579003. PMID: CN-01258209. Exclusion Code: X2.
134. Farahmand M, Tehrani FR, Dovom MR, et al. Menarcheal Age and Risk of Type 2 Diabetes: A Community-Based Cohort Study. *J Clin Res Pediatr Endocrinol.* 2017 Jun 1;9(2):156-62. doi: 10.4274/jcrpe.3370. PMID: 27840328. Exclusion Code: X5.
135. Faulkner MS, Michaliszyn SF. Exercise Adherence in Hispanic Adolescents with Obesity or Type 2 Diabetes. *J Pediatr Nurs.* 2021 Jan-Feb;56:7-12. doi: 10.1016/j.pedn.2020.09.012. PMID: 33181374. Exclusion Code: X5.
136. Feigerlová E, Pruhová S, Dittertová L, et al. Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents. *Eur J Pediatr.* 2006 Jul;165(7):446-52. doi: 10.1007/s00431-006-0106-3. PMID: 16602010. Exclusion Code: X5.
137. Fernandes RA, Zanesco A. Early physical activity promotes lower prevalence of chronic diseases in adulthood. *Hypertens Res.* 2010 Sep;33(9):926-31. doi: 10.1038/hr.2010.106. PMID: 20574424. Exclusion Code: X8.
138. Fernandez RS, Frost S. Congruence between the Indian Diabetes Risk Score and Australian Type 2 Diabetes Risk Assessment tool screening in Asian-Indians. *Nurse Res.* 2013 Nov;21(2):36-9. doi: 10.7748/nr2013.11.21.2.36.e215. PMID: 24171636. Exclusion Code: X2.
139. Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. *Diabetes Care.* 2013 Dec;36(12):4015-21. doi: 10.2337/dc13-0663. PMID: 24186878. Exclusion Code: X2.
140. Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. *Diabet Med.* 2010 Mar;27(3):318-26. doi: 10.1111/j.1464-5491.2010.02938.x. PMID: 20536495. Exclusion Code: X2.
141. Fiorentino TV, Pedace E, Succurro E, et al. Individuals With Prediabetes Display Different Age-Related Pathophysiological Characteristics. *J Clin Endocrinol Metab.* 2019 Jul 1;104(7):2911-24. doi: 10.1210/jc.2018-02610. PMID: 30848793. Exclusion Code: X2.
142. Fogelholm M, Larsen TM, Westerterp-Plantenga M, et al. PREVIEW-Design, methods and baseline participant description of an international intervention to prevent type-2 diabetes. *Annals of nutrition and metabolism.* 2015;67:414. doi: 10.1159/000440895. PMID: CN-01160326. Exclusion Code: X2.
143. Fonseca V, Staels B, Morgan JD, 2nd, et al. Efficacy and safety of sitagliptin

## Appendix C. Excluded Articles

- added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. *J Diabetes Complications*. 2013 Mar-Apr;27(2):177-83. doi: 10.1016/j.jdiacomp.2012.09.007. PMID: 23116881. Exclusion Code: X2.
144. Forjuoh SN, Bolin JN, Huber JC, Jr., et al. Behavioral and technological interventions targeting glycemic control in a racially/ethnically diverse population: a randomized controlled trial. *BMC Public Health*. 2014 Jan 23;14:71. doi: 10.1186/1471-2458-14-71. PMID: 24450992. Exclusion Code: X2.
145. Forslund A, Weghuber D, Paulmichl K, et al. Exenatide once weekly reduces weight, liver fat and 2-hour postprandial glucose in obese adolescents. *Acta paediatrica, international journal of paediatrics*. 2017;106:14-5. PMID: CN-01439712. Exclusion Code: X10.
146. Foster GD, Linder B, Baranowski T, et al. A school-based intervention for diabetes risk reduction. *N Engl J Med*. 2010 Jul 29;363(5):443-53. doi: 10.1056/NEJMoa1001933. PMID: 20581420. Exclusion Code: X2.
147. Fox LA, Fraser IP, Neufield N, et al. Metabolic effects and safety of single rising-dose sitagliptin in adolescents with type 2 diabetes. *Diabetes*. 2013;62:A341. doi: 10.2337/db13-859-1394. PMID: CN-01065245. Exclusion Code: X10.
148. Fraser IP, Neufeld ND, Fox LA, et al. A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes. *Pediatr Diabetes*. 2019 Feb;20(1):48-56. doi: 10.1111/pedi.12790. PMID: 30346099. Exclusion Code: X2.
149. Freemark M, Bursey D. A therapeutic trial of metformin in obese adolescents predisposed to type 2 diabetes mellitus. *Pediatric research*. 2000;47(4):128A. PMID: CN-00400965. Exclusion Code: X2.
150. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. *Pediatrics*. 2001 Apr;107(4):E55. doi: 10.1542/peds.107.4.e55. PMID: 11335776. Exclusion Code: X2.
151. Galhardo J, Shield J. The role of haemoglobin A1c in screening obese children and adolescents for glucose intolerance and type 2 diabetes. *Acta Med Port*. 2015 May-Jun;28(3):307-15. PMID: 26421782. Exclusion Code: X8.
152. Gallwitz B, Vaag A, Falahati A, et al. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. *Int J Clin Pract*. 2010 Jan;64(2):267-76. doi: 10.1111/j.1742-1241.2009.02265.x. PMID: 19925617. Exclusion Code: X2.
153. Garnett SP, Baur LA, Noakes M, et al. Researching effective strategies to improve insulin sensitivity in children and teenagers - RESIST. A randomised control trial investigating the effects of two different diets on insulin sensitivity in young people with insulin resistance and/or pre-diabetes. *BMC Public Health*. 2010 Sep 25;10:575. doi: 10.1186/1471-2458-10-575. PMID: 20868506. Exclusion Code: X6.
154. Garnett SP, Gow M, Ho M, et al. Improved insulin sensitivity and body composition, irrespective of macronutrient intake, after a 12 month intervention in adolescents with pre-diabetes; RESIST a randomised control trial. *BMC Pediatr*. 2014 Nov 25;14:289. doi: 10.1186/s12887-014-0289-0. PMID: 25422027. Exclusion Code: X5.
155. Garnett SP, Srinivasan S, Birt SG, et al. Evaluation of glycaemic status in young people with clinical insulin resistance; fasting glucose, fasting insulin or an oral glucose tolerance test? *Clin Endocrinol (Oxf)*. 2010 Apr;72(4):475-80. doi:

## Appendix C. Excluded Articles

- 10.1111/j.1365-2265.2009.03677.x. PMID: 19656159. Exclusion Code: X8.
156. Gastaldelli A, Nauck MA, Balena R. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. *Metabolism*. 2013 Sep;62(9):1330-9. doi: 10.1016/j.metabol.2013.05.001. PMID: 23831441. Exclusion Code: X2.
157. Geloneck MM, Forbes BJ, Shaffer J, et al. Ocular complications in children with diabetes mellitus. *Ophthalmology*. 2015 Dec;122(12):2457-64. doi: 10.1016/j.ophtha.2015.07.010. PMID: 26341461. Exclusion Code: X4.
158. Gidding SS, Bacha F, Bjornstad P, et al. Cardiac biomarkers in youth with type 2 diabetes mellitus: results from the TODAY Study. *J Pediatr*. 2018 Jan;192:86-92.e5. doi: 10.1016/j.jpeds.2017.09.012. PMID: 29246363. Exclusion Code: X6.
159. Gillani SW. Determining Effective Diabetic Care; A Multicentre - Longitudinal Interventional Study. *Curr Pharm Des*. 2016;22(42):6469-76. doi: 10.2174/1381612822666160813235704. PMID: 27526787. Exclusion Code: X2.
160. Gillis B, Mobley C, Stadler DD, et al. Rationale, design and methods of the HEALTHY study nutrition intervention component. *Int J Obes (Lond)*. 2009 Aug;33 Suppl 4(Suppl 4):S29-36. doi: 10.1038/ijo.2009.114. PMID: 19623185. Exclusion Code: X6.
161. Glueck CJ, Mellies MJ, Srivastava L, et al. Insulin, obesity, and triglyceride interrelationships in sixteen children with familial hypertriglyceridemia. *Pediatr Res*. 1977 Jan;11(1 Pt 1):13-9. PMID: 318742. Exclusion Code: X6.
162. Gokcel A, Baltali M, Tarim E, et al. Detection of insulin resistance in Turkish adults: a hospital-based study. *Diabetes Obes Metab*. 2003 Mar;5(2):126-30. doi: 10.1046/j.1463-1326.2003.00253.x. PMID: 12630938. Exclusion Code: X2.
163. Gómez-Díaz RA, Talavera JO, Pool EC, et al. Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial. *Metabolism*. 2012 Sep;61(9):1247-55. doi: 10.1016/j.metabol.2012.02.003. PMID: 22424822. Exclusion Code: X9.
164. Gomis R, Espadero RM, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. *Diabetes Obes Metab*. 2011 Jul;13(7):653-61. doi: 10.1111/j.1463-1326.2011.01391.x. PMID: 21410628. Exclusion Code: X2.
165. Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. *Horm Metab Res*. 2009 May;41(5):368-73. doi: 10.1055/s-0028-1104604. PMID: 19221978. Exclusion Code: X2.
166. Goran MI, Shaibi GQ, Weigensberg MJ, et al. Deterioration of insulin sensitivity and beta-cell function in overweight Hispanic children during pubertal transition: a longitudinal assessment. *Int J Pediatr Obes*. 2006;1(3):139-45. doi: 10.1080/17477160600780423. PMID: 17899631. Exclusion Code: X4.
167. Gore MO, Eason SJ, Ayers CR, et al. Glycated hemoglobin in 14,850 adolescent blood donors: a pilot screening program. *Diabetes Care*. 2014;37(1):e3-4. doi: 10.2337/dc13-0908. PMID: 24356607. Exclusion Code: X3.
168. Gore MO, Eason SJ, Ayers CR, et al. High prevalence of elevated haemoglobin A1C among adolescent blood donors: Results from a voluntary screening programme including 31,546 adolescents. *Diab Vasc Dis Res*. 2015 Jul;12(4):272-8. doi: 10.1177/1479164115579799. PMID: 25972340. Exclusion Code: X8.



## Appendix C. Excluded Articles

169. Gow ML, Baur LA, Johnson NA, et al. Reversal of type 2 diabetes in youth who adhere to a very-low-energy diet: a pilot study. *Diabetologia*. 2017 Mar;60(3):406-15. doi: 10.1007/s00125-016-4163-5. PMID: 27889809. Exclusion Code: X5.
170. Grey M, Berry D, Davidson M, et al. Preliminary testing of a program to prevent type 2 diabetes among high-risk youth. *J Sch Health*. 2004 Jan;74(1):10-5. doi: 10.1111/j.1746-1561.2004.tb06595.x. PMID: 15022370. Exclusion Code: X2.
171. Grillo Mde F, Neumann CR, Scain SF, et al. Diabetes education in primary care: a randomized clinical trial. *Cad Saude Publica*. 2016 May 31;32(5)doi: 10.1590/0102-311x00097115. PMID: 27253458. Exclusion Code: X2.
172. Grønbæk H, Lange A, Birkebæk NH, et al. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. *J Pediatr Gastroenterol Nutr*. 2012 Feb;54(2):223-8. doi: 10.1097/MPG.0b013e31822cdef. PMID: 21760546. Exclusion Code: X5.
173. Groot CJ, Grond JV, Delgado Y, et al. High predictability of impaired glucose tolerance by combining cardiometabolic screening parameters in obese children. *J Pediatr Endocrinol Metab*. 2017 Feb 1;30(2):189-96. doi: 10.1515/jpem-2016-0289. PMID: 28076317. Exclusion Code: X8.
174. Gumbiner B, Esteves B, Dell V, et al. Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial. *Endocrine*. 2018 Nov;62(2):371-80. doi: 10.1007/s12020-018-1597-1. PMID: 30203123. Exclusion Code: X2.
175. Gumus P, Gomez R, Vargas A, et al. The relationship of insulin secretion and GAD65 antibody levels at diagnosis on glycemic control in type 2 diabetes. *J Pediatr Endocrinol Metab*. 2010 Oct;23(10):1025-9. doi: 10.1515/jpem.2010.163. PMID: 21158213. Exclusion Code: X8.
176. Gustavson SM, Chen D, Somayaji V, et al. Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus. *Diabetes, obesity & metabolism*. 2011;13(11):1056-8. doi: 10.1111/j.1463-1326.2011.01479.x. PMID: CN-00810261. Exclusion Code: X2.
177. Hagman E, Ek AE, Marcus C. Insulin function in obese children within the low and high ranges of impaired fasting glycemia. *Pediatr Diabetes*. 2019 Mar;20(2):160-5. doi: 10.1111/pedi.12804. PMID: 30537059. Exclusion Code: X2.
178. Hannon TS, Dugan TM, Saha CK, et al. Effectiveness of Computer Automation for the Diagnosis and Management of Childhood Type 2 Diabetes: A Randomized Clinical Trial. *JAMA Pediatr*. 2017 Apr 1;171(4):327-34. doi: 10.1001/jamapediatrics.2016.4207. PMID: 28192551. Exclusion Code: X4.
179. Hannon TS, Edelstein SL, Arslanian SA, et al. Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently-diagnosed type 2 diabetes. *Pediatr Diabetes*. 2020 Dec;21(8):1437-46. doi: 10.1111/pedi.13129. PMID: 32985775. Exclusion Code: X5.
180. Hansel B, Giral P, Gambotti L, et al. A Fully Automated Web-Based Program Improves Lifestyle Habits and HbA1c in Patients With Type 2 Diabetes and Abdominal Obesity: Randomized Trial of Patient E-Coaching Nutritional Support (The ANODE Study). *J Med Internet Res*. 2017 Nov 8;19(11):e360. doi: 10.2196/jmir.7947. PMID: 29117929. Exclusion Code: X2.
181. Harder-Lauridsen NM, Birk NM, Ried-Larsen M, et al. A randomized controlled trial on a multicomponent intervention for overweight school-aged children - Copenhagen, Denmark. *BMC pediatrics*. 2014;14:273. doi:

## Appendix C. Excluded Articles

- 10.1186/1471-2431-14-273. PMID: CN-01112964. Exclusion Code: X2.
182. Harris MA, Freeman KA, Beers M. Family therapy for adolescents with poorly controlled diabetes: initial test of clinical significance. *Journal of pediatric psychology*. 2009;34(10):1097-107. doi: 10.1093/jpepsy/jsp009. PMID: CN-00730018. Exclusion Code: X2.
183. Hasson RE, Adam TC, Davis JN, et al. Randomized controlled trial to improve adiposity, inflammation, and insulin resistance in obese African-American and Latino youth. *Obesity (Silver Spring)*. 2012 Apr;20(4):811-8. doi: 10.1038/oby.2010.343. PMID: 21293446. Exclusion Code: X2.
184. Hauner H, Hanisch J, Bramlage P, et al. Prevalence of undiagnosed Type-2-diabetes mellitus and impaired fasting glucose in German primary care: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). *Exp Clin Endocrinol Diabetes*. 2008 Jan;116(1):18-25. doi: 10.1055/s-2007-985359. PMID: 17926235. Exclusion Code: X2.
185. Hazreen MA, Su TT, Jalaludin MY, et al. An exploratory study on risk factors for chronic non-communicable diseases among adolescents in Malaysia: overview of the Malaysian Health and Adolescents Longitudinal Research Team study (The MyHeART study). *BMC Public Health*. 2014;14 Suppl 3(Suppl 3):S6. doi: 10.1186/1471-2458-14-s3-s6. PMID: 25437068. Exclusion Code: X5.
186. Heath GW, Leonard BE, Wilson RH, et al. Community-based exercise intervention: Zuni Diabetes Project. *Diabetes Care*. 1987 Sep-Oct;10(5):579-83. doi: 10.2337/diacare.10.5.579. PMID: 3677975. Exclusion Code: X2.
187. Henderson M, Benedetti A, Barnett TA, et al. Influence of adiposity, physical activity, fitness, and screen time on insulin dynamics over 2 years in children. *JAMA Pediatr*. 2016 Mar;170(3):227-35. doi: 10.1001/jamapediatrics.2015.3909. PMID: 26857733. Exclusion Code: X8.
188. Henderson M, Benedetti A, Gray-Donald K. Dietary composition and its associations with insulin sensitivity and insulin secretion in youth. *Br J Nutr*. 2014 Feb;111(3):527-34. doi: 10.1017/s0007114513002572. PMID: 24047611. Exclusion Code: X8.
189. Hennessey JV, Bustamante MA, Teter ML, et al. Bedtime dosing of glyburide and the treatment of type II diabetes mellitus. *Am J Med Sci*. 1994 Oct;308(4):234-8. doi: 10.1097/00000441-199430840-00004. PMID: 7942982. Exclusion Code: X2.
190. Henry RR, Aroda VR, Mudaliar S, et al. Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus. *Diabetes Obes Metab*. 2012 Jan;14(1):40-6. doi: 10.1111/j.1463-1326.2011.01486.x. PMID: 21831167. Exclusion Code: X2.
191. Henry RR, Mudaliar S, Kanitra L, et al. Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial. *J Clin Endocrinol Metab*. 2012 Jul;97(7):2370-9. doi: 10.1210/jc.2011-3253. PMID: 22539590. Exclusion Code: X2.
192. Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. *Int J Clin Pract*. 2012 May;66(5):446-56. doi: 10.1111/j.1742-1241.2012.02911.x. PMID: 22413962. Exclusion Code: X2.
193. Henry RR, Staels B, Fonseca VA, et al. Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study. *Diabetes Obes Metab*. 2014 Mar;16(3):223-30. doi: 10.1111/dom.12194. PMID: 23909985. Exclusion Code: X2.

## Appendix C. Excluded Articles

194. Herbst A, Kapellen T, Schober E, et al. Impact of regular physical activity on blood glucose control and cardiovascular risk factors in adolescents with type 2 diabetes mellitus--a multicenter study of 578 patients from 225 centres. *Pediatr Diabetes*. 2015 May;16(3):204-10. doi: 10.1111/peidi.12144. PMID: 24888254. Exclusion Code: X8.
195. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. *Diabetes Obes Metab*. 2007 Sep;9(5):733-45. doi: 10.1111/j.1463-1326.2007.00744.x. PMID: 17593236. Exclusion Code: X2.
196. Hingle MD, Turner T, Going S, et al. Feasibility of a family-focused YMCA-based diabetes prevention program in youth: The E.P.I.C. Kids (Encourage, Practice, and Inspire Change) Study. *Prev Med Rep*. 2019 Jun;14:100840. doi: 10.1016/j.pmedr.2019.100840. PMID: 30911460. Exclusion Code: X2.
197. Hitt JM, Velasquez-Mieryer P, Neira C, et al. Factors affecting hemoglobin A1C in the diagnosis of diabetes and prediabetes in youth. *J Pediatr Nurs*. 2016 Sep-Oct;31(5):511-8. doi: 10.1016/j.pedn.2016.03.020. PMID: 27132801. Exclusion Code: X8.
198. Ho M, Gow M, Baur LA, et al. Effect of fat loss on arterial elasticity in obese adolescents with clinical insulin resistance: RESIST study. *J Clin Endocrinol Metab*. 2014 Oct;99(10):E1846-53. doi: 10.1210/jc.2014-1944. PMID: 24955610. Exclusion Code: X6.
199. Ho M, Heath AM, Gow M, et al. Zinc Intake, Zinc Bioavailability and Plasma Zinc in Obese Adolescents with Clinical Insulin Resistance Following Low Energy Diets. *Annals of nutrition & metabolism*. 2016;69(2):135-41. doi: 10.1159/000450728. PMID: CN-01286479. Exclusion Code: X8.
200. Hogg J, Diaz A, Del Cid M, et al. An after-school dance and lifestyle education program reduces risk factors for heart disease and diabetes in elementary school children. *J Pediatr Endocrinol Metab*. 2012;25(5-6):509-16. doi: 10.1515/jpem-2012-0027. PMID: 22876547. Exclusion Code: X2.
201. Hollander P, Lasko B, Barnett AH, et al. Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study). *Obesity (Silver Spring)*. 2013 Feb;21(2):238-47. doi: 10.1002/oby.20042. PMID: 23404788. Exclusion Code: X2.
202. Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. *J Clin Endocrinol Metab*. 2009 Dec;94(12):4810-9. doi: 10.1210/jc.2009-0550. PMID: 19864452. Exclusion Code: X2.
203. Hollander PA, Amod A, Litwak LE, et al. Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial. *Diabetes care*. 2010;33(3):605-7. doi: 10.2337/dc09-0455. PMID: CN-00748784. Exclusion Code: X2.
204. Horowitz M, Flint A, Jones KL, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. *Diabetes Res Clin Pract*. 2012 Aug;97(2):258-66. doi: 10.1016/j.diabres.2012.02.016. PMID: 22446097. Exclusion Code: X2.
205. Hsia SH. Insulin glargine compared to NPH among insulin-naïve, U.S. inner city, ethnic minority type 2 diabetic patients. *Diabetes research and clinical practice*. 2011;91(3):293-9. doi: 10.1016/j.diabres.2010.11.028. PMID: CN-00785671. Exclusion Code: X5.
206. Huang SH, Weng KP, Hsieh KS, et al. Effects of a classroom-based weight-control intervention on cardiovascular disease in elementary-school obese

## Appendix C. Excluded Articles

- children. *Acta Paediatr Taiwan*. 2007 Jul-Aug;48(4):201-6. PMID: 18265541. Exclusion Code: X2.
207. Huo X, Spatz ES, Ding Q, et al. Design and rationale of the Cardiovascular Health and Text Messaging (CHAT) Study and the CHAT-Diabetes Mellitus (CHAT-DM) Study: two randomised controlled trials of text messaging to improve secondary prevention for coronary heart disease and diabetes. *BMJ Open*. 2017 Dec 21;7(12):e018302. doi: 10.1136/bmjopen-2017-018302. PMID: 29273661. Exclusion Code: X2.
208. Huus K, Åkerman L, Raustorp A, et al. Physical Activity, Blood Glucose and C-Peptide in Healthy School-Children, a Longitudinal Study. *PLoS One*. 2016;11(6):e0156401. doi: 10.1371/journal.pone.0156401. PMID: 27270732. Exclusion Code: X4.
209. Huys N, Van Stappen V, Shadid S, et al. Effectiveness of a family-, school- and community-based intervention on physical activity and its correlates in Belgian families with an increased risk for type 2 diabetes mellitus: the Feel4Diabetes-study. *BMC Public Health*. 2020 Aug 12;20(1):1231. doi: 10.1186/s12889-020-09336-7. PMID: 32787943. Exclusion Code: X2.
210. Inci F, Atmaca M, Ozturk M, et al. Pantoprazole may improve beta cell function and diabetes mellitus. *J Endocrinol Invest*. 2014 May;37(5):449-54. doi: 10.1007/s40618-013-0040-y. PMID: 24682913. Exclusion Code: X5.
211. Inge TH, Laffel LM, Jenkins TM, et al. Comparison of surgical and medical therapy for type 2 diabetes in severely obese adolescents. *JAMA Pediatr*. 2018 May 1;172(5):452-60. doi: 10.1001/jamapediatrics.2017.5763. PMID: 29532078. Exclusion Code: X5.
212. Islam N, Gepts T, Lief I, et al. Protocol for the CHORD project (community health outreach to reduce diabetes): a cluster-randomized community health worker trial to prevent diabetes. *BMC Public Health*. 2018 Apr 19;18(1):521. doi: 10.1186/s12889-018-5419-4. PMID: 29673333. Exclusion Code: X2.
213. Jackman MM, Nabors LA, McPherson CL, et al. Feasibility, Acceptability, and Preliminary Effectiveness of the OpenMind (OM) Program for Pre-School Children. *Journal of child and family studies*. 2019;28(10):2910-21. doi: 10.1007/s10826-019-01506-5. PMID: CN-02117498. Exclusion Code: X2.
214. Jaiswal M, Divers J, Dabelea D, et al. Prevalence of and risk factors for diabetic peripheral neuropathy in youth with type 1 and type 2 diabetes: SEARCH for diabetes in youth study. *Diabetes Care*. 2017 Sep;40(9):1226-32. doi: 10.2337/dc17-0179. PMID: 28674076. Exclusion Code: X8.
215. Jakicic JM. Exercise demonstrates a dose-response effect on insulin resistance, fatness, and visceral fat. *Journal of pediatrics*. 2013;162(3):649-50. doi: 10.1016/j.jpeds.2012.12.059. PMID: CN-00908824. Exclusion Code: X8.
216. Jani RH, Pai V, Jha P, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). *Diabetes Technol Ther*. 2014 Feb;16(2):63-71. doi: 10.1089/dia.2013.0253. PMID: 24138536. Exclusion Code: X2.
217. Janson A, Jarvholm K, Gronowitz E, et al. A randomized controlled trial comparing intensive non-surgical treatment with bariatric surgery in adolescents aged 13–16 years (AMOS2): rationale, study design, and patient recruitment. *Contemporary clinical trials communications*. 2020;19doi: 10.1016/j.conctc.2020.100592. PMID: CN-02141054. Exclusion Code: X4.
218. Javed A, Vella A, Balagopal PP, et al. Effects of vitamin D supplementation on

## Appendix C. Excluded Articles

- insulin sensitivity and beta cell function in obese adolescents. *Endocrine reviews. Conference: 96th annual meeting and expo of the endocrine society, ENDO 2014. Chicago, IL united states. Conference start: 20140621. Conference end: 20140624. Conference publication: (var.pagings)*. 2014;35(no pagination)PMID: CN-01267325. Exclusion Code: X5.
219. Jayaram S, Hariharan RS, Madhavan R, et al. A prospective, parallel group, open-labeled, comparative, multicentric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes. *J Assoc Physicians India*. 2010 Nov;58:679-82, 87. PMID: 21510461. Exclusion Code: X2.
220. Jefferies C, Carter P, Reed PW, et al. The incidence, clinical features, and treatment of type 2 diabetes in children <15 yr in a population-based cohort from Auckland, New Zealand, 1995–2007. *Pediatr Diabetes*. 2012 Jun;13(4):294-300. doi: 10.1111/j.1399-5448.2012.00851.x. PMID: 22646236. Exclusion Code: X6.
221. Jeffery SC, Hosking J, Jeffery AN, et al. Insulin resistance is higher in prepubertal girls but switches to become higher in boys at age 16: A Cohort Study (EarlyBird 57). *Pediatr Diabetes*. 2018 Mar;19(2):223-30. doi: 10.1111/pedi.12571. PMID: 28851041. Exclusion Code: X8.
222. Ji L, Sun N, Zhang Y, et al. Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical study. *Diabetes Obes Metab*. 2020 Feb;22(2):158-66. doi: 10.1111/dom.13884. PMID: 31512365. Exclusion Code: X2.
223. Johnson MS, Figueroa-Colon R, Huang TT, et al. Longitudinal changes in body fat in African American and Caucasian children: influence of fasting insulin and insulin sensitivity. *J Clin Endocrinol Metab*. 2001 Jul;86(7):3182-7. doi: 10.1210/jcem.86.7.7665. PMID: 11443186. Exclusion Code: X6.
224. Johnson SR, Carter HE, Leo P, et al. Cost-effectiveness analysis of routine screening using massively parallel sequencing for maturity-onset diabetes of the young in a pediatric diabetes cohort: reduced health system costs and improved patient quality of life. *Diabetes Care*. 2019 Jan;42(1):69-76. doi: 10.2337/dc18-0261. PMID: 30523035. Exclusion Code: X2.
225. Joslowski G, Halim J, Goletzke J, et al. Dietary glycemic load, insulin load, and weight loss in obese, insulin resistant adolescents: RESIST study. *Clin Nutr*. 2015 Feb;34(1):89-94. doi: 10.1016/j.clnu.2014.01.015. PMID: 24534012. Exclusion Code: X8.
226. Kaar JL, Schmiede SJ, Drews K, et al. Evaluation of the longitudinal change in health behavior profiles across treatment groups in the TODAY clinical trial. *Pediatric diabetes*. 2020;21(2):224-32. doi: 10.1111/pedi.12976. PMID: CN-02233381. Exclusion Code: X6.
227. Kabaroğlu C, Ersoy B, Onur E, et al. Elevated glucose level at 30 minutes during an oral glucose tolerance test in obese adolescents: a new disorder of glucose tolerance. *Endocr J*. 2013;60(2):197-205. doi: 10.1507/endocrj.ej12-0079. PMID: 23095208. Exclusion Code: X2.
228. Kasliwal R, Wilton LV, Shakir SA. Monitoring the safety of pioglitazone : results of a prescription-event monitoring study of 12,772 patients in England. *Drug Saf*. 2008;31(10):839-50. doi: 10.2165/00002018-200831100-00003. PMID: 18759508. Exclusion Code: X2.
229. Katakura M, Aizawa T, Naka M, et al. Long-term prognosis of islet cell antibody-negative ketosis-onset diabetes with subsequent non-insulin dependency. *Diabetes care*. 1999;22(9):1584-6. doi:

## Appendix C. Excluded Articles

- 10.2337/diacare.22.9.1584a. PMID: CN-00167283. Exclusion Code: X8.
230. Katz LL, Anderson BJ, McKay SV, et al. Correlates of medication adherence in the TODAY cohort of youth with type 2 diabetes. *Diabetes Care*. 2016 Nov;39(11):1956-62. doi: 10.2337/dc15-2296. PMID: 27352955. Exclusion Code: X6.
231. Kaufman FR, Hirst K, Linder B, et al. Risk factors for type 2 diabetes in a sixth- grade multiracial cohort: the HEALTHY study. *Diabetes Care*. 2009 May;32(5):953-5. doi: 10.2337/dc08-1774. PMID: 19196888. Exclusion Code: X4.
232. Kawamori R, Kadowaki T, Onji M, et al. Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan. *Diabetes Res Clin Pract*. 2007 May;76(2):229-35. doi: 10.1016/j.diabres.2006.08.017. PMID: 17109986. Exclusion Code: X2.
233. Kay JP, Alemzadeh R, Langley G, et al. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. *Metabolism*. 2001 Dec;50(12):1457-61. doi: 10.1053/meta.2001.28078. PMID: 11735093. Exclusion Code: X2.
234. Kelly AS, Auerbach P, Barrientos Perez M, et al. Liraglutide for weight management in pubertal adolescents with obesity: a randomized controlled trial. *Obesity reviews*. 2020;21(SUPPL 1)doi: 10.1111/obr.13115. PMID: CN-02230039. Exclusion Code: X2.
235. Kelly AS, Auerbach P, Barrientos-Perez M, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. *N Engl J Med*. 2020 May 28;382(22):2117-28. doi: 10.1056/NEJMoA1916038. PMID: 32233338. Exclusion Code: X2.
236. Kelly AS, Metzger AM, Rudser KD, et al. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. *Obesity (Silver Spring)*. 2012 Feb;20(2):364-70. doi: 10.1038/oby.2011.337. PMID: 22076596. Exclusion Code: X2.
237. Kelly AS, Wetzsteon RJ, Kaiser DR, et al. Inflammation, insulin, and endothelial function in overweight children and adolescents: the role of exercise. *Journal of pediatrics*. 2004;145(6):731-6. doi: 10.1016/j.jpeds.2004.08.004. PMID: CN-00503886. Exclusion Code: X2.
238. Kelly L, Holmberg PM, Schroeder ET, et al. Effect of home-based strength training program on IGF-I, IGFBP-1 and IGFBP-3 in obese Latino boys participating in a 16-week randomized controlled trial. *Journal of pediatric endocrinology & metabolism*. 2019;32(10):1121-9. doi: 10.1515/jpem-2019-0073. PMID: CN-01997339. Exclusion Code: X2.
239. Kelly LA, Loza A, Lin X, et al. The effect of a home-based strength training program on type 2 diabetes risk in obese Latino boys. *Journal of pediatric endocrinology & metabolism*. 2015;28(3-4):315-22. doi: 10.1515/jpem-2014-0470. PMID: CN-01256726. Exclusion Code: X2.
240. Kendall D, Vail A, Amin R, et al. Metformin in obese children and adolescents: the MOCA trial. *J Clin Endocrinol Metab*. 2013 Jan;98(1):322-9. doi: 10.1210/jc.2012-2710. PMID: 23175691. Exclusion Code: X6.
241. Kim HS, Yoo YS, Shim HS. Effects of an Internet-based intervention on plasma glucose levels in patients with type 2 diabetes. *J Nurs Care Qual*. 2005 Oct-Dec;20(4):335-40. doi: 10.1097/00001786-200510000-00009. PMID: 16177585. Exclusion Code: X2.
242. Kim JS, Lê KA, Mahurkar S, et al. Influence of elevated liver fat on circulating adipocytokines and insulin resistance in obese Hispanic adolescents. *Pediatric obesity*. 2012;7(2):158-64. doi: 10.1111/j.2047-6310.2011.00014.x. PMID: CN-00872236. Exclusion Code: X5.
243. Kim JY, Bacha F, Tfayli H, et al. Adipose Tissue Insulin Resistance in

## Appendix C. Excluded Articles

- Youth on the Spectrum From Normal Weight to Obese and From Normal Glucose Tolerance to Impaired Glucose Tolerance to Type 2 Diabetes. *Diabetes Care*. 2019 Feb;42(2):265-72. doi: 10.2337/dc18-1178. PMID: 30455334. Exclusion Code: X4.
244. Kim MS, Jo DS, Lee DY. Comparison of HbA1c and OGTT for the diagnosis of type 2 diabetes in children at risk of diabetes. *Pediatr Neonatol*. 2019 Aug;60(4):428-34. doi: 10.1016/j.pedneo.2018.11.002. PMID: 30497969. Exclusion Code: X8.
245. Klein DJ, Aronson Friedman L, Harlan WR, et al. Obesity and the development of insulin resistance and impaired fasting glucose in black and white adolescent girls: a longitudinal study. *Diabetes Care*. 2004 Feb;27(2):378-83. doi: 10.2337/diacare.27.2.378. PMID: 14747217. Exclusion Code: X3.
246. Klein DJ, Battelino T, Chatterjee DJ, et al. Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. *Diabetes Technol Ther*. 2014 Oct;16(10):679-87. doi: 10.1089/dia.2013.0366. PMID: 25036533. Exclusion Code: X2.
247. Klein S, Ghosh A, Cremieux PY, et al. Economic impact of the clinical benefits of bariatric surgery in diabetes patients with BMI  $\geq 35$  kg/m<sup>2</sup>. *Obesity (Silver Spring)*. 2011 Mar;19(3):581-7. doi: 10.1038/oby.2010.199. PMID: 20829800. Exclusion Code: X2.
248. Kloppenborg JT, Gamborg M, Fonvig CE, et al. The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment. *Pediatr Diabetes*. 2018 May;19(3):366-74. doi: 10.1111/pedi.12605. PMID: 29159854. Exclusion Code: X5.
249. Kobayashi K, Amemiya S, Higashida K, et al. Pathogenic factors of glucose intolerance in obese Japanese adolescents with type 2 diabetes. *Metabolism*. 2000 Feb;49(2):186-91. doi: 10.1016/s0026-0495(00)91221-6. PMID: 10690942. Exclusion Code: X4.
250. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. *Am J Health Syst Pharm*. 2005 Jan 15;62(2):173-81. doi: 10.1093/ajhp/62.2.173. PMID: 15700891. Exclusion Code: X2.
251. Komamine M, Kajiyama K, Ishiguro C, et al. Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study. *Pharmacoepidemiol Drug Saf*. 2019 Sep;28(9):1166-74. doi: 10.1002/pds.4847. PMID: 31338935. Exclusion Code: X5.
252. Koro CE, Sowell MO, Stender M, et al. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis. *Clin Ther*. 2008 Mar;30(3):535-42. doi: 10.1016/j.clinthera.2008.02.008. PMID: 18405791. Exclusion Code: X2.
253. Kothny W, Foley J, Kozlovski P, et al. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. *Diabetes Obes Metab*. 2013 Mar;15(3):252-7. doi: 10.1111/dom.12020. PMID: 23039321. Exclusion Code: X2.
254. Krall J, Gabbay R, Zickmund S, et al. Current perspectives on psychological insulin resistance: primary care provider and patient views. *Diabetes Technol Ther*. 2015 Apr;17(4):268-74. doi: 10.1089/dia.2014.0268. PMID: 25551737. Exclusion Code: X2.
255. Kriska A, Delahanty L, Edelstein S, et al. Sedentary behavior and physical activity in youth with recent onset of type 2 diabetes. *Pediatrics*. 2013 Mar;131(3):e850-6. doi: 10.1542/peds.2012-0620. PMID: 23400602. Exclusion Code: X5.
256. Kriska A, El Ghormli L, Copeland KC, et al. Impact of lifestyle behavior change

## Appendix C. Excluded Articles

- on glycemic control in youth with type 2 diabetes. *Pediatr Diabetes*. 2018 Feb;19(1):36-44. doi: 10.1111/pedi.12526. PMID: 28378429. Exclusion Code: X6.
257. Krysiak R, Okopien B. The effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucose. *Metabolism*. 2013 Jan;62(1):39-43. doi: 10.1016/j.metabol.2012.06.009. PMID: 22841520. Exclusion Code: X2.
258. Kuk JL, Lee S. Assessing the utility of cardiorespiratory fitness, visceral fat and liver fat in predicting changes in insulin sensitivity beyond simple changes in body weight after exercise training in adolescents. *Appl Physiol Nutr Metab*. 2020 Jul 16doi: 10.1139/apnm-2020-0284. PMID: 32674604. Exclusion Code: X2.
259. Kumar VS, Wentzell KJ, Mikkelsen T, et al. The DAILY (Daily Automated Intensive Log for Youth) trial: a wireless, portable system to improve adherence and glycemic control in youth with diabetes. *Diabetes Technol Ther*. 2004 Aug;6(4):445-53. doi: 10.1089/1520915041705893. PMID: 15320998. Exclusion Code: X2.
260. Kwak JH, Lee JH, Ahn CW, et al. Black soy peptide supplementation improves glucose control in subjects with prediabetes and newly diagnosed type 2 diabetes mellitus. *Journal of medicinal food*. 2010;13(6):1307-12. doi: 10.1089/jmf.2010.1075. PMID: CN-00779772. Exclusion Code: X2.
261. Laffel L, Chang N, Grey M, et al. Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study. *Pediatr Diabetes*. 2012 Aug;13(5):369-75. doi: 10.1111/j.1399-5448.2011.00846.x. PMID: 22369102. Exclusion Code: X5.
262. Laffel LMB, Tamborlane WV, Yver A, et al. Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial. *Diabet Med*. 2018 Aug;35(8):1096-104. doi: 10.1111/dme.13629. PMID: 29655290. Exclusion Code: X5.
263. Lankisch MR, Ferlinz KC, Leahy JL, et al. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. *Diabetes, obesity & metabolism*. 2008;10(12):1178-85. doi: 10.1111/j.1463-1326.2008.00967.x. PMID: CN-00700127. Exclusion Code: X2.
264. Lawson C, Ahmed SN, Brady C, et al. A clinic-based approach to diagnosis and management of prediabetes in high-risk children and adolescents. *J Endocr Soc*. 2020 Apr 1;4(4):bvaa008. doi: 10.1210/jendso/bvaa008. PMID: 32215353. Exclusion Code: X8.
265. Le PT, Huisinigh CE, Ashraf AP. Glycemic control and diabetic dyslipidemia in adolescents with type 2 diabetes. *Endocr Pract*. 2013 Nov-Dec;19(6):972-9. doi: 10.4158/ep13016.or. PMID: 23807519. Exclusion Code: X6.
266. Lee HS, Park HK, Hwang JS. HbA1c and glucose intolerance in obese children and adolescents. *Diabet Med*. 2012 Jul;29(7):e102-5. doi: 10.1111/j.1464-5491.2012.03596.x. PMID: 22273110. Exclusion Code: X8.
267. Lee JM, Eason A, Nelson C, et al. Screening practices for identifying type 2 diabetes in adolescents. *J Adolesc Health*. 2014 Feb;54(2):139-43. doi: 10.1016/j.jadohealth.2013.07.003. PMID: 23968881. Exclusion Code: X8.
268. Lee KT, Yeh YH, Chang SH, et al. Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus: A propensity score-matched nationwide study. *Medicine (Baltimore)*. 2017 Jul;96(28):e7507. doi: 10.1097/md.00000000000007507. PMID: 28700501. Exclusion Code: X2.



## Appendix C. Excluded Articles

269. Lee S, Deldin AR, White D, et al. Aerobic exercise but not resistance exercise reduces intrahepatic lipid content and visceral fat and improves insulin sensitivity in obese adolescent girls: a randomized controlled trial. *American journal of physiology. Endocrinology and metabolism*. 2013;305(10):E1222-9. doi: 10.1152/ajpendo.00285.2013. PMID: CN-01015548. Exclusion Code: X2.
270. Lee S, Libman I, Hughan K, et al. Effects of Exercise Modality on Insulin Resistance and Ectopic Fat in Adolescents with Overweight and Obesity: A Randomized Clinical Trial. *J Pediatr*. 2019 Mar;206:91-8.e1. doi: 10.1016/j.jpeds.2018.10.059. PMID: 30554789. Exclusion Code: X5.
271. Lennerz BS, Moss A, von Schnurbein J, et al. Do adolescents with extreme obesity differ according to previous treatment seeking behavior? The Youth with Extreme obesity Study (YES) cohort. *Int J Obes (Lond)*. 2019 Jan;43(1):103-15. doi: 10.1038/s41366-018-0237-4. PMID: 30368525. Exclusion Code: X8.
272. Lentferink YE, van der Aa MP, van Mill E, et al. Long-term metformin treatment in adolescents with obesity and insulin resistance, results of an open label extension study. *Nutrition and diabetes*. 2018;8(1) (no pagination)doi: 10.1038/s41387-018-0057-6. PMID: CN-01644417. Exclusion Code: X2.
273. Levitt Katz LE, Bacha F, Gidding SS, et al. Lipid Profiles, Inflammatory Markers, and Insulin Therapy in Youth with Type 2 Diabetes. *Journal of pediatrics*. 2018;196:208-16.e2. doi: 10.1016/j.jpeds.2017.12.052. PMID: CN-01708409. Exclusion Code: X5.
274. Li FF, Jiang LL, Yan RN, et al. Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial. *Medicine (Baltimore)*. 2016 Oct;95(43):e5229. doi: 10.1097/md.0000000000005229. PMID: 27787387. Exclusion Code: X2.
275. Li G, Han L, Wang Y, et al. Evaluation of ADA HbA1c criteria in the diagnosis of pre-diabetes and diabetes in a population of Chinese adolescents and young adults at high risk for diabetes: a cross-sectional study. *BMJ Open*. 2018 Aug 8;8(8):e020665. doi: 10.1136/bmjopen-2017-020665. PMID: 30093511. Exclusion Code: X8.
276. Li J, Bergmann A, Reimann M, et al. A more simplified Finnish diabetes risk score for opportunistic screening of undiagnosed type 2 diabetes in a German population with a family history of the metabolic syndrome. *Horm Metab Res*. 2009 Feb;41(2):98-103. doi: 10.1055/s-0028-1087191. PMID: 18975253. Exclusion Code: X6.
277. Li R, Wang G. To evaluate the efficacy of GLP-1 analogues on the blood sugar levels, insulin resistance, islet  $\beta$ -cell function and pre-diabetes of the children. *Biomedical research (india)*. 2017;28(10):4460-5. PMID: CN-01769274. Exclusion Code: X6.
278. Li W, Li M, Kong D. Clinical efficacy of metformin combined with lifestyle intervention for treatment of childhood obesity with hyperinsulinemia. *International journal of clinical and experimental medicine*. 2019;12(6):7644-50. PMID: CN-01980780. Exclusion Code: X6.
279. Li X, Bao C, Zhao Y, et al. Statistical analysis on threshold of haemoglobin A1C (HbA1c) for diabetes diagnosis and the relationship between HbA1c and plasma glucose concentrations in Chinese diabetic high-risk groups. *Clin Lab*. 2019 Mar 1;65(3)doi: 10.7754/Clin.Lab.2018.180711. PMID: 30868839. Exclusion Code: X2.
280. Li X, Ting TH, Sheng H, et al. Genetic and clinical characteristics of Chinese children with Glucokinase-maturity-onset diabetes of the young (GCK-MODY). *BMC Pediatr*. 2018 Mar 6;18(1):101. doi: 10.1186/s12887-018-

## Appendix C. Excluded Articles

- 1060-8. PMID: 29510678. Exclusion Code: X6.
281. Li Y, Feng D, Esangbedo IC, et al. Insulin resistance, beta-cell function, adipokine profiles and cardiometabolic risk factors among Chinese youth with isolated impaired fasting glucose versus impaired glucose tolerance: the BCAMS study. *BMJ Open Diabetes Res Care*. 2020 Feb;8(1)doi: 10.1136/bmjdr-2019-000724. PMID: 32049638. Exclusion Code: X8.
282. Liang J, Fu J, Jiang Y, et al. TriGlycerides and high-density lipoprotein cholesterol ratio compared with homeostasis model assessment insulin resistance indexes in screening for metabolic syndrome in the chinese obese children: a cross section study. *BMC Pediatr*. 2015 Sep 28;15:138. doi: 10.1186/s12887-015-0456-y. PMID: 26416207. Exclusion Code: X8.
283. Liao ZH, Chen YL, Li FP, et al. Multicenter clinical study on the efficacy and safety of inhalable insulin aerosol in the treatment of type 2 diabetes. *Chinese medical journal*. 2008;121(13):1159-64. PMID: CN-00650556. Exclusion Code: X2.
284. Liese AD, Bortsov A, Günther AL, et al. Association of DASH diet with cardiovascular risk factors in youth with diabetes mellitus: the SEARCH for Diabetes in Youth study. *Circulation*. 2011 Apr 5;123(13):1410-7. doi: 10.1161/circulationaha.110.955922. PMID: 21422385. Exclusion Code: X4.
285. Lindquist CH, Gower BA, Goran MI. Role of dietary factors in ethnic differences in early risk of cardiovascular disease and type 2 diabetes. *Am J Clin Nutr*. 2000 Mar;71(3):725-32. doi: 10.1093/ajcn/71.3.725. PMID: 10702165. Exclusion Code: X8.
286. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. *Diabetes Care*. 2009 Apr;32(4):650-7. doi: 10.2337/dc08-1863. PMID: 19114612. Exclusion Code: X2.
287. Lochrie AS, Wysocki T, Buckloh LM, et al. Effects of a family based intervention study for overweight children: 6 month medical outcome data. *Diabetes*. 2010PMID: CN-01009176. Exclusion Code: X2.
288. LoRe D, Leung CY, Brenner L, et al. Parent-directed intervention in promoting knowledge of pediatric nutrition and healthy lifestyle among low-SES families with toddlers: a randomized controlled trial. *Child*. 2019;45(4):518-22. doi: 10.1111/cch.12682. PMID: CN-02116872. Exclusion Code: X6.
289. Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. *J Pediatr*. 2008 Jun;152(6):817-22. doi: 10.1016/j.jpeds.2008.01.018. PMID: 18492523. Exclusion Code: X2.
290. Low JC, Felner EI, Muir AB, et al. Do obese children with diabetic ketoacidosis have type 1 or type 2 diabetes? *Prim Care Diabetes*. 2012 Apr;6(1):61-5. doi: 10.1016/j.pcd.2011.11.001. PMID: 22230097. Exclusion Code: X5.
291. Lown EA, Lui CK, Karriker-Jaffe K, et al. Adverse childhood events and risk of diabetes onset in the 1979 National longitudinal survey of youth cohort. *BMC Public Health*. 2019 Jul 27;19(1):1007. doi: 10.1186/s12889-019-7337-5. PMID: 31351463. Exclusion Code: X8.
292. Lukashevich V, Del Prato S, Araga M, et al. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. *Diabetes Obes Metab*. 2014 May;16(5):403-9. doi: 10.1111/dom.12229. PMID: 24199686. Exclusion Code: X2.
293. Luu KT, Morgan ES, Bhanot S, et al. Population pharmacokinetics and pharmacodynamics of IONIS-GCGRRx, an antisense oligonucleotide for type 2 diabetes mellitus: a red blood cell

## Appendix C. Excluded Articles

- lifespan model. *Journal of pharmacokinetics and pharmacodynamics*. 2017;44(3):179-91. doi: 10.1007/s10928-017-9505-5. PMID: CN-01454871. Exclusion Code: X2.
294. Maclean JR, Chapman RH, Ferrufino CP, et al. Drug titration patterns and HbA 1c levels in type 2 diabetes. *Int J Clin Pract*. 2009 Jul;63(7):1008-16. doi: 10.1111/j.1742-1241.2009.02094.x. PMID: 19570118. Exclusion Code: X2.
295. Mader JK, Jensen L, Ingwersen SH, et al. Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus. *Clin Pharmacokinet*. 2016 Nov;55(11):1457-63. doi: 10.1007/s40262-016-0413-4. PMID: 27282158. Exclusion Code: X2.
296. Magkos F, Nikonova E, Fain R, et al. Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus. *Obesity (Silver Spring, Md.)*. 2017;25(5):842-9. doi: 10.1002/oby.21798. PMID: CN-01426236. Exclusion Code: X2.
297. Maki KC, Rains TM, Dicklin MR, et al. Repeatability of indices of insulin sensitivity and secretion from standard liquid meal tests in subjects with type 2 diabetes mellitus or normal or impaired fasting glucose. *Diabetes technology & therapeutics*. 2010;12(11):895-900. doi: 10.1089/dia.2010.0083. PMID: CN-00772753. Exclusion Code: X2.
298. Maldonado-Hernández J, Martínez-Basila A, Salas-Fernández A, et al. The 13C-glucose breath test for insulin resistance assessment in adolescents: comparison with fasting and post-glucose stimulus surrogate markers of insulin resistance. *J Clin Res Pediatr Endocrinol*. 2016 Dec 1;8(4):419-24. doi: 10.4274/jcrpe.3260. PMID: 27354200. Exclusion Code: X8.
299. Maleki F, Hosseini Nodeh Z, Rahnavard Z, et al. Effectiveness of training on preventative nutritional behaviors for type-2 diabetes among the female adolescents: Examination of theory of planned behavior. *Med J Islam Repub Iran*. 2016;30:349. PMID: 27390718. Exclusion Code: X2.
300. Malloy J, Capparelli E, Gottschalk M, et al. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. *Clin Ther*. 2009 Apr;31(4):806-15. doi: 10.1016/j.clinthera.2009.04.005. PMID: 19446153. Exclusion Code: X2.
301. Mancioffi V, Solito A, Ricotti R, et al. Good-day: efficacy of gamification of an educational training to mediterranean diet on weight and metabolic control in paediatric obesity. preliminary data at 6 months. *High blood pressure & cardiovascular prevention*. 2019;26(2):171-2. doi: 10.1007/s40292-019-00308-6. PMID: CN-01976011. Exclusion Code: X6.
302. Manco M, Grugni G, Di Pietro M, et al. Triglycerides-to-HDL cholesterol ratio as screening tool for impaired glucose tolerance in obese children and adolescents. *Acta Diabetol*. 2016 Jun;53(3):493-8. doi: 10.1007/s00592-015-0824-y. PMID: 26687197. Exclusion Code: X8.
303. Manios Y, Mavrogianni C, Lambrinou CP, et al. Two-stage, school and community-based population screening successfully identifies individuals and families at high-risk for type 2 diabetes: the Feel4Diabetes-study. *BMC Endocr Disord*. 2020 Mar 12;20(Suppl 1):12. doi: 10.1186/s12902-019-0478-9. PMID: 32164646. Exclusion Code: X8.
304. Manning RM, Jung RT, Leese GP, et al. The comparison of four weight reduction strategies aimed at overweight diabetic patients. *Diabet Med*. 1995 May;12(5):409-15. doi: 10.1111/j.1464-5491.1995.tb00504.x. PMID: 7648803. Exclusion Code: X2.
305. Mansour AA, Wanoose HL, Hani I, et al. Diabetes screening in Basrah, Iraq: a population-based cross-sectional study. *Diabetes Res Clin Pract*. 2008

## Appendix C. Excluded Articles

- Jan;79(1):147-50. doi: 10.1016/j.diabres.2007.07.016. PMID: 17767973. Exclusion Code: X2.
306. Marcus MD, Wilfley DE, El Ghormli L, et al. Weight change in the management of youth-onset type 2 diabetes: the TODAY clinical trial experience. *Pediatr Obes.* 2017 Aug;12(4):337-45. doi: 10.1111/ijpo.12148. PMID: 27161901. Exclusion Code: X6.
307. Marley JV, Oh MS, Hadgraft NT, et al. Using glycated haemoglobin testing to simplify diabetes screening in remote Aboriginal Australian health care settings. *Med J Aust.* 2015 Jul 6;203(1):28-32. doi: 10.5694/mja14.01575. PMID: 26126564. Exclusion Code: X8.
308. Matsuura N, Amemiya S, Sugihara S, et al. Metformin monotherapy in children and adolescents with type 2 diabetes mellitus in Japan. *Diabetol Int.* 2019 Jan;10(1):51-7. doi: 10.1007/s13340-018-0361-3. PMID: 30800563. Exclusion Code: X5.
309. Matthews DR, Wallace TM. Children with type 2 diabetes: the risks of complications. *Horm Res.* 2002;57 Suppl 1:34-9. doi: 10.1159/000053310. PMID: 11979020. Exclusion Code: X8.
310. Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. *J Clin Endocrinol Metab.* 2008 Dec;93(12):4810-7. doi: 10.1210/jc.2008-1518. PMID: 18812476. Exclusion Code: X2.
311. Mauras N, DelGiorno C, Hossain J, et al. Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat. *J Pediatr Endocrinol Metab.* 2012;25(1-2):33-40. doi: 10.1515/jpem-2011-0450. PMID: 22570948. Exclusion Code: X2.
312. Mayengbam S, Virtanen H, Hittel DS, et al. Artificially sweetened vitamin drink consumption reduces insulin sensitivity and alters one-carbon, b-vitamin dependent metabolism in adolescents. *FASEB journal.* 2018;32(1) PMID: CN-01613734. Exclusion Code: X2.
313. Mayer-Davis EJ, Nichols M, Liese AD, et al. Dietary intake among youth with diabetes: the SEARCH for Diabetes in Youth Study. *J Am Diet Assoc.* 2006 May;106(5):689-97. doi: 10.1016/j.jada.2006.02.002. PMID: 16647326. Exclusion Code: X8.
314. McCormack SE, McCarthy MA, Harrington SG, et al. Effects of exercise and lifestyle modification on fitness, insulin resistance, skeletal muscle oxidative phosphorylation and intramyocellular lipid content in obese children and adolescents. *Pediatr Obes.* 2014 Aug;9(4):281-91. doi: 10.1111/j.2047-6310.2013.00180.x. PMID: 23801526. Exclusion Code: X2.
315. McGavock J, Dart A, Wicklow B. Lifestyle therapy for the treatment of youth with type 2 diabetes. *Curr Diab Rep.* 2015 Jan;15(1):568. doi: 10.1007/s11892-014-0568-z. PMID: 25398207. Exclusion Code: X8.
316. McGavock J, Hay J, Wittmeier K, et al. Physical activity intensity and type 2 diabetes risk in overweight youth: the power trial, a randomized, controlled trial. *Diabetes.* 2014;63:A317-. doi: 10.2337/db14-833-1316. PMID: CN-01009458. Exclusion Code: X6.
317. McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. *Diabetes Care.* 2013 Feb;36(2):237-44. doi: 10.2337/dc12-0706. PMID: 23033241. Exclusion Code: X2.
318. McLaughlin T, Schweitzer P, Carter S, et al. Persistence of improvement in insulin sensitivity following a dietary weight loss programme. *Diabetes Obes Metab.* 2008 Dec;10(12):1186-94. doi: 10.1111/j.1463-1326.2008.00877.x. PMID: 18476986. Exclusion Code: X2.

## Appendix C. Excluded Articles

319. Meulepas MA, Braspenning JC, de Grauw WJ, et al. Patient-oriented intervention in addition to centrally organised checkups improves diabetic patient outcome in primary care. *Quality & safety in health care*. 2008;17(5):324-8. doi: 10.1136/qshc.2006.021204. PMID: CN-00687097. Exclusion Code: X2.
320. Mijailović V, Micić D, Mijailović M. Effects of a one-year weight reduction program and physical activity on obesity and comorbid conditions. *Medicinski preglod*. 2004;57(1-2):55-9. doi: 10.2298/mpns0402055m. PMID: CN-00520769. Exclusion Code: X1.
321. Ming-Qiang Z, Yang-Li D, Ke H, et al. Maturity onset diabetes of the young (MODY) in Chinese children: genes and clinical phenotypes. *J Pediatr Endocrinol Metab*. 2019 Jul 26;32(7):759-65. doi: 10.1515/jpem-2018-0446. PMID: 31216263. Exclusion Code: X3.
322. Mollaoğlu M, Beyazit E. Influence of diabetic education on patient metabolic control. *Appl Nurs Res*. 2009 Aug;22(3):183-90. doi: 10.1016/j.apnr.2007.12.003. PMID: 19616166. Exclusion Code: X2.
323. Morrison JA, Glueck CJ, Daniels S, et al. Determinants of persistent obesity and hyperinsulinemia in a biracial cohort: a 15-year prospective study of schoolgirls. *J Pediatr*. 2010 Oct;157(4):559-65. doi: 10.1016/j.jpeds.2010.04.030. PMID: 20553845. Exclusion Code: X4.
324. Morrison KM, Xu L, Tarnopolsky M, et al. Screening for dysglycemia in overweight youth presenting for weight management. *Diabetes Care*. 2012 Apr;35(4):711-6. doi: 10.2337/dc11-1659. PMID: 22271926. Exclusion Code: X8.
325. Muzaffar H, Castelli DM, Scherer J, et al. The impact of web-based HOT (Healthy Outcomes for Teens) Project on risk for type 2 diabetes: a randomized controlled trial. *Diabetes Technol Ther*. 2014 Dec;16(12):846-52. doi: 10.1089/dia.2014.0073. PMID: 25127372. Exclusion Code: X6.
326. Na LX, Li Y, Pan HZ, et al. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. *Molecular nutrition & food research*. 2013;57(9):1569-77. doi: 10.1002/mnfr.201200131. PMID: CN-00987896. Exclusion Code: X2.
327. Naik H, Vakilynejad M, Wu J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. *Journal of clinical pharmacology*. 2012;52(7):1007-16. doi: 10.1177/0091270011409230. PMID: CN-00972576. Exclusion Code: X2.
328. Najafipour H, Sanjari M, Shokoohi M, et al. Epidemiology of diabetes mellitus, pre-diabetes, undiagnosed and uncontrolled diabetes and its predictors in general population aged 15 to 75 years: A community-based study (KERCADRS) in southeastern Iran. *J Diabetes*. 2015 Sep;7(5):613-21. doi: 10.1111/1753-0407.12195. PMID: 25042896. Exclusion Code: X2.
329. Naughton MJ, Yi-Frazier JP, Morgan TM, et al. Longitudinal associations between sex, diabetes self-care, and health-related quality of life among youth with type 1 or type 2 diabetes mellitus. *J Pediatr*. 2014 Jun;164(6):1376-83.e1. doi: 10.1016/j.jpeds.2014.01.027. PMID: 24582483. Exclusion Code: X2.
330. Naylor LH, Davis EA, Kalic RJ, et al. Exercise training improves vascular function in adolescents with type 2 diabetes. *Physiological reports*. 2016;4(4)doi: 10.14814/phy2.12713. PMID: CN-01179606. Exclusion Code: X6.
331. Nelson P, Poon T, Guan X, et al. The incretin mimetic exenatide as a monotherapy in patients with type 2

## Appendix C. Excluded Articles

- diabetes. *Diabetes Technol Ther.* 2007 Aug;9(4):317-26. doi: 10.1089/dia.2006.0024. PMID: 17705687. Exclusion Code: X2.
332. Newfield RS, Dewan AK, Jain S. Dyslipidemia in children with type 2 diabetes vs. obesity. *Pediatr Diabetes.* 2008 Apr;9(2):115-21. doi: 10.1111/j.1399-5448.2007.00345.x. PMID: 18221437. Exclusion Code: X8.
333. Newsome P, Francque S, Harrison S, et al. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. *Aliment Pharmacol Ther.* 2019 Jul;50(2):193-203. doi: 10.1111/apt.15316. PMID: 31246368. Exclusion Code: X2.
334. Ngaosuwan K, Osataphan S. Diabetes Mellitus Treated with Medical Nutritional Therapy and Self Blood Glucose Monitoring: a Randomized Controlled Trial. *Chotmaihet thangphaet [Journal of the Medical Association of Thailand]*. 2015;98 Suppl 10:S66-73. PMID: CN-01165933. Exclusion Code: X2.
335. Ning G, Wang W, Li L, et al. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus. *J Diabetes.* 2016 May;8(3):345-53. doi: 10.1111/1753-0407.12303. PMID: 25929739. Exclusion Code: X2.
336. Nip ASY, Reboussin BA, Dabelea D, et al. Disordered Eating Behaviors in Youth and Young Adults With Type 1 or Type 2 Diabetes Receiving Insulin Therapy: The SEARCH for Diabetes in Youth Study. *Diabetes Care.* 2019 May;42(5):859-66. doi: 10.2337/dc18-2420. PMID: 30862656. Exclusion Code: X8.
337. Noe A, Howard C, Thuren T, et al. Pharmacokinetic and pharmacodynamic characteristics of single-dose Canakinumab in patients with type 2 diabetes mellitus. *Clin Ther.* 2014 Nov 1;36(11):1625-37. doi: 10.1016/j.clinthera.2014.08.004. PMID: 25240532. Exclusion Code: X2.
338. Nsiah-Kumi PA, Lasley S, Whiting M, et al. Diabetes, pre-diabetes and insulin resistance screening in Native American children and youth. *Int J Obes (Lond).* 2013 Apr;37(4):540-5. doi: 10.1038/ijo.2012.199. PMID: 23229738. Exclusion Code: X8.
339. Numbenjapon N, Nakavachara P, Santiprabhob J, et al. Successful strategy to improve glucose tolerance in Thai obese youth. *J Med Assoc Thai.* 2010 Nov;93 Suppl 6:S131-8. PMID: 21280526. Exclusion Code: X5.
340. Nupponen M, Pahkala K, Juonala M, et al. Metabolic syndrome from adolescence to early adulthood: effect of infancy-onset dietary counseling of low saturated fat: the Special Turku Coronary Risk Factor Intervention Project (STRIP). *Circulation.* 2015 Feb 17;131(7):605-13. doi: 10.1161/circulationaha.114.010532. PMID: 25605660. Exclusion Code: X2.
341. Odnoletkova I, Goderis G, Nobels F, et al. Optimizing diabetes control in people with Type 2 diabetes through nurse-led telecoaching. *Diabet Med.* 2016 Jun;33(6):777-85. doi: 10.1111/dme.13092. PMID: 26872105. Exclusion Code: X2.
342. Olson BP, Matter NI, Ediger MN, et al. Noninvasive skin fluorescence spectroscopy is comparable to hemoglobin A1c and fasting plasma glucose for detection of abnormal glucose tolerance. *J Diabetes Sci Technol.* 2013 Jul 1;7(4):990-1000. doi: 10.1177/193229681300700422. PMID: 23911181. Exclusion Code: X2.
343. O'Malley G, Santoro N, Northrup V, et al. High normal fasting glucose level in obese youth: a marker for insulin resistance and beta cell dysregulation. *Diabetologia.* 2010 Jun;53(6):1199-209. doi: 10.1007/s00125-010-1693-0. PMID: 20204321. Exclusion Code: X8.
344. Osman A, Osman NR, Fouad DA, et al. Vitamin D deficiency in obese children and adolescents and relation to glucose

## Appendix C. Excluded Articles

- homeostasis. *QJM : monthly journal of the Association of Physicians*. 2018;111:i59-. doi: 10.1093/qjmed/hcy200. PMID: CN-02094737. Exclusion Code: X8.
345. Pan C, Xing X, Han P, et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. *Diabetes Obes Metab*. 2012 Aug;14(8):737-44. doi: 10.1111/j.1463-1326.2012.01593.x. PMID: 22369287. Exclusion Code: X2.
346. Paprott R, Scheidt-Nave C, Heidemann C. Determinants of Change in Glycemic Status in Individuals with Prediabetes: Results from a Nationwide Cohort Study in Germany. *J Diabetes Res*. 2018;2018:5703652. doi: 10.1155/2018/5703652. PMID: 30406150. Exclusion Code: X8.
347. Park CY, Kang JG, Chon S, et al. Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes. *PLoS One*. 2014;9(3):e87799. doi: 10.1371/journal.pone.0087799. PMID: 24614911. Exclusion Code: X2.
348. Park SH, Jung MH, Cho WK, et al. Incretin secretion in obese Korean children and adolescents with newly diagnosed type 2 diabetes. *Clin Endocrinol (Oxf)*. 2016 Jan;84(1):72-9. doi: 10.1111/cen.12802. PMID: 25903996. Exclusion Code: X6.
349. Parkinson J, Tang W, Johansson CC, et al. Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus. *Diabetes, obesity & metabolism*. 2016;18(7):685-92. doi: 10.1111/dom.12647. PMID: CN-01425024. Exclusion Code: X6.
350. Pastor-Villaescusa B, Canete MD, Caballero-Villarraso J, et al. Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial. *Pediatrics*. 2017 Jul;140(1)doi: 10.1542/peds.2016-4285. PMID: 28759403. Exclusion Code: X2.
351. Patrick K, Norman GJ, Davila EP, et al. Outcomes of a 12-month technology-based intervention to promote weight loss in adolescents at risk for type 2 diabetes. *J Diabetes Sci Technol*. 2013 May 1;7(3):759-70. doi: 10.1177/193229681300700322. PMID: 23759410. Exclusion Code: X2.
352. Pearson S, Brøløs EJ, Herner EB, et al. Screening Copenhagen school children at risk of type 2 diabetes mellitus using random capillary blood glucose. *Acta Paediatr*. 2007 Jun;96(6):885-9. doi: 10.1111/j.1651-2227.2007.00305.x. PMID: 17537018. Exclusion Code: X6.
353. Peimani M, Rambod C, Omidvar M, et al. Effectiveness of short message service-based intervention (SMS) on self-care in type 2 diabetes: A feasibility study. *Prim Care Diabetes*. 2016 Aug;10(4):251-8. doi: 10.1016/j.pcd.2015.11.001. PMID: 26653014. Exclusion Code: X2.
354. Pena A, Olson ML, Soltero EG, et al. Evaluating a pragmatic estimate of insulin sensitivity in Latino youth with obesity. *Clinical obesity*. 2020;10(2)doi: 10.1111/cob.12353. PMID: CN-02100501. Exclusion Code: X6.
355. Peplies J, Börnhorst C, Günther K, et al. Longitudinal associations of lifestyle factors and weight status with insulin resistance (HOMA-IR) in preadolescent children: the large prospective cohort study IDEFICS. *Int J Behav Nutr Phys Act*. 2016 Sep 2;13(1):97. doi: 10.1186/s12966-016-0424-4. PMID: 27590045. Exclusion Code: X4.
356. Petri KC, Jacobsen LV, Klein DJ. Comparable liraglutide pharmacokinetics in pediatric and adult populations with type 2 diabetes: a population pharmacokinetic analysis. *Clin Pharmacokinet*. 2015 Jun;54(6):663-70. doi: 10.1007/s40262-014-0229-z. PMID: 25603819. Exclusion Code: X8.
357. Petrykiv SI, Laverman GD, de Zeeuw D, et al. The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.

## Appendix C. Excluded Articles

- Diabetes, obesity & metabolism.* 2017;19(10):1363-70. doi: 10.1111/dom.12936. PMID: CN-01423531. Exclusion Code: X2.
358. Phatale P, Phatale H. Prevalence of pre-diabetes, diabetes, pre-hypertension, and hypertension in children weighing more than normal. *Indian J Endocrinol Metab.* 2012 Dec;16(Suppl 2):S483-5. doi: 10.4103/2230-8210.104139. PMID: 23565474. Exclusion Code: X5.
359. Pildes RS. Adult-onset diabetes mellitus in childhood. *Metabolism.* 1973 Feb;22(2):307-15. doi: 10.1016/0026-0495(73)90178-9. PMID: 4687954. Exclusion Code: X5.
360. Pi-Sunyer X, Shanahan W, Fain R, et al. Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders. *Postgrad Med.* 2016 Aug;128(6):591-7. doi: 10.1080/00325481.2016.1208618. PMID: 27389084. Exclusion Code: X2.
361. Plavsic L, Knezevic OM, Sovtic A, et al. Effects of high-intensity interval training and nutrition advice on cardiometabolic markers and aerobic fitness in adolescent girls with obesity. *Appl Physiol Nutr Metab.* 2020 Mar;45(3):294-300. doi: 10.1139/apnm-2019-0137. PMID: 31386826. Exclusion Code: X2.
362. Pollock N, Gower B, Wenger K, et al. Effects of aerobic exercise on carboxylated and undercarboxylated forms of osteocalcin and their relationship to exercise-induced changes in insulin sensitivity and visceral and total body fat in overweight children. *Journal of bone and mineral research.* 2012;27PMID: CN-01025454. Exclusion Code: X6.
363. Pozzan R, Brandão AA, da Silva SL, et al. Hyperglycemia, hyperinsulinemia, overweight, and high blood pressure in young adults: the Rio de Janeiro Study. *Hypertension.* 1997 Sep;30(3 Pt 2):650-3. doi: 10.1161/01.hyp.30.3.650. PMID: 9322998. Exclusion Code: X2.
364. Proietto J, Malloy J, Zhuang D, et al. Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial. *Diabetologia.* 2018 Sep;61(9):1918-22. doi: 10.1007/s00125-018-4677-0. PMID: 29992370. Exclusion Code: X2.
365. Pulgarón ER, Hernandez J, Dehaan H, et al. Clinic attendance and health outcomes of youth with type 2 diabetes mellitus. *Int J Adolesc Med Health.* 2015 Aug;27(3):271-4. doi: 10.1515/ijamh-2014-0021. PMID: 25153557. Exclusion Code: X8.
366. Quilliam BJ, Ozbay AB, Sill BE, et al. The association between adherence to oral anti-diabetic drugs and hypoglycaemia in persons with Type 2 diabetes. *Diabet Med.* 2013 Nov;30(11):1305-13. doi: 10.1111/dme.12217. PMID: 23586474. Exclusion Code: X2.
367. Raben A, Fogelholm M, Larsen TM, et al. PREVIEW: prevention of diabetes through lifestyle intervention and population studies in Europe and a round the world. Over 2,000 volunteers randomized to the 3-y RCT. *Obesity facts.* 2015;8:126. doi: 10.1159/000382140. PMID: CN-01100834. Exclusion Code: X5.
368. Raile K, Schober E, Konrad K, et al. Treatment of young patients with HNF1A mutations (HNF1A-MODY). *Diabet Med.* 2015 Apr;32(4):526-30. doi: 10.1111/dme.12662. PMID: 25483937. Exclusion Code: X8.
369. Ramadas A, Quek KF, Chan CK, et al. Randomised-controlled trial of a web-based dietary intervention for patients with type 2 diabetes mellitus: study protocol of myDIDeA. *BMC Public Health.* 2011 May 21;11:359. doi: 10.1186/1471-2458-11-359. PMID: 21599990. Exclusion Code: X6.
370. Raman A, Ritchie LD, Lustig RH, et al. Insulin resistance is improved in overweight African American boys but not in girls following a one-year multidisciplinary community



## Appendix C. Excluded Articles

- intervention program. *J Pediatr Endocrinol Metab.* 2010 Jan-Feb;23(1-2):109-20. doi: 10.1515/jpem.2010.23.1-2.109. PMID: 20432814. Exclusion Code: X2.
371. Ramjan KA, Broderick CR, Briody JN, et al. The effect of whole body vibration training on insulin sensitivity in overweight adolescents: a randomized controlled trial. *Endocrine reviews.* 2011;32(3) PMID: CN-01005815. Exclusion Code: X5.
372. Ranasinghe P, Galappaththy P, Constantine GR, et al. Cinnamomum zeylanicum (Ceylon cinnamon) as a potential pharmaceutical agent for type-2 diabetes mellitus: study protocol for a randomized controlled trial. *Trials.* 2017 Sep 29;18(1):446. doi: 10.1186/s13063-017-2192-0. PMID: 28962661. Exclusion Code: X2.
373. Rasli MH, Zacharin MR. Foot problems and effectiveness of foot care education in children and adolescents with diabetes mellitus. *Pediatr Diabetes.* 2008 Dec;9(6):602-8. doi: 10.1111/j.1399-5448.2008.00432.x. PMID: 18647245. Exclusion Code: X5.
374. Rautio N, Jokelainen J, Oksa H, et al. Family history of diabetes and effectiveness of lifestyle counselling on the cardio-metabolic risk profile in individuals at high risk of Type 2 diabetes: 1-year follow-up of the FIN-D2D project. *Diabet Med.* 2012 Feb;29(2):207-11. doi: 10.1111/j.1464-5491.2011.03388.x. PMID: 21781153. Exclusion Code: X2.
375. Rave K, Roggen K, Dellweg S, et al. Improvement of insulin resistance after diet with a whole-grain based dietary product: results of a randomized, controlled cross-over study in obese subjects with elevated fasting blood glucose. *British journal of nutrition.* 2007;98(5):929-36. doi: 10.1017/S0007114507749267. PMID: CN-00700397. Exclusion Code: X2.
376. Raz I, Fonseca V, Kipnes M, et al. Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1). *Diabetes care.* 2012;35(3):485-7. doi: 10.2337/dc11-1942. PMID: CN-00842751. Exclusion Code: X2.
377. Reinehr T, Andler W, Kapellen T, et al. Clinical characteristics of type 2 diabetes mellitus in overweight European caucasian adolescents. *Exp Clin Endocrinol Diabetes.* 2005 Mar;113(3):167-70. doi: 10.1055/s-2005-837522. PMID: 15789276. Exclusion Code: X5.
378. Reinehr T, Elfers C, Lass N, et al. Irisin and its relation to insulin resistance and puberty in obese children: a longitudinal analysis. *J Clin Endocrinol Metab.* 2015 May;100(5):2123-30. doi: 10.1210/jc.2015-1208. PMID: 25781361. Exclusion Code: X8.
379. Reinehr T, Kleber M, Toschke AM. Lifestyle intervention in obese children is associated with a decrease of the metabolic syndrome prevalence. *Atherosclerosis.* 2009 Nov;207(1):174-80. doi: 10.1016/j.atherosclerosis.2009.03.041. PMID: 19442975. Exclusion Code: X2.
380. Reinehr T, Schober E, Roth CL, et al. Type 2 diabetes in children and adolescents in a 2-year follow-up: insufficient adherence to diabetes centers. *Horm Res.* 2008;69(2):107-13. doi: 10.1159/000111814. PMID: 18059091. Exclusion Code: X5.
381. Rhee EJ, Lee WY, Min KW, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. *Diabetes Obes Metab.* 2013 Jun;15(6):523-30. doi: 10.1111/dom.12060. PMID: 23320436. Exclusion Code: X2.
382. Rissanen A, Howard CP, Botha J, et al. Effect of anti-IL-1 $\beta$  antibody (canakinumab) on insulin secretion rates

## Appendix C. Excluded Articles

- in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. *Diabetes Obes Metab*. 2012 Dec;14(12):1088-96. doi: 10.1111/j.1463-1326.2012.01637.x. PMID: 22726220. Exclusion Code: X2.
383. Ritchie LD, Sharma S, Ikeda JP, et al. Taking Action Together: a YMCA-based protocol to prevent type-2 diabetes in high-BMI inner-city African American children. *Trials*. 2010 May 21;11:60. doi: 10.1186/1745-6215-11-60. PMID: 20492667. Exclusion Code: X6.
384. Roberge JB, Van Hulst A, Barnett TA, et al. Lifestyle habits, dietary factors, and the metabolically unhealthy obese phenotype in youth. *J Pediatr*. 2019 Jan;204:46-52.e1. doi: 10.1016/j.jpeds.2018.08.063. PMID: 30366774. Exclusion Code: X2.
385. Rocchini AP, Katch V, Schork A, et al. Insulin and blood pressure during weight loss in obese adolescents. *Hypertension (dallas, tex. : 1979)*. 1987;10(3):267-73. doi: 10.1161/01.hyp.10.3.267. PMID: CN-00049641. Exclusion Code: X2.
386. Roginsky MS, Barnett J. Double-blind study of phenethylguanide in weight control of obese nondiabetic subjects. *Am J Clin Nutr*. 1966 Oct;19(4):223-6. doi: 10.1093/ajcn/19.4.223. PMID: 5331741. Exclusion Code: X2.
387. Rosenbaum M, Fennoy I, Accacha S, et al. Racial/ethnic differences in clinical and biochemical type 2 diabetes mellitus risk factors in children. *Obesity (Silver Spring)*. 2013 Oct;21(10):2081-90. doi: 10.1002/oby.20483. PMID: 23596082. Exclusion Code: X4.
388. Rosenbaum M, Nonas C, Weil R, et al. School-based intervention acutely improves insulin sensitivity and decreases inflammatory markers and body fatness in junior high school students. *J Clin Endocrinol Metab*. 2007 Feb;92(2):504-8. doi: 10.1210/jc.2006-1516. PMID: 17090635. Exclusion Code: X7.
389. Rosenbloom AL, Bianchi R, Chin FT. Chemical diabetes mellitus in siblings of children with overt diabetes. *Isr J Med Sci*. 1972 Jun;8(6):841-2. PMID: 4559426. Exclusion Code: X6.
390. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. *Diabetes Care*. 2012 Jun;35(6):1232-8. doi: 10.2337/dc11-1926. PMID: 22492586. Exclusion Code: X2.
391. Rosenstock J, Banarer S, Fonseca VA, et al. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. *Diabetes Care*. 2010 Jul;33(7):1516-22. doi: 10.2337/dc09-2315. PMID: 20413513. Exclusion Code: X2.
392. Rosenstock J, Bergenstal R, Defronzo RA, et al. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. *Diabetes Care*. 2008 Nov;31(11):2177-82. doi: 10.2337/dc08-0315. PMID: 18678610. Exclusion Code: X2.
393. Rosenstock J, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. *Diabetes Obes Metab*. 2009 Dec;11(12):1145-52. doi: 10.1111/j.1463-1326.2009.01124.x. PMID: 19758359. Exclusion Code: X2.
394. Rothman RL, Malone R, Bryant B, et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. *American journal of medicine*. 2005;118(3):276-84. doi: 10.1016/j.amjmed.2004.09.017. PMID: CN-00502496. Exclusion Code: X2.

## Appendix C. Excluded Articles

395. Sahakitrungruang T, Klomchan T, Supornsilchai V, et al. Obesity, metabolic syndrome, and insulin dynamics in children after craniopharyngioma surgery. *Eur J Pediatr*. 2011 Jun;170(6):763-9. doi: 10.1007/s00431-010-1347-8. PMID: 21107605. Exclusion Code: X2.
396. Sahin NM, Kinik ST, Tekindal MA. OGTT results in obese adolescents with normal HOMA-IR values. *J Pediatr Endocrinol Metab*. 2013;26(3-4):285-91. doi: 10.1515/jpem-2012-0206. PMID: 23327814. Exclusion Code: X2.
397. Saletsky RD, Trief PM, Anderson BJ, et al. Parenting style, parent-youth conflict, and medication adherence in youth with type 2 diabetes participating in an intensive lifestyle change intervention. *Fam Syst Health*. 2014 Jun;32(2):176-85. doi: 10.1037/fsh0000008. PMID: 24548045. Exclusion Code: X6.
398. Saponaro F, Sonaglioni A, Rossi A, et al. Improved diastolic function in type 2 diabetes after a six month liraglutide treatment. *Diabetes Res Clin Pract*. 2016 Aug;118:21-8. doi: 10.1016/j.diabres.2016.04.046. PMID: 27485853. Exclusion Code: X2.
399. Sauder KA, Dabelea D, Bailey-Callahan R, et al. Targeting risk factors for type 2 diabetes in American Indian youth: the Tribal Turning Point pilot study. *Pediatr Obes*. 2018 May;13(5):321-9. doi: 10.1111/ijpo.12223. PMID: 28635082. Exclusion Code: X6.
400. Saunders TJ, Chaput JP, Goldfield GS, et al. Prolonged sitting and markers of cardiometabolic disease risk in children and youth: a randomized crossover study. *Metabolism: clinical and experimental*. 2013;62(10):1423-8. doi: 10.1016/j.metabol.2013.05.010. PMID: CN-00963424. Exclusion Code: X2.
401. Savoye M, Caprio S, Dziura J, et al. A community-based intervention for diabetes risk reduction in innercity obese adolescents. *Diabetologia*. 2013;56:S342-. doi: 10.1007/s00125-013-3012-z. PMID: CN-01010694. Exclusion Code: X6.
402. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. *Lancet*. 2006 Nov 11;368(9548):1660-72. doi: 10.1016/s0140-6736(06)69571-8. PMID: 17098084. Exclusion Code: X2.
403. Schiel R, Voigt U, Ross IS, et al. Structured diabetes therapy and education improves the outcome of patients with insulin treated diabetes mellitus. The 10 year follow-up of a prospective, population-based survey on the quality of diabetes care (the JEVIN Trial). *Exp Clin Endocrinol Diabetes*. 2006 Jan;114(1):18-27. doi: 10.1055/s-2005-873079. PMID: 16450312. Exclusion Code: X2.
404. Schober E, Waldhoer T, Rami B, et al. Incidence and time trend of type 1 and type 2 diabetes in Austrian children 1999-2007. *J Pediatr*. 2009 Aug;155(2):190-3.e1. doi: 10.1016/j.jpeds.2009.03.010. PMID: 19476954. Exclusion Code: X5.
405. Schwertner R, Engelsberger I, Rabl W, et al. Prophylactic intermititary insulin therapy in pre-diabetic children and adolescents. *Monatsschrift fur kinderheilkunde*. 1994;142(Suppl 1):S 68. PMID: CN-00339593. Exclusion Code: X1.
406. Scott SE, Breckon JD, Copeland RJ. An integrated motivational interviewing and cognitive-behavioural intervention promoting physical activity maintenance for adults with chronic health conditions: a feasibility study. *Chronic illness*. 2019;15(4):276-92. doi: 10.1177/1742395318769370. PMID: CN-02117501. Exclusion Code: X2.
407. Seino Y, Min KW, Niemoeller E, et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). *Diabetes Obes Metab*. 2012 Oct;14(10):910-7. doi:

## Appendix C. Excluded Articles

- 10.1111/j.1463-1326.2012.01618.x.  
PMID: 22564709. Exclusion Code: X2.
408. Sénéchal M, Rempel M, Duhamel TA, et al. Fitness is a determinant of the metabolic response to endurance training in adolescents at risk of type 2 diabetes mellitus. *Obesity (Silver Spring)*. 2015 Apr;23(4):823-32. doi: 10.1002/oby.21032. PMID: 25755198. Exclusion Code: X8.
409. Setayeshgar S, Ekwaru JP, Maximova K, et al. Dietary intake and prospective changes in cardiometabolic risk factors in children and youth. *Appl Physiol Nutr Metab*. 2017 Jan;42(1):39-45. doi: 10.1139/apnm-2016-0215. PMID: 27959641. Exclusion Code: X4.
410. Shah AS, El Ghormli L, Vajravelu ME, et al. Heart Rate Variability and Cardiac Autonomic Dysfunction: prevalence, Risk Factors, and Relationship to Arterial Stiffness in the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. *Diabetes care*. 2019;42(11):2143-50. doi: 10.2337/dc19-0993. PMID: CN-01989622. Exclusion Code: X6.
411. Shah R, McKay SV, Levitt Katz LE, et al. Adherence to multiple medications in the TODAY (Treatment Options for type 2 Diabetes in Adolescents and Youth) cohort: effect of additional medications on adherence to primary diabetes medication. *J Pediatr Endocrinol Metab*. 2020 Feb 25;33(2):191-8. doi: 10.1515/jpem-2019-0315. PMID: 31809265. Exclusion Code: X6.
412. Shahbazian H, Aleali AM, Rashidi H, et al. Frequency of type I and II diabetes in newly diagnosed diabetic patients: Measuring C-Peptide level. *Diabetes Metab Syndr*. 2019 May-Jun;13(3):1833-5. doi: 10.1016/j.dsx.2019.04.018. PMID: 31235102. Exclusion Code: X2.
413. Shaibi GQ, Cruz ML, Ball GD, et al. Effects of resistance training on insulin sensitivity in overweight Latino adolescent males. *Medicine and science in sports and exercise*. 2006;38(7):1208-15. doi: 10.1249/01.mss.0000227304.88406.0f. PMID: CN-00571078. Exclusion Code: X2.
414. Shalitin S, Abrahami M, Lilos P, et al. Insulin resistance and impaired glucose tolerance in obese children and adolescents referred to a tertiary-care center in Israel. *Int J Obes (Lond)*. 2005 Jun;29(6):571-8. doi: 10.1038/sj.ijo.0802919. PMID: 15889115. Exclusion Code: X8.
415. Sharma S, Fleming SE. Use of HbA(1C) testing to diagnose pre-diabetes in high risk African American children: a comparison with fasting glucose and HOMA-IR. *Diabetes Metab Syndr*. 2012 Jul-Sep;6(3):157-62. doi: 10.1016/j.dsx.2012.09.004. PMID: 23158980. Exclusion Code: X2.
416. Shaw M, Savoye M, Cali A, et al. Effect of a successful intensive lifestyle program on insulin sensitivity and glucose tolerance in obese youth. *Diabetes Care*. 2009 Jan;32(1):45-7. doi: 10.2337/dc08-0808. PMID: 18840769. Exclusion Code: X6.
417. Shiner M. EFFECT OF A GLUTEN-FREE DIET IN 17 PATIENTS WITH IDIOPATHIC STEATORRHEA; A FOLLOW-UP STUDY. *Am J Dig Dis*. 1963 Dec;8:969-83. doi: 10.1007/bf02239489. PMID: 14084540. Exclusion Code: X8.
418. Shivaprasad HN, Bhanumathy M, Sushma G, et al. Salacia reticulata improves serum lipid profiles and glycemic control in patients with prediabetes and mild to moderate hyperlipidemia: a double-blind, placebo-controlled, randomized trial. *J Med Food*. 2013 Jun;16(6):564-8. doi: 10.1089/jmf.2013.2751. PMID: 23767865. Exclusion Code: X2.
419. Shoemaker A, Cheng P, Gal RL, et al. Predictors of Loss to Follow-Up among Children with Type 2 Diabetes. *Horm Res Paediatr*. 2017;87(6):377-84. doi: 10.1159/000475595. PMID: 28505610. Exclusion Code: X4.

## Appendix C. Excluded Articles

420. Shomaker LB, Kelly NR, Pickworth CK, et al. A randomized controlled trial to prevent depression and ameliorate insulin resistance in adolescent girls at risk for type 2 diabetes. *Ann Behav Med.* 2016 Oct;50(5):762-74. doi: 10.1007/s12160-016-9801-0. PMID: 27333897. Exclusion Code: X4.
421. Short KR, Teague AM, Klein JC, et al. The Effect of Handcycle Ergometer Exercise on Glucose Tolerance in Ambulatory and Non-Ambulatory Adolescents. *Pediatr Exerc Sci.* 2017 Feb;29(1):63-72. doi: 10.1123/pes.2016-0047. PMID: 27176627. Exclusion Code: X2.
422. Shultis WA, Leary SD, Ness AR, et al. Haemoglobin A1c is not a surrogate for glucose and insulin measures for investigating the early life and childhood determinants of insulin resistance and Type 2 diabetes in healthy children. An analysis from the Avon Longitudinal Study of Parents and Children (ALSPAC). *Diabet Med.* 2006 Dec;23(12):1357-63. doi: 10.1111/j.1464-5491.2006.01990.x. PMID: 17116188. Exclusion Code: X6.
423. Sigal RJ, Alberga AS, Goldfield GS, et al. Effects of aerobic exercise, resistance exercise or both on % body fat in overweight adolescents: the HEARTY trial. *Diabetes.* 2013;62:A185. doi: 10.2337/db13-680-858. PMID: CN-01062018. Exclusion Code: X5.
424. Silic A, Janez A, Tomazic J, et al. Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial. *Croat Med J.* 2007 Dec;48(6):791-9. doi: 10.3325/cmj.2007.6.791. PMID: 18074413. Exclusion Code: X2.
425. Simon D, Coignet MC, Thibult N, et al. Comparison of glycosylated hemoglobin and fasting plasma glucose with two-hour post-load plasma glucose in the detection of diabetes mellitus. *Am J Epidemiol.* 1985 Oct;122(4):589-93. doi: 10.1093/oxfordjournals.aje.a114138. PMID: 4025302. Exclusion Code: X2.
426. Skrivaneck Z, Gaydos BL, Chien JY, et al. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). *Diabetes Obes Metab.* 2014 Aug;16(8):748-56. doi: 10.1111/dom.12305. PMID: 24762094. Exclusion Code: X2.
427. Soltero EG, Konopken YP, Olson ML, et al. Preventing diabetes in obese Latino youth with prediabetes: a study protocol for a randomized controlled trial. *BMC Public Health.* 2017 Mar 16;17(1):261. doi: 10.1186/s12889-017-4174-2. PMID: 28302101. Exclusion Code: X6.
428. Soltero EG, Olson ML, Williams AN, et al. Effects of a community-based diabetes prevention program for Latino youth with obesity: a randomized controlled trial. *Obesity (Silver Spring).* 2018 Dec;26(12):1856-65. doi: 10.1002/oby.22300. PMID: 30426694. Exclusion Code: X2.
429. Songer TJ, Haymond MW, Glazner JE, et al. Healthcare and associated costs related to type 2 diabetes in youth and adolescence: the TODAY clinical trial experience. *Pediatr Diabetes.* 2019 Sep;20(6):702-11. doi: 10.1111/pedi.12869. PMID: 31119838. Exclusion Code: X8.
430. Sönksen PH, Lowy C, Perkins JR, et al. Non-insulin-dependent diabetes: 10-year outcome in relation to initial response to diet and subsequent sulfonylurea therapy. *Diabetes Care.* 1984 May-Jun;7 Suppl 1:59-66. PMID: 6376030. Exclusion Code: X2.
431. Sorkin DH, Mavandadi S, Rook KS, et al. Dyadic collaboration in shared health behavior change: the effects of a randomized trial to test a lifestyle intervention for high-risk Latinas. *Health psychology.* 2014;33(6):566-75.

## Appendix C. Excluded Articles

- doi: 10.1037/hea0000063. PMID: CN-00996445. Exclusion Code: X2.
432. Spruijt-Metz D, Belcher BR, Hsu YW, et al. Temporal relationship between insulin sensitivity and the pubertal decline in physical activity in peripubertal Hispanic and African American females. *Diabetes Care*. 2013 Nov;36(11):3739-45. doi: 10.2337/dc13-0083. PMID: 23846812. Exclusion Code: X5.
433. Srinivasan S, Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. *J Clin Endocrinol Metab*. 2006 Jun;91(6):2074-80. doi: 10.1210/jc.2006-0241. PMID: 16595599. Exclusion Code: X2.
434. Srinivasan SR, Frontini MG, Berenson GS. Longitudinal changes in risk variables of insulin resistance syndrome from childhood to young adulthood in offspring of parents with type 2 diabetes: the Bogalusa Heart Study. *Metabolism*. 2003 Apr;52(4):443-50; discussion 51-3. doi: 10.1053/meta.2003.50065. PMID: 12701056. Exclusion Code: X6.
435. Stagi S, Ricci F, Bianconi M, et al. Retrospective evaluation of metformin and/or metformin plus a new polysaccharide complex in treating severe hyperinsulinism and insulin resistance in obese children and adolescents with metabolic syndrome. *Nutrients*. 2017 May 20;9(5)doi: 10.3390/nu9050524. PMID: 28531113. Exclusion Code: X5.
436. Staiano AE, Abraham AA, Calvert SL. Adolescent exergame play for weight loss and psychosocial improvement: a controlled physical activity intervention. *Obesity (Silver Spring)*. 2013 Mar;21(3):598-601. doi: 10.1002/oby.20282. PMID: 23592669. Exclusion Code: X2.
437. Starkman HS, Soeldner JS, Gleason RE. Oral glucose tolerance: relationship with hemoglobin A1c. *Diabetes Res Clin Pract*. 1987 Nov-Dec;3(6):343-9. doi: 10.1016/s0168-8227(87)80059-1. PMID: 3311681. Exclusion Code: X4.
438. Stefanaki C, Michos A, Mastorakos G, et al. Probiotics in Adolescent Prediabetes: A Pilot RCT on Glycemic Control and Intestinal Bacteriome. *J Clin Med*. 2019 Oct 21;8(10)doi: 10.3390/jcm8101743. PMID: 31640224. Exclusion Code: X4.
439. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. *Diabetes Obes Metab*. 2013 Apr;15(4):372-82. doi: 10.1111/dom.12054. PMID: 23279307. Exclusion Code: X2.
440. Sunehag AL, Toffolo G, Campioni M, et al. Short-term high dietary fructose intake had no effects on insulin sensitivity and secretion or glucose and lipid metabolism in healthy, obese adolescents. *J Pediatr Endocrinol Metab*. 2008 Mar;21(3):225-35. doi: 10.1515/jpem.2008.21.3.225. PMID: 18540249. Exclusion Code: X5.
441. Sweeney NM, Stewart C, Gaines R, et al. Screening for overweight and diabetes in rural Hispanic and Caucasian fifth-grade children. *J Pediatr Nurs*. 2007 Dec;22(6):432-9. doi: 10.1016/j.pedn.2007.09.001. PMID: 18036463. Exclusion Code: X8.
442. Sylvetsky AC, Chandran A, Talegawkar SA, et al. Consumption of Beverages Containing Low-Calorie Sweeteners, Diet, and Cardiometabolic Health in Youth With Type 2 Diabetes. *J Acad Nutr Diet*. 2020 Aug;120(8):1348-58.e6. doi: 10.1016/j.jand.2020.04.005. PMID: 32711855. Exclusion Code: X6.
443. Sylvetsky AC, Nandagopal R, Nguyen TT, et al. Buddy Study: partners for better health in adolescents with type 2 diabetes. *World J Diabetes*. 2015 Dec 25;6(18):1355-62. doi: 10.4239/wjd.v6.i18.1355. PMID: 26722619. Exclusion Code: X4.

## Appendix C. Excluded Articles

444. Taha DR, Castells S, Umpaichitra V, et al. Beta-cell response to intravenous glucagon in African-American and Hispanic children with type 2 diabetes mellitus. *J Pediatr Endocrinol Metab.* 2002 Jan;15(1):59-67. doi: 10.1515/jpem.2002.15.1.59. PMID: 11822582. Exclusion Code: X6.
445. Tam CH, Wang Y, Luan J, et al. Non-linear relationship between birthweight and cardiometabolic risk factors in Chinese adolescents and adults. *Diabet Med.* 2015 Feb;32(2):220-5. doi: 10.1111/dme.12630. PMID: 25388749. Exclusion Code: X4.
446. Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. Liraglutide in children and adolescents with type 2 diabetes. *N Engl J Med.* 2019 Aug 15;381(7):637-46. doi: 10.1056/NEJMoa1903822. PMID: 31034184. Exclusion Code: X2.
447. Tamborlane WV, Laffel LM, Weill J, et al. Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes. *Pediatr Diabetes.* 2018 Jun;19(4):640-8. doi: 10.1111/pedi.12616. PMID: 29171139. Exclusion Code: X2.
448. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. *Diabetes Obes Metab.* 2011 Jan;13(1):65-74. doi: 10.1111/j.1463-1326.2010.01326.x. PMID: 21114605. Exclusion Code: X2.
449. Taylor JH, Xu Y, Li F, et al. Psychosocial predictors and moderators of weight management programme outcomes in ethnically diverse obese youth. *Pediatr Obes.* 2017 Dec;12(6):453-61. doi: 10.1111/ijpo.12165. PMID: 27384496. Exclusion Code: X5.
450. Terlemez S, Bozdemir E, Kalkan Uçar S, et al. Insulin resistance in children with familial hyperlipidemia. *J Pediatr Endocrinol Metab.* 2018 Dec 19;31(12):1349-54. doi: 10.1515/jpem-2018-0337. PMID: 30433876. Exclusion Code: X8.
451. Tester J, Sharma S, Jasik CB, et al. Gender differences in prediabetes and insulin resistance among 1356 obese children in Northern California. *Diabetes Metab Syndr.* 2013 Jul-Sep;7(3):161-5. doi: 10.1016/j.dsx.2013.06.002. PMID: 23953182. Exclusion Code: X8.
452. The NS, Richardson AS, Gordon-Larsen P. Timing and duration of obesity in relation to diabetes: findings from an ethnically diverse, nationally representative sample. *Diabetes Care.* 2013 Apr;36(4):865-72. doi: 10.2337/dc12-0536. PMID: 23223352. Exclusion Code: X4.
453. Tirucherai GS, LaCreta F, Ismat FA, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus. *Diabetes, obesity & metabolism.* 2016;18(7):678-84. doi: 10.1111/dom.12638. PMID: CN-01166739. Exclusion Code: X5.
454. Toiari M, Davì MV, Dalle Carbonare L, et al. Presentation, diagnostic features and glucose handling in a monocentric series of insulinomas. *J Endocrinol Invest.* 2013 Oct;36(9):753-8. doi: 10.3275/8942. PMID: 23608735. Exclusion Code: X2.
455. Toledo-Corral CM, Alderete TL, Richey J, et al. Fasting, post-OGTT challenge, and nocturnal free fatty acids in prediabetic versus normal glucose tolerant overweight and obese Latino adolescents. *Acta Diabetol.* 2015 Apr;52(2):277-84. doi: 10.1007/s00592-014-0634-7. PMID: 25109287. Exclusion Code: X6.
456. Tomlin A, Dovey S, Tilyard M. Health outcomes for diabetes patients returning for three annual general practice checks. *N Z Med J.* 2007 Apr 13;120(1252):U2493. PMID: 17460743. Exclusion Code: X4.
457. Torres-García R, Camarillo-Romero ES, Majluf-Cruz A, et al. Effect of exercise

## Appendix C. Excluded Articles

- on the serum concentrations of leptin and adiponectin in adolescents with risk factors of developing diabetes. *Revista medica del instituto mexicano del seguro social*. 2017;55(6):708-14. PMID: CN-01621763. Exclusion Code: X1.
458. Tricò D, Natali A, Arslanian S, et al. Identification, pathophysiology, and clinical implications of primary insulin hypersecretion in nondiabetic adults and adolescents. *JCI Insight*. 2018 Dec 20;3(24)doi: 10.1172/jci.insight.124912. PMID: 30568042. Exclusion Code: X2.
459. Turner KM, Percival J, Dunger DB, et al. Adolescents' views and experiences of treatments for Type 2 diabetes: a qualitative study. *Diabet Med*. 2015 Feb;32(2):250-6. doi: 10.1111/dme.12577. PMID: 25186101. Exclusion Code: X4.
460. Uçkun-Kitapçı A, Teziç T, Firat S, et al. Obesity and type 2 diabetes mellitus: a population-based study of adolescents. *J Pediatr Endocrinol Metab*. 2004 Dec;17(12):1633-40. doi: 10.1515/jpem.2004.17.12.1633. PMID: 15645697. Exclusion Code: X8.
461. Vajravelu ME, Lee JM, Shah R, et al. Association between prediabetes diagnosis and body mass index trajectory of overweight and obese adolescents. *Pediatr Diabetes*. 2020 Aug;21(5):743-6. doi: 10.1111/peidi.13028. PMID: 32314478. Exclusion Code: X8.
462. Van Buren DJ, Wilfley DE, Marcus MD, et al. Depressive symptoms and glycemic control in youth with type 2 diabetes participating in the TODAY clinical trial. *Diabetes Res Clin Pract*. 2018 Jan;135:85-7. doi: 10.1016/j.diabres.2017.11.008. PMID: 29146120. Exclusion Code: X5.
463. van den Burg EL, Schoonakker MP, van Peet PG, et al. Fasting in diabetes treatment (FIT) trial: study protocol for a randomised, controlled, assessor-blinded intervention trial on the effects of intermittent use of a fasting-mimicking diet in patients with type 2 diabetes. *BMC Endocr Disord*. 2020 Jun 24;20(1):94. doi: 10.1186/s12902-020-00576-7. PMID: 32580710. Exclusion Code: X2.
464. van der Aa MP, Elst MA, van de Garde EM, et al. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. *Nutr Diabetes*. 2016 Aug 29;6(8):e228. doi: 10.1038/nutd.2016.37. PMID: 27571249. Exclusion Code: X2.
465. van der Aa MP, Elst MA, van Mil EG, et al. METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents - study protocol of a randomized controlled study. *Trials*. 2014 Jun 5;15:207. doi: 10.1186/1745-6215-15-207. PMID: 24899137. Exclusion Code: X6.
466. van der Aa MP, Fazeli Farsani S, Kromwijk LA, et al. How to screen obese children at risk for type 2 diabetes mellitus? *Clin Pediatr (Phila)*. 2014 Apr;53(4):337-42. doi: 10.1177/0009922813509480. PMID: 24243989. Exclusion Code: X8.
467. Van Hulst A, Paradis G, Harnois-Leblanc S, et al. Lowering saturated fat and increasing vegetable and fruit intake may increase insulin sensitivity 2 years later in children with a family history of obesity. *J Nutr*. 2018 Nov 1;148(11):1838-44. doi: 10.1093/jn/nxy189. PMID: 30383280. Exclusion Code: X5.
468. Vangeepuram N, Townsend K, Arniella G, et al. Recruitment in clinical versus community-based sites for a pilot youth diabetes prevention program, East Harlem, New York, 2011-2012. *Prev Chronic Dis*. 2016 Jan 28;13:E14. doi: 10.5888/pcd13.150449. PMID: 26820046. Exclusion Code: X5.
469. Vellanki P, Smiley DD, Stefanovski D, et al. Randomized controlled study of metformin and sitagliptin on long-term normoglycemia remission in African American patients with hyperglycemic crises. *Diabetes Care*. 2016



## Appendix C. Excluded Articles

- Nov;39(11):1948-55. doi: 10.2337/dc16-0406. PMID: 27573938. Exclusion Code: X2.
470. Ventura E, Davis J, Byrd-Williams C, et al. Reduction in risk factors for type 2 diabetes mellitus in response to a low-sugar, high-fiber dietary intervention in overweight Latino adolescents. *Arch Pediatr Adolesc Med.* 2009 Apr;163(4):320-7. doi: 10.1001/archpediatrics.2009.11. PMID: 19349560. Exclusion Code: X2.
471. Viitasalo A, Schnurr TM, Pitkänen N, et al. Abdominal adiposity and cardiometabolic risk factors in children and adolescents: a Mendelian randomization analysis. *Am J Clin Nutr.* 2019 Nov 1;110(5):1079-87. doi: 10.1093/ajcn/nqz187. PMID: 31504107. Exclusion Code: X4.
472. Vijayadeva V, Nichols GA. Impact of implementing glycosylated hemoglobin testing for identification of dysglycemia in youth. *Perm J.* 2014 Fall;18(4):21-7. doi: 10.7812/tpp/14-029. PMID: 25141989. Exclusion Code: X8.
473. Vitale M, Masulli M, Rivellese AA, et al. Pasta Consumption and Connected Dietary Habits: Associations with Glucose Control, Adiposity Measures, and Cardiovascular Risk Factors in People with Type 2 Diabetes-TOSCA.IT Study. *Nutrients.* 2019 Dec 30;12(1)doi: 10.3390/nu12010101. PMID: 31905885. Exclusion Code: X2.
474. Vos RC, Wit JM, Pijl H, et al. The effect of family-based multidisciplinary cognitive behavioral treatment in children with obesity: study protocol for a randomized controlled trial. *Trials.* 2011 May 6;12:110. doi: 10.1186/1745-6215-12-110. PMID: 21548919. Exclusion Code: X6.
475. Wagner KA, Braun E, Armah SM, et al. Dietary Intervention for Glucose Tolerance In Teens (DIG IT): protocol of a randomized controlled trial using health coaching to prevent youth-onset type 2 diabetes. *Contemp Clin Trials.* 2017 Feb;53:171-7. doi: 10.1016/j.cct.2016.12.018. PMID: 28011388. Exclusion Code: X6.
476. Walders-Abramson N, Venditti EM, Ievers-Landis CE, et al. Relationships among stressful life events and physiological markers, treatment adherence, and psychosocial functioning among youth with type 2 diabetes. *J Pediatr.* 2014 Sep;165(3):504-8.e1. doi: 10.1016/j.jpeds.2014.05.020. PMID: 24948348. Exclusion Code: X6.
477. Wallace AS, Wang D, Shin JI, et al. Screening and Diagnosis of Prediabetes and Diabetes in US Children and Adolescents. *Pediatrics.* 2020 Sep;146(3)doi: 10.1542/peds.2020-0265. PMID: 32778539. Exclusion Code: X6.
478. Waller K, Kaprio J, Lehtovirta M, et al. Leisure-time physical activity and type 2 diabetes during a 28 year follow-up in twins. *Diabetologia.* 2010 Dec;53(12):2531-7. doi: 10.1007/s00125-010-1875-9. PMID: 20706830. Exclusion Code: X2.
479. Walsh JJ, D'Angiulli A, Cameron JD, et al. Changes in the Brain-Derived Neurotrophic Factor Are Associated with Improvements in Diabetes Risk Factors after Exercise Training in Adolescents with Obesity: The HEARTY Randomized Controlled Trial. *Neural Plast.* 2018;2018:7169583. doi: 10.1155/2018/7169583. PMID: 30363954. Exclusion Code: X5.
480. Wan Q, Wang F, Wang F, et al. Regression to normoglycaemia by fenofibrate in pre-diabetic subjects complicated with hypertriglyceridaemia: a prospective randomized controlled trial. *Diabet Med.* 2010 Nov;27(11):1312-7. doi: 10.1111/j.1464-5491.2010.03107.x. PMID: 20968112. Exclusion Code: X2.
481. Wang G, Radovick S, Xu X, et al. Strategy for early identification of prediabetes in lean populations: New insight from a prospective Chinese twin cohort of children and young adults. *Diabetes Res Clin Pract.* 2018 Dec;146:101-10. doi:

## Appendix C. Excluded Articles

- 10.1016/j.diabres.2018.10.003. PMID: 30312713. Exclusion Code: X8.
482. Wang J, Light K, Henderson M, et al. Consumption of added sugars from liquid but not solid sources predicts impaired glucose homeostasis and insulin resistance among youth at risk of obesity. *J Nutr*. 2014 Jan;144(1):81-6. doi: 10.3945/jn.113.182519. PMID: 24198307. Exclusion Code: X5.
483. Wang SY, Andrews CA, Herman WH, et al. Incidence and risk factors for developing diabetic retinopathy among youths with type 1 or type 2 diabetes throughout the United States. *Ophthalmology*. 2017 Apr;124(4):424-30. doi: 10.1016/j.ophtha.2016.10.031. PMID: 27914837. Exclusion Code: X8.
484. Wang X, Wang T, Yu M, et al. Screening of HNF1A and HNF4A mutation and clinical phenotype analysis in a large cohort of Chinese patients with maturity-onset diabetes of the young. *Acta Diabetol*. 2019 Mar;56(3):281-8. doi: 10.1007/s00592-018-1232-x. PMID: 30293189. Exclusion Code: X5.
485. Warnakulasuriya LS, Fernando MMA, Adikaram AVN, et al. Metformin in the Management of Childhood Obesity: A Randomized Control Trial. *Child Obes*. 2018 Nov/Dec;14(8):553-65. doi: 10.1089/chi.2018.0043. PMID: 30070925. Exclusion Code: X6.
486. Weghuber D, Forslund A, Ahlström H, et al. A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity. *Pediatric obesity*. 2020;15(7):1-11. doi: 10.1111/ijpo.12624. PMID: CN-02198805. Exclusion Code: X2.
487. Weghuber D, Forslund A, Ahlström H, et al. A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity. *Pediatr Obes*. 2020 Jul;15(7):e12624. doi: 10.1111/ijpo.12624. PMID: 32062862. Exclusion Code: X2.
488. Weghuber D, Forslund A, Ahlstrom H, et al. Effect of exenatide on BMI-SDS and 2-hour postprandial glucose in obese adolescents. *Obesity facts*. 2018;11:215-. doi: 10.1159/000489691. PMID: CN-01612822. Exclusion Code: X10.
489. Weigensberg MJ, Lane CJ, Ávila Q, et al. Imagine HEALTH: results from a randomized pilot lifestyle intervention for obese Latino adolescents using Interactive Guided ImagerySM. *BMC Complement Altern Med*. 2014 Jan 17;14:28. doi: 10.1186/1472-6882-14-28. PMID: 24433565. Exclusion Code: X5.
490. Weinstock RS, Braffett BH, McGuigan P, et al. Self-monitoring of blood glucose in youth-onset type 2 diabetes: results from the TODAY Study. *Diabetes Care*. 2019 May;42(5):903-9. doi: 10.2337/dc18-1854. PMID: 30833375. Exclusion Code: X6.
491. Weinstock RS, Trief PM, El Ghormli L, et al. Parental Characteristics Associated With Outcomes in Youth With Type 2 Diabetes: results From the TODAY Clinical Trial. *Diabetes care*. 2015;38(5):784-92. doi: 10.2337/dc14-2393. PMID: CN-01110117. Exclusion Code: X8.
492. Whaley-Connell A, Sowers JR, McCullough PA, et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). *Am J Kidney Dis*. 2009 Apr;53(4 Suppl 4):S11-21. doi: 10.1053/j.ajkd.2009.01.004. PMID: 19285607. Exclusion Code: X2.
493. Wiegand S, Dannemann A, Krude H, et al. Impaired glucose tolerance and type 2 diabetes mellitus: a new field for pediatrics in Europe. *Int J Obes (Lond)*. 2005 Sep;29 Suppl 2:S136-42. doi: 10.1038/sj.ijo.0803081. PMID: 16385766. Exclusion Code: X8.
494. Wiegand S, l'Allemand D, Hubel H, et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. *Eur J*

## Appendix C. Excluded Articles

- Endocrinol.* 2010 Oct;163(4):585-92. doi: 10.1530/EJE-10-0570. PMID: 20639355. Exclusion Code: X2.
495. Wijesuriya M, Fountoulakis N, Guess N, et al. A pragmatic lifestyle modification programme reduces the incidence of predictors of cardio-metabolic disease and dysglycaemia in a young healthy urban South Asian population: a randomised controlled trial. *BMC Med.* 2017 Aug 30;15(1):146. doi: 10.1186/s12916-017-0905-6. PMID: 28851373. Exclusion Code: X5.
496. Wijesuriya M, Gulliford M, Vasantharajah L, et al. DIABRISK-SL prevention of cardio-metabolic disease with life style modification in young urban Sri Lankan's--study protocol for a randomized controlled trial. *Trials.* 2011 Sep 26;12:209. doi: 10.1186/1745-6215-12-209. PMID: 21943067. Exclusion Code: X2.
497. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. *Int J Clin Pract.* 2013 Dec;67(12):1267-82. doi: 10.1111/ijcp.12322. PMID: 24118688. Exclusion Code: X2.
498. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. *Ann Intern Med.* 2012 Mar 20;156(6):405-15. doi: 10.7326/0003-4819-156-6-201203200-00003. PMID: 22431673. Exclusion Code: X2.
499. Wilfley D, Berkowitz R, Goebel-Fabbri A, et al. Binge eating, mood, and quality of life in youth with type 2 diabetes: baseline data from the today study. *Diabetes Care.* 2011 Apr;34(4):858-60. doi: 10.2337/dc10-1704. PMID: 21357794. Exclusion Code: X6.
500. Williams AN, Konopken YP, Keller CS, et al. Culturally-grounded diabetes prevention program for obese Latino youth: Rationale, design, and methods. *Contemp Clin Trials.* 2017 Mar;54:68-76. doi: 10.1016/j.cct.2017.01.004. PMID: 28104469. Exclusion Code: X6.
501. Wilson DM, Abrams SH, Aye T, et al. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. *Arch Pediatr Adolesc Med.* 2010 Feb;164(2):116-23. doi: 10.1001/archpediatrics.2009.264. PMID: 20124139. Exclusion Code: X2.
502. Xiao H, Adams SR, Goler N, et al. Wellness coaching for people with prediabetes: a randomized encouragement trial to evaluate outreach methods at Kaiser Permanente, Northern California, 2013. *Prev Chronic Dis.* 2015 Nov 25;12:E207. doi: 10.5888/pcd12.150251. PMID: 26605707. Exclusion Code: X2.
503. Xu HY, Si HY. Clinical effect of subcutaneous insulin injection combined with metformin for type 2 diabetes mellitus in children. *World chinese journal of digestology.* 2014;22(10):1479-83. doi: 10.11569/wcjd.v22.i10.1479. PMID: CN-01001330. Exclusion Code: X1.
504. Yanovski JA, Krakoff J, Salaita CG, et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. *Diabetes.* 2011 Feb;60(2):477-85. doi: 10.2337/db10-1185. PMID: 21228310. Exclusion Code: X6.
505. Yin C, Zhang H, Xiao Y, et al. Shape of glucose curve can be used as a predictor for screening prediabetes in obese children. *Acta Paediatr.* 2014 May;103(5):e199-205. doi: 10.1111/apa.12572. PMID: 24460776. Exclusion Code: X8.
506. Yin J, Wong R, Au S, et al. Effects of Providing Peer Support on Diabetes Management in People With Type 2 Diabetes. *Ann Fam Med.* 2015 Aug;13 Suppl 1(Suppl 1):S42-9. doi: 10.1370/afm.1853. PMID: 26304971. Exclusion Code: X2.

## Appendix C. Excluded Articles

507. Yoon JS, So CH, Lee HS, et al. Glycated hemoglobin A1c as a screening test for detecting type 2 diabetes mellitus in obese children and adolescents. *J Pediatr Endocrinol Metab.* 2018 Apr 25;31(5):503-6. doi: 10.1515/jpem-2017-0463. PMID: 29652667. Exclusion Code: X8.
508. Zannolli R, Rebeggiani A, Chiarelli F, et al. Hyperinsulinism as a marker in obese children. *Am J Dis Child.* 1993 Aug;147(8):837-41. doi: 10.1001/archpedi.1993.02160320039016. PMID: 8352218. Exclusion Code: X6.
509. Zdravković V, Sajić S, Mitrović J, et al. The diagnosis of prediabetes in adolescents. *J Med Biochem.* 2015 Jan;34(1):38-45. doi: 10.2478/jomb-2014-0062. PMID: 28356822. Exclusion Code: X8.
510. Zeitler P, Hirst K, Copeland KC, et al. HbA1c after a short period of monotherapy with metformin identifies durable glycemic control among adolescents with type 2 diabetes. *Diabetes Care.* 2015 Dec;38(12):2285-92. doi: 10.2337/dc15-0848. PMID: 26537182. Exclusion Code: X6.
511. Zhang T, Zhang H, Li Y, et al. Long-term Impact of Temporal Sequence from Childhood Obesity to Hyperinsulinemia on Adult Metabolic Syndrome and Diabetes: The Bogalusa Heart Study. *Sci Rep.* 2017 Feb 23;7:43422. doi: 10.1038/srep43422. PMID: 28230104. Exclusion Code: X4.
512. Zhong X, Wang Z, Fisher EB, et al. Peer Support for Diabetes Management in Primary Care and Community Settings in Anhui Province, China. *Ann Fam Med.* 2015 Aug;13 Suppl 1(Suppl 1):S50-8. doi: 10.1370/afm.1799. PMID: 26304972. Exclusion Code: X2.
513. Zhou QX, Wang ZY, Zhao HF, et al. The effects of GLP-1 analogues on pre-diabetes of the children. *Exp Ther Med.* 2017 Apr;13(4):1426-30. doi: 10.3892/etm.2017.4129. PMID: 28413488. Exclusion Code: X9.
514. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). *Diabetes Care.* 2009 Jul;32(7):1224-30. doi: 10.2337/dc08-2124. PMID: 19289857. Exclusion Code: X2.
515. Zuhri-Yafi MI, Brosnan PG, Hardin DS. Treatment of type 2 diabetes mellitus in children and adolescents. *J Pediatr Endocrinol Metab.* 2002 Apr;15 Suppl 1:541-6. PMID: 12017229. Exclusion Code: X8.

**Appendix D Table 1. Quality Assessment of Randomized, Controlled Clinical Trials (All KQs)**

First Author, Year Trial Name	Was random- ization adequate?	Was allocation concealment adequate?	Were groups similar at baseline?	What was the reported adherence to the intervention?	Did the study have cross- overs or contamination raising concern for bias?	What was the overall attrition? Enter values for both loss to f/u (missing data) and non- completers	What was the differential attrition?	Did the study have high differential attrition (>10% but think about how it might bias) or overall high attrition (depends on duration and outcome; generally 20%) raising concern for bias?
Kelsey, 2016 <sup>62</sup> Zeitler, 2012 <sup>53</sup> TODAY Study Group <sup>58</sup> TODAY Study Group <sup>59</sup> Levitt Katz, 2015 <sup>60</sup> Zeitler, 2007 <sup>61</sup> Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) Study	Yes	Yes	Yes	Adherence to the medication regimen before the primary outcome was reached or the study was completed ranged from 84% at month 8 to 57% at month 60 but did not differ significantly across treatments. The rate of attendance at lifestyle program visits during the first 24 months was 75.2%; 53.6% of participants met the preplanned target of attending 75% or more of visits over these 2 years.	No	Combining withdrawing consent and data censored: 6.4% (15/232) vs. 8.6% (20/233) vs. 6.4% (15/234)	2.2%	No
Jones, 2002 <sup>63</sup>	Unclear	Unclear	No, placebo had higher FPG and higher A1c and TG. Metformin group had higher C-peptide.	7.5% of placebo (3/40) and 45.2% (19/42) completed metformin	Yes	At 16 weeks: 10/82=12.2% overall	At 16 weeks: Metformin group 6/42=14.3%  At 16 weeks: Placebo group 4/40=10%  Between-group difference of 4.3%	No

**Appendix D Table 1. Quality Assessment of Randomized, Controlled Clinical Trials (All KQs)**

First Author, Year Trial Name	Was random-ization adequate?	Was allocation concealment adequate?	Were groups similar at baseline?	What was the reported adherence to the intervention?	Did the study have cross-overs or contamination raising concern for bias?	What was the overall attrition? Enter values for both loss to f/u (missing data) and non-completers	What was the differential attrition?	Did the study have high differential attrition (>10% but think about how it might bias) or overall high attrition (depends on duration and outcome; generally 20%) raising concern for bias?
Savoie, 2014 <sup>64</sup>	Yes	Yes	Yes	2/38 in the intervention group never attended the intervention visits, and 5 others did not finish the study intervention.	No	23% (6-month followup assessments were missing for 17/75 participants)	8.6% (18.4% [7/38] vs. 27.0% [10/37])	Yes

**Appendix D Table 1. Quality Assessment of Randomized, Controlled Clinical Trials (All KQs)**

First Author, Year Trial Name	Were outcome measurements equal, valid and reliable?	Were patients masked?	Were providers masked?	Were outcome assessors masked?	Was the duration of followup adequate to assess the outcome?	What was the method used to handle missing data?	Did the study use an ITT analysis? (i.e., analyze people in the groups they were randomized to)	Quality Rating (for benefits)	Comments
Kelsey, 2016 <sup>62</sup> Zeitler, 2012 <sup>53</sup> TODAY Study Group <sup>58</sup> TODAY Study Group <sup>59</sup> Levitt Katz, 2015 <sup>60</sup> Zeitler, 2007 <sup>61</sup> Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) Study	Yes	Yes	Yes	Yes	Yes	Censored; all randomized participants were included in the time-to-event analysis.	Yes (all participants included in time-to-event analysis)	Good	
Jones, 2002 <sup>63</sup>	Yes	Yes	Unclear	Unclear	Yes	NR	No	Fair	
Savoie, 2014 <sup>64</sup>	Yes	No	No	Yes	Unclear	Multiple imputation	Yes	Fair	

**Abbreviations:** FPG=fasting plasma glucose; ITT=intention to treat; KQ=key question; NR=not reported; TG=triglycerides; TODAY=Treatment Options for Type 2 Diabetes in Adolescents and Youth.

**Appendix D Table 2. Quality Assessment of Randomized, Controlled Clinical Trials: Additional Questions for Studies Reporting Harms (KQ 2 and KQ 4 Only)**

First Author, Year Trial Name	Were harms prespecified and defined?	Were ascertainment techniques for harms adequately described?	Were ascertainment techniques for harms equal, valid, and reliable?	Was duration of followup adequate for harms assessment?	Quality Rating (for harms)	Comments
Kelsey, 2016 <sup>62</sup> Zeitler, 2012 <sup>53</sup> TODAY Study Group <sup>58</sup> TODAY Study Group <sup>59</sup> Levitt Katz, 2015 <sup>60</sup> Zeitler, 2007 <sup>61</sup> Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) Study	Yes	Yes	Yes	Yes	Good	
Jones, 2002 <sup>63</sup>	Unclear	No	Unclear	Yes	Fair	Unsure how measured harms data.

**For RCTs and cohorts, definition of ratings based on above criteria:**

**Good:** Meets all criteria: Comparable groups are assembled initially and maintained throughout the study (followup  $\geq 80\%$ ); reliable and valid measurement instruments are used and applied equally to all groups; interventions are spelled out clearly; all important outcomes are considered; and appropriate attention to confounders in analysis. In addition, intention-to-treat analysis is used for RCTs.

**Fair:** Studies are graded “fair” if any or all of the following problems occur, without the fatal flaws noted in the “poor” category below: Generally comparable groups are assembled initially, but some question remains whether some (although not major) differences occurred with followup; measurement instruments are acceptable (although not the best) and generally applied equally; some but not all important outcomes are considered; and some but not all potential confounders are accounted for. Intention-to-treat analysis is used for RCTs.

**Poor:** Studies are graded “poor” if any of the following fatal flaws exist: Groups assembled initially are not close to being comparable or maintained throughout the study; unreliable or invalid measurement instruments are used or not applied equally among groups (including not masking outcome assessment); and key confounders are given little or no attention. Intention-to-treat analysis is lacking for RCTs.

**Abbreviations:** RCT=randomized, controlled trial; TODAY=Treatment Options for Type 2 Diabetes in Adolescents and Youth.